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Abstract 
Post-prenylation processing enzymes Rce1, Ste24, and Icmt function to increase 
the hydrophobicity of prenylated proteins and assist in targeting them to cellular 
membranes. Rce1 and Ste24 are CAAX endoproteases that cleave the –AAX residues off 
the C-termini of prenylated proteins that are then methylated by Icmt. Many prenylated 
proteins play key roles in the progression of cancer, such as the prenylated G-protein 
family Ras. Most therapeutic efforts in this area focused on preventing protein 
prenylation by inhibiting the prenyltransferase enzymes. However, other means of 
preventing oncogenic signal transduction can be accomplished by disrupting the function 
of Rce1, Ste24, and Icmt. This thesis focuses on the synthesis and application of small 
molecules and functionalized peptides to study isoprenoid recognizing enzymes.  
In order to evaluate Icmt’s topology, mechanism of methylation, and substrate 
recognition, isoprenoid-containing photoactivatable analogues were developed that 
crosslink to residues in or near the reactive sites. Initial studies focused on the synthesis 
and evaluation of benzophenone-containing peptide probes that resemble the natural, 
prenylated substrate. After the functionalized peptides were determined to be substrates, 
UV wavelength photolysis was used to cross-link the benzophenone moiety to adjacent 
Icmt isoprenoid binding site residues. To improve the efficiency of the substrate 
recognition and enhance labeling of Icmt, a new diazirine isoprenoid analogue was 
developed. Additionally, the peptide backbone was modified to contain both a biotin 
moiety and a fluorophore for facile in-gel fluoresces detection of the crosslinked material. 
These improvements should assist the ability for the cross-linked active site to be 
  iv 
determined for Icmt after proteolysis and LC-MS-MS analysis, a task that has yet to be 
solved.  
Ste24p has two different proteolysis roles in the maturation of the yeast mating 
pheromone, a-factor. The first site is the CAAX motif, while the second site is upstream 
toward the N-terminus, each having a unique amino acid sequences. As a way to observe 
the reaction kinetics of both sites, peptide analogues that contain a fluorescent donor-
quencher pair were developed. By monitoring the increase in fluorescence upon 
proteolysis, reaction kinetics of both cleavage positions were determined. 
To explore the pool of cellular proteins that recognize isoprenoid diphosphates, 
photoaffinity isoprenoid diphosphate analogues were synthesized. Two types of 
isoprenoid diphosphate derivatives were developed: diphosphate and 
phosphonophosphate. Each of the derivatives contain a diazirine motif as the photophore. 
The diphosphate analogue was shown to be an alternative substrate for both yeast and 
mammalian farnesyltransferase. The photoaffinity phosphonophosphate analogues were 
proven to be inhibitors of farnesyltransferase, demonstrated the ability to label isoprenoid 
binding proteins SmgGDS-607 and SmgGDS-558, and should be suitable for identifying 
unknown binding partners in future cellular lysate labeling experiments. 
Lastly, effort was put forth to synthesize a small molecule inhibitor for Icmt. The 
inhibitor incorporates both substrates recognized by Icmt: a prenylcysteine carboxylate, 
and the methyl donor S-adenosine methionine. In order to make the bisubstrate molecule 
an inhibitor, the appendage between the two substrates is through an amide bond that 
replaces the cysteine carboxylate moiety. It is hypothesized that by combining both 
  v 
substrates into one entity, the bisubstrate compound will bind more efficiently with Icmt 
and enhance inhibitor potency. The bisubstrate inhibitor was shown to inhibit mammalian 
Icmt, but had little effect on the yeast homologue. 
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Chapter 1: Synthetic Probes for the Analysis of Enzymes Involved in the processing 
of Prenylated Proteins  
1.1 Introduction to Protein Prenylation 
Many proteins and peptides found in eukaryotic biological systems are translated 
in an immature state. Expressing proteins in an inactive form is advantageous for the 
cellular system, allowing the cell to control when and where full maturity is reached. 
Before obtaining full utility within the cell, proteins require one or more enzymatic 
transformations known collectively as post-translational modifications (PTMs).1 PTMs 
are carried out by a wide range of cellular enzymes, and account for the manipulation of 
multiple different functional groups.2 A particular post-translational modification of 
growing interest for its potential use in cancer treatments is known as protein 
prenylation.3 Prenylation renders the target protein more hydrophobic, enabling the 
prenylated protein to anchor itself to the cellular membrane, and is essential for 
membrane-associated functions involving protein-protein interactions, signal 
transduction, and cellular homeostasis regulation.4 Among the many translated proteins in 
a mammalian host, roughly 2% of the proteome is prenylated.5 A specific family of 
prenylated proteins, known as the Ras superfamily, has been the primary focus for anti-
cancer research, due to studies linking Ras mutations with approximately 30% of known 
cancer.6  
Ras, whose name is derived from Rat Sarcoma,7,8 is a superfamily of small g-
proteins (GTPases) that bear a prenylated C terminus.9 GTPases are monomeric proteins 
that participate in guanosine triphosphate (GTP) exchange and act as molecular switches 
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in signal transduction cascades by alternating between an inactive GDP-bound form and 
an active GTP-bound state.10 The primary function of the Ras enzymes is to regulate gene 
expression, along with cytoskeletal assembly, intracellular vesicular trafficking, and 
nucleocytoplasmic transport.11 The translation of mutations in the Ras genes that cause 
constitutive activation of the enzymatic function results in abnormal cell growth and 
division.10-12 Of the three members of the Ras superfamily (H, N and K),13 K-Ras is often 
found mutated in cancer, especially in the pancreas.14 Crucially, transformation of both 
wild type and mutated Ras proteins cannot be reached until a CAAX signal motif is 
completely processed,3 providing the opportunity to design methods to inhibit cancer-
linked mutations. 
A CAAX motif is the last four amino acids at the C terminus of a protein: C, 
cysteine; A, an aliphatic amino acid; and X, any amino acid. In order to reach complete 
maturity, the CAAX sequence undergoes three enzymatic structural modifications, 
known as the isoprenylation pathway (Figure 1.1).15-21 The initial step is prenylation, the 
attachment of an isoprenoid moiety to the cysteine amino acid residue through a thioether 
linkage. Enzymes farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase) 
catalyze the covalent attachment of the cysteine’s free thiol with either all-trans-farnesyl 
(C15) or all-trans-geranylgeranyl (C20) pyrophosphate, respectively.22-24 Specificity 
between the two enzymes is determined by the identity of the terminal X amino acid of 
the CAAX motif.25 The second step, endoproteolysis, is the removal of the -AAX 
tripeptide from the C-terminus by Ras converting enzyme (Rce1) and zincmetalloprotein 
Sterile 24 (Ste24).26,27 The final step of the CAAX transformation is the methylation of 
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the newly revealed C-terminal cysteine carboxylate by isoprenylcysteine carboxyl 
methyltransferase (Icmt).28,29 The complete series of modifications to the CAAX 
sequence increases the hydrophobicity of the protein, and facilitates membrane 
localization. 
 
Figure 1.1. Isoprenylation pathway: prenylation by FTase or GGTase; endoproteolysis 
by Rce1 or Ste24; methylation by Icmt. 
 
Due to the important role CAAX proteins play in the biogenesis of cancer, 
research has centered on developing CAAX processing inhibitors. The most successful 
anti-cancer agents thus far have been farnesyltransferase inhibitors (FTIs) which prevent 
farnesylation of these proteins.5,30 Unfortunately, Ras proteins were found to become 
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alternatively prenylated with geranylgeranyl isoprenoids in the presence of FTIs, limiting 
treatment effectiveness for Ras-induced tumors. Because of this alternative prenylation 
phenomenon, disruption of the proteolysis and methylation steps in the isoprenylation 
pathway have been considered as a possible cancer treatment strategy. The following 
reviews the small molecule tools used to define substrate specificity, inhibit enzymatic 
activity, and explore structural characteristics of Rce1, Ste24, and Icmt. 
1.2 Ras Converting Enzyme 1 (Rce1) and Zincmetalloprotein Sterile 24 (Ste24) 
1.2.1 Background 
Following isoprenoid attachment along the isoprenylation pathway is 
endoproteolysis of the last three amino acids in the CAAX motif (Figure 1.1). In 
mammalians there are two enzymes that perform this function: Ras converting enzyme 1 
(Rce1)31 was the first to be characterized, followed by zincmetalloprotein sterile 24 
(Ste24).32 Both enzymes are localized in the endoplasmic reticulum (ER) and contain 
seven transmembrane a-helices (TMH), with Rce1 (329 AA) being slightly smaller than 
Ste24 (457 AA).33 Although some overlap occurs in substrate recognition, Rce1 is 
exclusively responsible for the processing of the Ras superfamily, while recent findings 
contradict assumptions that prelamin A was the only substrate for Ste24.34,35 Despite 
being analogous in function, only Ste24 contains the zinc binding motif, HEXXH, 
characteristic of zinc-dependent metalloproteases,
36
 while Rce1 has no sequence typical 
of any of the well-defined protease classes. 
Efforts targeting the proteolysis step of prenylation are supported by studies 
showing that K-Ras and H-Ras activity was attenuated when the genes encoding Rce1 
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were deleted.36,37 Deletion of the gene encoding Rce1 in mice to further study the 
endoproteolytic processing of Ras proteins resulted in embryonic lethality late in 
gestation (following day 15.5) or shortly after birth.38 Similarly, phosphodiesterase 6 
transformation and localization was impacted, causing a reduction in mice photoreceptor 
cell viability and ability to respond to light.39 Moreover, fibroblast cells derived from the 
Rce1-deficient mice embryos were not carboxymethylated, the final step in the 
processing of Ras proteins which requires prior proteolysis. Most importantly, Rce1-
deficient cells were unable to process farnesylated H-Ras, N-Ras and K-Ras or 
geranylgeranylated K-Ras proteins which became mislocalized within cells to the 
cytoplasm.31,38 Mislocalization indicated that Rce1 was essential for the proper 
membrane association of Ras proteins, which is a requirement for enzymatic activity. 
Proper functioning of Ste24 has also been shown to be crucial for proper nuclei structure. 
The nuclear lamina is composed of lamin filaments and associated membrane 
proteins that provide structural integrity to most eukaryotic nuclei.40 Of the three types of 
lamin proteins, lamin A and B are translated with C-terminal CAAX motifs that require 
the isoprenylation pathway modifications to reach maturity.41-43 Interestingly, prelamin A 
is endoproteolyzed 15 residues upstream from the C-terminal by Ste24, after 
carboxymethylation by Icmt, to release lamina A into the nucleoplasm.36 If prelamin A or 
Ste24 undergo mutations that block this cleavage, prelamin A accumulates in the nuclear 
membrane, causing a class of disease called laminopathy.41 Depending on the impact of 
the mutation on Ste24 activity levels, laminopathy severity can range from skin or bone 
abnormalities up to Hutchinson-Gilford progeria syndrome or restrictive dermopathy.42,44-
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47 Although disrupting endoproteolysis activity can be beneficial for controlling Ras 
associated diseases, laminopathy symptoms highlight the importance for selectively 
inhibiting Rce1 while leaving Ste24 unaffected. To approach this difficult challenge, the 
scientific community worked heavily with Rce1 and Ste24 enzymes found in yeast. 
The yeast homologues Rce1p and Ste24p have catalytic function and cellular 
localization that is similar to mammalian endoproteases, making them ideal candidates 
for comparison studies.33,48 While it was initially thought that Rce1p was the only ER 
localized endoprotease, later work in Saccharomyces cerevisiae (S. cerevisiae) found two 
splice variants of the protease, leading to the discovery of Ste24p.26,27 Ste24p performs 
the proteolytic cleavage of the C-terminal CAAX motif from the precursor peptide of a-
factor, a yeast mating pheromone.49 Additionally, Ste24p performs an unrelated N-
terminal cleavage on the a-factor precursor peptide, an event which normally takes place 
after the C-terminal modification is complete,50 but is not dependent upon completion.51 
Like Ste24, Ste24p possesses a consensus zinc metalloprotease motif, requires zinc for 
optimal activity, and is inhibited by zinc chelating compounds such as 1,10-
phenanthroline.52,53 Rce1p is also capable of cleaving the C-terminus of the a-factor 
precursor as well as other yeast CAAX proteins.34 Unlike Rce1, sequential analysis of 
Rce1p identified invariant residues reminiscent of a consensus HEXXH motif found in 
metalloproteases;54,55 however, these findings don’t rule out the possibility of an 
undiscovered protease mechanism.56 Due to the lack of structural details on the 
membrane-bound proteases, an array of small molecule and peptide based tools have 
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been developed to explore substrate specificity and structure-activity relationships (SAR) 
for these enzymes. 
1.2.2 CAAX Protease Substrates 
Substrate recognition for Rce1p and Ste24p is dependent upon the presence of an 
isoprenylated CAAX sequence at the C-terminus of a protein or peptide.15 Although the 
tetra amino acid sequences undergo endoproteolytic cleavage most efficiently, 
isoprenylated tri (CXX) and di (CX) amino acid sequences are also found to undergo 
cleavage at the scissile bond.57 Interestingly, N-acetyl-S-farnesyl-cysteine-amide is not 
processed, confining substrate recognition to a dipeptide across the scissile bond. 
Dipeptides whose C-terminus was a methyl ester weren’t recognized, adding the 
requirement of a C-terminal carboxylate functionality.58 The specificity of the amino 
acids in the CAAX sequence was also explored. 
Using a tetrapeptide library that varied at the positions downstream to the 
prenylated cysteine in the CAAX motif (CA1A2X) (Figure 1.1), the specificity of each 
position was determined. Studies found that the endoproteases prefer large hydrophobic 
residues in both the A1 and A2 positions.
59 Small hydrophobic residues, or hydrophilic, 
uncharged residues in both the A1 and A2 positions are also recognized. Endoprotease 
activity was not found when the substrate peptide contained nonnative D amino acids at 
any position in the CAAX sequence, emphasizing stereoselectivity for substrate 
recognition.58 Varying the length of the isoprenoid appended to the tetrapeptide showed 
that farnesylated peptides where processed more readily compared to the 
geranylgeranylated versions.54 Most importantly, it was found that specific sequences 
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were only processed by one of the proteases, demonstrating that Rce1p and Ste24p had 
distinct substrate selectivity.54  
1.2.3 CAAX Protease Inhibitors 
Initial inhibitor design for the endoproteases began when commercially available 
protease inhibitors for cysteine (E-64 and leupeptin), serine (APMSF and aprotinin), 
aspartyl (pepstatin), and metalloproteases (phosphoramidon, EDTA) failed to block 
complete activity.60 As a starting point, N-acetyl-S-farnesyl-cysteine (AFC) 1.1, and N-
tert-butyloxycarbonyl-S-farnesyl-cysteine (BFC) 1.2 (Figure 1.2), were explored as 
product based inhibitors, but results showed mild effects.60 Using the BFC scaffold, a 
series of derivatives were developed that replaced the carboxylate moiety with several 
other functional groups: primary alcohol, aldehyde, ketone, statine, and difluorostatine. 
All derivatives proved to be inactive, with the exception of the aldehyde analogue, 1.3 
(Figure 1.2), which was a low micromolar competitive inhibitor.60 This finding suggested 
that the mechanistic mode of proteolysis was serine or cysteine based, because aldehyde 
analogues are known to be potent transition state derivatives that mimic the tetrahedral 
intermediates through either the hydrate form of the aldehyde, or by a complex with the 
active site serine or cysteine amino acid.61 In an attempt to enhance potency, peptide 
based inhibitors were designed. 
The first peptide based inhibitors were designed from the carboxyl terminus of 
retinal transducing, AFC-Val-Ile-Ser, a tetrapeptide known to be a substrate for 
endoproteolytic activity62. Di, tri, and tetrapeptide substrates were constructed that 
contained a statine motif 1.4 (Figure 1.2) in place of the scissile bond, and tested against 
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the proteases.60 Each of the peptides tested as inhibitors, with potency increasing as 
sequence length increased, consistent with substrate activity for the endoprotease.57 
Similar results with other pseudopeptides led to the conclusion that modifications in 
which cleavage at the scissile bond is prevented will generate active inhibitors. In 
attempts to purify the mammalian endoproteases, a more potent class of inhibitor was 
revealed. 
Working with the classical protease labeling agent, halomethyl ketones, the first 
irreversible inhibitor of endoprotease activity was discovered. Treatment with N-tosyl-
phenylalanine-chloromethyl ketone (TPCK), was found to block protease activity, 
presumably by alkylating the active-site residue.
63 However, N-tosyl-lysine-chloromethyl 
ketone (TLCK), a specific irreversible inhibitor of the serine based protease trypsin and 
trypsin-like enzymes, did not inhibit the enzyme activity under the same conditions. 
Competition experiments with the reversible inhibitor 1.4 prevented unrecoverable loss in 
proteolysis activity when co-treated with TPCK; however, pretreatment with TPCK in the 
experiment resulted in no proteolysis activity upon recovery. These findings support the 
view that TPCK is a specific active-site-directed irreversible inhibitor, and suggest the 
mechanistic mode of proteolysis to be cysteine based. 
Efforts to improve chloromethyl ketone inhibitor potency afforded two 
farnesylcysteine analogues:  N-tert-butyloxycarbonyl-S-farnesyl-cysteine-chloromethyl 
ketone (BFCCMK) 1.5 (Figure 1.2), and N-tert-benzyloxycarbonylglycylgylcyl-S-
farnesyl-cysteine-chloromethyl ketone (ZGGFCCMK). While both farnesylcysteine 
analogues were affective, BFCCMK had the strongest inhibitor effect, presumably by 
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mimicking the wild type substrate to a higher extent.63 Additional improvement to 
BFCCMK was afforded years later by replacing the farnesyl moiety with a dodecyl group 
and the thioether connectivity with a methylene unit.64 Removing the thioether unit 
produced a more biologically stable linkage and increased cell permeability, enhancing 
the inhibition affect. These results provide further evidence of a thiol based proteolysis 
mechanism and suggest that the farnesylcysteine moiety, or a close mimic, is crucial for 
potent and selective inhibitor design.  
Similar to the chloromethyl ketone, acyloxy methyl ketone analogues were 
studied as endoprotease inhibitors. Envisioned to chemically alkylate the catalytic 
residue, peptidyl (acyloxy)methyl ketone (AOMK) 1.6 (Figure 1.2), showed that both 
yeast Rce1p and Ste24p were inhibited upon treatment.65 Peptidyl AOMKs were  initially 
an intriguing discovery because they inhibited both Rce1p and Ste24p to a similar extent, 
lacked the farnesylcysteine motif, and the inhibition effect was thought to be tunable 
based on the stability of the acyloxy leaving group.65 Years later, while studying the 
structural elements that contribute to the inhibitor properties of AOMK toward Rce1p and 
Ste24p, inhibition was found for dipeptides lacking the acyloxy functionality.66 This 
finding suggested that the inhibition observed was from reversible, noncompetitive 
binding, unrelated to the formerly mentioned chloromethyl ketone analogues. Although 
unfortunate, the result supported the theory that Rce1p is not a cysteine protease. 
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Figure 1.2. Early inhibitors of Rce1 and Ste24: AFC 1.1, BFC 1.2, AFC-Aldehyde 1.3, 
BFC-Statine-VIM peptide 1.4, BFCCMK 1.5, Dipeptide-AOMKs 1.6. 
Non-peptidic, non-prenylic small molecules have also been developed as 
endoprotease inhibitors. The first studies of this type used a bisubstrate approach by 
incorporating a farnesyl mimetic conjugated though a linker to a peptidomimetic motif 
for the inhibitor design. Out of the 16 analogues tested, the most potent was a cinnamyl 
prenyl mimetic appended though a β-Ala linker to a benzenesulfonamide motif as an 
A1A2-mimetic, indicating that the X-amino acid is of minor importance, 1.7 (Figure 
1.3).67 Interestingly, many of the analogues showed inhibitor effects to the prenylation 
enzyme, PFTase, but didn’t affect the subsequent methylation enzyme, Icmt. This 
advancement toward more drug-like inhibitors was further developed with the aid of 
high-throughput screening. 
Using high-throughput screening methodology the NCI DTP Diversity Set library 
was tested for inhibitors of Rce1p. Out of the 1981 compounds 46 were found to be 
inhibitors, of which 9 passed a secondary screening protocol. Many structure similarities 
were observed for the lead compounds: three contained a diphenylmethane motif, two 
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were hexachloro-substituted bicycloheptene based, two were nearly identical mercury-
based, multi-cyclic ring structures containing purine nucleoside substructures, and the 
remaining had a pyridine and hydrazinecarbothioate core. All of the compounds were 
determined to have low micromolar inhibition effects, with the most potent, NSC1011 
1.8 (Figure 1.3), having an IC50 value of 9 µM. Inhibition of Rce1p in vitro persisted 
through washing treatment, suggesting that the compounds are irreversible competitive 
inhibitors.68 In vivo tests with the lead compounds have been shown to displace GFP-
Ras2p reporters upon treatment in yeast, while displaying low cytotoxicity to the treated 
cells.69 The majority of the lead compounds were also shown to inhibit Ste24p and the 
yeast methyltransferase, Ste14p.68,69 Although promiscuous, this study yielded 
compounds that represent new and useful tools for the in vitro and in vivo 
characterization of Rce1p.  
Most recently, advancement in the selectively of Rce1 non-peptidic, non-prenylic 
small molecule inhibitors has been demonstrated. Using a design based on the 
endoprotease inhibitor 1.8,68 a library of 58 analogues was developed in an attempt to 
increase specificity for Rce1 over Ste24. Several of the 8-hydroxylquiolin based 
analogues caused reduction in Rce1 activity in vitro (IC50 < 10 µM), exhibited low cell 
toxicity, and induced mislocalization of EGFP-Ras from the plasma membrane in human 
colon carcinoma cells.70 Surprisingly, some of the inhibitors, particularly the 8-
hydroxylquiolin derivative 1.9 (Figure 1.3), were more effective at mislocalizing K-Ras 
compared to a potent farnesyltransferase inhibitor (FTI). Similar inhibition results with 
1.9 and the non-metal chelating 1-naphthol derivative, 1.10 (Figure 1.3), infers that Rce1 
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may not be a zinc metalloprotease. Most importantly, 1.9 and other 8-hydroxylquiolin 
based analogues that tested positive for Rce1 failed to inhibit Ste24. This study presents a 
new guideline for effective Rce1 inhibitor design and demonstrates SAR differences 
between Ste24 and Rce1. 
 
Figure 1.3 Non-preptidic, non-prenyl based Rce1 and Ste24p inhibitors: original 
bisubstrate inhibitor 1.7, NSC1011 1.8, 8-hydroxylquiolin derivative 1.9, 1-naphthol 
derivative 1.10. 
 
Inhibition experiments of Ste24 with HIV protease inhibitors (HIV-PIs) have been 
performed with varying success.71-73 Using GFP fusion forms of prelamin A, inhibition 
effects of lopinavir (LPV), Tipranavir (TPV), and ritonavir (RTV) on Ste24 activity were 
explored by in vitro treatment of transfected HEK293 cells. Western blots using 
antibodies against GFP, and prelamin A clearly showed evidence of the accumulation of 
prelamin A upon treatment with HIV-PIs. To verify that Ste24 was being inhibited, the 
HIV-PIs were treated in vitro with yeast cells and a-factor processing was quantified in a 
coupled endoproteolysis/methylation assay, affording IC50
 values in the low micromolar 
range.71,73 Interestingly, in a follow-up study with the potent HIV-PI Darunavir, no Ste24 
inhibition or prelamin A accumulation was found.72 Given the fact that the HIV protease 
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is a known aspartyl protease, it is perplexing how LPV, TPV, and RTV interacts with the 
zinc dependent protease and only minimally with Rce1. 
1.2.4 CAAX Protease Photoactive Probes 
Structural characterization of membrane-bound proteins has been limited, due to 
their hydrophobic nature and low cellular abundance. A solution to this challenge is 
offered by the technique known as photoaffinity labeling. Photoaffinity labeling is 
employed to identify noncovalent interactions between molecules, including protein-
ligand and protein-protein complexes. By incorporating a photoactive motif into protein 
substrates or ligands, the site of interaction with the protein is captured upon UV 
photolysis, covalently bonding the interacting partners together. After enrichment and 
proteolysis of the bound complex, the crosslinked segments can be identified and used to 
map substrate binding sites,74 or potentially reveal unknown binding partners.75 To 
address these membrane-bound limitations with Rce1p, photoaffinity peptides and 
isoprenoid analogues were designed.  
To date, only two attempts have been reported to characterize Rce1p by utilizing 
the photoaffinity labeling strategy. Both studies designed peptide based probes that 
mimicked the C-terminal sequence of the Ras protein K-Ras4B, KSKTKC(Fr)VIM. The 
first study analyzed Rce1p though the use of photoactive isoprenoid analogues appended 
to the K-Ras4B peptide in place of the farnesyl group on the CAAX motif. Several 
isoprenoid analogues incorporating the photocrosslinking motifs aryl azide, 
diazotrifluoropropionate, and benzophenone have been successful in labeling 
experiments with the prenyltransferase enzymes; however, due to their superior stability 
  15 
properties,76,77 only benzophenone-containing derivatives were employed. Using a 
fluorescent based assay, Rce1p was shown to recognize and process peptide 1.11 (Figure 
1.4), a peptide substrate prenylated with a benzophenone isoprenoid, though slower than 
the wild type farnesylated peptide.56 Given the recognition of 1.11 by Rce1p, peptide 
1.12 (Figure 1.4), bearing a biotin moiety at the N-terminus, was synthesized to crosslink 
Rce1p. Using the biotin as a handle, the ability of 1.12 to label Rce1p was demonstrated 
via streptavidin pull-down, SDS–PAGE, and Western blot analysis.56 Labeling of Rce1p 
with 1.12 was shown to be reduced by competition with the farnesylated version of the 
peptide. Taken together, these results demonstrate that benzophenone-containing peptides 
can serve as substrates for Rce1p and suggest that the enzyme is being labeled in the 
isoprenoid binding site. 
Enhancement in crosslinking was shown in the subsequent study, where 
benzoylphenylalanine (Bpa), 1.13 (Figure 1.4) was incorporated in the backbone of the 
peptide.78 Rce1p substrate determination for 1.13 was verified by monitoring cleavage by 
HPLC and product detection by MS. Interestingly, moving the Bpa moiety to different 
positions in the peptide sequence resulted in varying crosslinking efficiency not 
dependent on the proximity of Bpa to the scissile bond. Bpa crosslinking results suggest 
that residues upstream of the CAAX motif are in contact with Rce1p, a notion overlooked 
by previous substrate and inhibitor work with Rce1p. By increasing the labeling 
efficiency of substrate photoprobes, further structural information on Rce1p may be 
obtained via isolation and characterization of the covalent enzyme–probe complex. 
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Figure 1.4. Rce1 photoaffinity labeling peptide probes: Self-quenching fluorescence 
assay probe 1.11, K-Ras4b-C5-Benzophenone probe 1.12, K-Ras4b-Bpa probe 1.13. 
 
1.2.5 Perspective and Conclusion 
 
 The development of small molecule and peptide based compounds to study Rce1 
and Ste24 have largely been centered on substrate-product design. Given the potential of 
inhibiting Rce1 as a cancer therapeutic, while avoiding Ste24 associated laminopathy 
syndromes, non-prenylic small molecule inhibitors are an attractive alternative for 
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selectively attenuating Rce1 activity. However, studies have shown that Rce1 activity is 
crucial for the proper functioning of other vital cellular enzymes,39,79 which may limit the 
applicability of Rce1 inhibitors as a therapy strategy. Undoubtedly, new compounds will 
be pursued to further explore the structure and function of the endoproteases. 
 Advancement in x-ray crystallography has afforded three-dimensional crystal 
structures of Ste24 and Ste24p.80,81 These images have shown the presence of a 
voluminous membrane-enclosed hallow chamber containing several fenestration. The 
chamber size and number of entry points presents a challenging puzzle for defining their 
role in Ste24’s substrate selectivity and dual proteolysis function. X-ray studies in 
combination with photoaffinity labeling compounds should aid in mapping the structural 
features of Ste24 that are associated in the processing of substrates. 
 
1.3 Isoprenylcysteine Carboxyl Methyltransferase (Icmt) 
1.3.1 Background 
Isoprenylcysteine carboxyl methyltransferase (Icmt) catalyzes the methyl 
esterification of C-terminal isoprenylcysteine generated after proteolysis of the CAAX 
motif (Figure 1.1).82,83 Like its yeast homologue Ste14p, Icmt and Ste14p are putative 
polytopic membrane proteins that have been shown to be localized in the ER,84 which is 
unique among S-adenosyl-methionine (SAM)-dependent methyltransferases.85 Kinetic 
analysis showed that Icmt follows a Bi Bi mechanism, with SAM binding initially 
followed by the prenylated substrate.86,87 Yeast and human Icmt share 41% sequence 
identity,88 which contains a novel tripartite consensus motif that has been shown to be 
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crucial for enzymatic function.89 Ste14p and Icmt contain multiple transmembrane α-
helices, with Ste14p having 6 segments and Icmt containing 8 segments. The two 
additional N-terminal segments in Icmt are thought to play a regulatory role.90 Catalytic 
function and substrate recognition is mutual between the homologues, with Icmt shown 
to recover methylation activity in yeast Ste14pΔ mutants.85 
Icmt and Ste14p behave as metalloenzymes,88,91 although by what mechanism and 
metal is still in question. Incubation with the metal chelator 1,10-phenanthroline and 
Zircon caused Icmt to lose activity, but treatment with the water-soluble chelator EDTA 
had no effect on enzymatic activity. Similarly, treatment of Icmt with chelator 
nitrilotriacetic acid (NTA) showed little inhibition, but conjugation of NTA though a 
lysine linker to a hydrophobic compound, such as cholesterol, eliminated activity.92,93 
Collectively, these findings suggest that the metal ion is located in a hydrophobic 
segment of the enzyme. 
The discovery of Icmt began with the isolation of a peptide that contained an 
isoprenylcysteine methyl ester C-terminus from two fungi, Tremella mesenterica and 
Tremella brasiliensis.94,95 Nearly a decade later, the yeast gene for Ste14p was uncovered 
after the identification of the yeast mating hormone, a-factor, that bared the 
isoprenylcysteine methyl ester functionality.28,29,96 The discovery of yeast Ste14p ignited 
the search of its mammalian homologue, Icmt, that was first found in bovine retinal rod 
outer and rat liver cells.97-99 
The methyl esterification reaction has several important physiological roles in 
protein function and cellular homoeostasis.26,27,100,101 The conversion of a negatively 
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charged carboxylate to a methyl ester renders the C-terminus more hydrophobic and 
enhances the partitioning of the protein to the cell membrane, facilitating proper cellular 
localization.27,100,101 Carboxyl methylation has been suggested to protect the precursor 
poly peptide from proteolytic digestion.26 The methyl esterification of proteins also aids 
in the proper recognition of plasma and intercellular membrane receptors, and mediating 
protein-protein interactions.100,101 As an example highlighting the requirement for proper 
enzymatic function by Icmt, mice embryos lacking Icmt were shown to die ten days into 
gestation, exhibiting abnormal cell structure and division.102 Although the function of 
Icmt is important in the development of mammalian cells, significant effort has been 
devoted toward targeting Icmt as an anti-cancer therapeutic. 
Efforts to target the methylation modification in the prenylation pathway began 
when studies showed that Ras protein activity was attenuated in cells that lack Icmt.103,104 
It was found that Icmt deficiency in embryonic stem cells caused mislocalization of K-
Ras away from the plasma membrane and trapped it within the cytoplasm, while wild 
type cells showed proper plasma membrane association.103 In addition, inactivation of 
Icmt in a mouse fibroblast cell line resulted in inhibition of cell growth and reduced 
oncogenic transformation of K-Ras and its downstream receptor B-Raf.104 More recently, 
down regulation of Icmt in mice dispositioned with progeria showed recovery in 
phenotype characteristics and increased lifespans.105 From these studies, it is clear that 
Icmt is critical for proper membrane targeting and biological function of Ras proteins, 
and a promising target in oncogenesis research.106 
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1.3.2 Icmt Substrates 
Icmt substrate recognition is dependent upon the incorporation of an 
isoprenylcysteine moiety. Using Icmt isolated from rat liver, the binding affinity for the 
synthetic peptide LARYKC was studied in the non-prenylated, S-geranylated, S-
farnesylated, and S-geranylgeranylated forms.97 As predicted, Icmt only recognized the 
prenylated substrates, with farnesylated (Km = 2.2 µM) and geranylgeranylated (Km = 
10.9 µM) peptides having the strongest binding. It is important to note that the 
geranylated derivative had a substantial decrease in affinity to the enzyme when 
compared to farnesyl and geranylgeranyl versions, suggesting a minimum 15-carbon 
length of the isoprenoid moiety for optimum substrate recognition.97 Additionally, 
modifying the sulfhydryl moiety to an n-alkyl derivative also decreased the affinity of the 
substrate, highlighting the importance of the conjugated, rigid isoprenoid structure.97  
Several studies with N-acetyl-S-farnesyl-cysteine (AFC) 1.1 (Figure 1.2) and the 
longer N-acetyl-S-geranylgeranyl-L-cysteine (AGGC) have found them to be good 
substrates for recognition by Icmt.86,88,101,107,108 Km values for AFC (7 µM) and AGGC 
(20 µM) are within an order of magnitude compared to the peptide substrates,97 
signifying that the majority of substrate specificity is dependent upon the spatial 
relationship between the isoprenoid moiety the carboxylic group. The stereoselectivity of 
Icmt was also tested with D-AFC and racemic DL-Homocysteine, which were shown to 
be non-substrates and only mild inhibitors of Icmt.98 Interestingly, the unmodified amino 
version of AFC, farnesylcysteine (FC), wasn’t a substrate but acted as an inhibitor of 
Icmt, suggesting that a peptide like modification of the amino group is required for 
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substrate activity.98 These findings led researchers to believe that the minimal recognition 
element for Icmt was an amino acetylated, isoprenylated cysteine moiety. 
Removal of the amino group from AFC, creating S-farnesyl thiopropionic acid 
(FTP) 1.14 (Figure 1.5), was shown to be recognized and methylated by Icmt.98 FTP was 
found to have a Km of 14 µM, similar to that of AFC, thereby reducing the minimal 
structure requirement for Icmt recognition. S-farnesyl thioacetic acid (FTA) 1.15 (Figure 
1.5), one methylene unit shorter between the carboxylic and thiol functionality than FTP, 
resulted in loss of substrate activity;98 however, FTA did test as a potent competitive 
inhibitor to Icmt with a KI of 3.9 µM. Overall, discovery of FTP helped simplify inhibitor 
synthesis by eliminating amino acid chirality, reducing molecular weight, and increasing 
ligand efficiency.109 To refine substrate requirements for Icmt, heteroatom derivatives 
were examined. 
Using AFC and FTP as templates, a series of heteroatom analogues were designed 
to test the substrate specificity of Icmt. The role of the thioether connectivity in AFC was 
first studied by oxidation of the sulfur atom to the racemic mixture of sulfoxide 
diastereomers. Neither of the sulfoxide analogues were substrates of Icmt, but tested as a 
mixture to be competitive inhibitors.98 Additionally, racemic selenium derivatives of 
AFC and FTP were tested to be substrates but had a large Km and smaller Vmax.
 Only 
weak substrates for Icmt were afforded when replacing the sulfur atom in oxo and amino 
analogues of FTP.98 Several years later, the thioether moiety in AFC was exchanged with 
a methylene unit, desthio-AFC 1.16 (Figure 1.5), which lacked both substrate and 
inhibitor activity for Icmt.110 The thioether moiety in FTP was also replaced with a 
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triazole group. Triazole-FTP 1.17 (Figure 1.5) lost substrate activity, but tested as a 
potent competitive inhibitor.111 Taken together, these works demonstrate the importance 
of the thioether moiety in Icmt recognition, and establish its importance in future 
inhibitor designs. Many inhibition studies have been performed in an attempt to further 
understand the nature of Icmt substrate specificity. 
 
Figure 1.5. Small molecules to study Icmt substrate specificity: FTP 1.14, FTS 1.15, 
desthio-AFC 1.16 and Triazole-FTP 1.17. 
 
1.3.3 Icmt Inhibitors 
Initial Icmt inhibition studies worked with AFC and AGGC, utilizing their 
competitive inhibitor and cell-permeable properties, while avoiding inhibition of other 
cellular methyltransferases.98,107,112-114 Treatment of cells with AFC and AGGC induced 
an array of biological effects thought to be caused by specifically inhibiting Icmt. 
Examples included a decrease in methylated Ras proteins, disruption of signaling for 
insulin releasing, interruption of the Ras signaling pathway, and interference of 
superoxide release in human neutrophils.114-120 Conversely, it was shown that AFC and 
AGGC induced cellular effects that are unrelated to the inhibition of Icmt,117,121,122 
indicating that AFC and AGGC were most likely dominant inhibitors of prenylcysteine-
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dependent interactions not exclusively limited to Icmt. Nevertheless, due to their 
important impact on the mislocalization of Ras, and endothelial cell apoptosis,102,104 
analogues of AFC and AGGC were pursued. 
Based on the FTP framework, a series of rigid carboxylic acid analogues were 
designed as small molecule Icmt inhibitors. Using thiosalicylic acid in place of 
thiopropionic, S-farnesyl thiosalicyclic acid (FTS) was synthesized that restricted 
carboxylate and thiol functionalities to a cis confirmation by the aromatic ring, limiting 
the degree of rotational freedom while maintaining the two carbon spacer in FTP. In cell 
free inhibition studies, FTS was shown to be a competitive inhibitor of Icmt (KI = 2.8 
µM), and also caused mislocalization of human Ras in transformed Rat1 cells.123 
Additional structural isomers of FTS resulted in a decrease in inhibition activity as well 
as the exchange of the thioether linkage to a secondary amine. Adding chloro and fluoro 
substituents to the aromatic ring had varying effects. Halogens at the 5-position 
maintained comparable inhibitor activity to FTS, but at positions 3 and 4 considerably 
diminished inhibition.124 Unfortunately, in vivo inhibition assays with FTS showed only 
mild inhibitor effects on Icmt, leading to the conclusion that like AFC, FTS was a 
dominant inhibitor of prenylcysteine-dependent interactions.125  
Based on the findings that AFC acted as a substrate and FC did not, design and 
synthesis of Icmt inhibitors that varied functionality at the amide position were pursued. 
The first series of amino-FC derivatives were synthesized by acylation of the free amine 
with various acid anhydrides and evaluated on human platelet methyltransferase. FC 
analogues incorporating a N-isobutyl or N-isovaleryl were found to be substrates for 
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Icmt, but increasing the steric bulk to N-(Trimethylacetyl)pivaloyl or N-Benzoyl 
eliminated substrate activity.122,126 Interestingly, when glycine spacers were inserted 
between FC and the benzolyl motif, substrate recognition was recovered.126 These 
findings suggested that Icmt has a steric limit in proximity to the isoprenoid recognition 
site. 
The amide-substituted FC approach for inhibitor design was expanded a decade 
later through the development of a 23-member analogue library. Library screening results 
supported the previous finding, demonstrating that only small alkyl derivatives were 
substrates for Icmt, while also identifying a modest inhibitor, adamentyl-FC 1.18 (Figure 
1.6).127 Streamlining the amino-substituted FC approach by implementing solid-phase 
synthesis, o-phenoxyphenyl FC (POP-FC) 1.19 (Figure 1.6) was identified to be a potent 
Icmt inhibitor (IC50 = 4.3 µM).
128 The discovery of 1.19 is perplexing due to the lack of 
inhibitor activity found for N-Benzoyl-FC. Additionally, a library of sulfonamide-
substituted FC analogues was synthesized and evaluated, resulting in another potent 
inhibitor, 2-thienyl-sulfonamide-FC (IC50 = 4.3 µM) 1.20 (Figure 1.6).
129
  Taken together, 
these works demonstrate that Icmt might have a more spatially robust binding site than 
was earlier assumed. 
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Figure 1.6. Amino-substituted FC Icmt inhibitors: Adementyl-FC 1.18, POP-FC 1.19,   
2-thienyl-sulfonamide-FC 1.20. 
To more accurately understand the role of the isoprenoid motif in Icmt substrate 
recognition and potentially uncover effective inhibitors, farnesyl-modified AFC 
analogues were explored. The first studies tested two AFC analogues: one containing an 
isobutenyl substitution at position 3 of AFC (3-iBAFC) 1.21, the other replacing the 
terminal isoprene domain with a biphenyl motif (3MB-AFC) 1.22 (Figure 1.7). Results 
showed 3-iBAFC was an inhibitor of Ste14p but a substrate for Icmt.130 In contrast, 3MB-
AFC acted as a mild mixed-mode inhibitor of Icmt with the competitive component being 
more dominant (IC50  = 259 µM).
130 Follow-up studies showed that a derivative of 3MB-
AFC that incorporated a C8 alkyl tail, compound 1.23 (Figure 1.7), in place of the 
terminal biphenyl motif increased Icmt inhibition (IC50  = 35 µM).
111 The most potent 
inhibitor was reported when amide-substitution with o-phenoxyphenyl was linked to 
3MB-AFC, creating POP-3MB-FC 1.24 (Figure 1.7), with a IC50 value of 2.5 µM.
128 
These efforts highlight several important findings: the correct (E)-geometry of the first 
isoprene must be maintained for efficient recognition, hydrophobic substitutions in the 
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farnesyl motif at or beyond position 3 are tolerated, and yeast and human Icmt have 
distinct substrate specificities. 
A more recent farnesyl-modified approach evaluated triazole containing 
analogues of FTP. Using the well-characterized azide-alkyne click chemistry, a library of 
21 triazole-FTP analogues was synthesized and tested as inhibitors for Icmt. Of these 
triazole-FTP analogues, the most potent inhibitor of Icmt in vitro (IC50 = 0.8 µM) 
incorporated a triazole in place of the second isoprene unit connected by a two methylene 
spacer to a para substituted biphenyl motif (TAB) 1.25 (Figure 1.7).131 The lead 
compound was also shown to displace GFP-K-Ras from the membrane in transfected 
PaTu-8902 cells. Analogues with alterative orientations of the biphenyl moiety or fewer 
methylene units in the spacer decreased inhibition affect, highlighting the importance of 
the flexibility and linearity in the isoprenoid chain. Compound 1.25 represents the first 
Icmt inhibitor with submicromolar efficiency, possessing lower molecular weight than 
previous compounds, and exhibiting improved ligand efficiency.  
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Figure 1.7. Isoprenoid-substituted FC Icmt inhibitors: 3-iBAFC 1.21, 3MB-AFC 1.22, 
C8 alkyl tail 1.23, POP-3MB-FC 1.24, TAB 1.25. 
Another class of Icmt inhibitors that has been researched extensively is based off 
the byproduct S-adenosylhomocysteine (SAH) 1.26 (Figure 1.8). During methyl 
esterification catalysis, Icmt consumes S-adenosylmethionine 1.27 (Figure 1.8) as the 
methyl donor, releasing SAH and the methylated substrate.86 SAH has been shown to 
bind to methyltransferases, consequently acting as a competitive inhibitor of Icmt and 
other related enzymes.132 Using strategies to increase cellular levels of SAH, studies have 
shown its ability to block proliferation of multiple cell types.133-135 As a recent example, 
treatment with adenosine dialdehyde inhibited Ras cancer cell proliferation via SAH 
inhibition of Icmt.136 Unfortunately, the use of SAH as an Icmt inhibitor is limited by the 
fact that it also inhibits most cellular methyltransferases.132,137 
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Figure 1.8. Cofactor and byproduct of Icmt methylations: S-adenosylhomocysteine 1.26, 
S-adenosylmethionine 1.27. 
Advances in high-throughput screening techniques have allowed new Icmt 
inhibitors to be found that are not derived from substrate-product based framework. 
Screening of a small molecule library composed of approximately 10,000 compounds led 
to the discovery of Icmt inhibitors that shared a unique indole core motif. The lead 
compound for the indole core inhibitors was coined cysmethynil 1.28 (Figure 1.9).138 
Cysmethynil is a potent time-dependent inhibitor of Icmt with a IC50 value of 2.4 µM.
139 
Inhibition with cysmethynil is highly Icmt specific and does not inhibit the other 
prenylation enzymes FTase, GGTase-I, Rce1, and Ste24, or the SAM-dependent DNA 
methyltransferase.140 Treatment with cysmethynil has shown Icmt inhibition effects in a 
variety of different cell lines: induced mislocalization of GFP-K-Ras constructs in MEF, 
stopped soft agar growth of DKOB8, induced autophagic-dependent apoptosis in PC3, 
and reduced migration of the highly metastatic MDA-MB-231 breast cancer cell line.141-
145 HPLC methodology for the quantification of cysmethynil effects in mouse plasma has 
also been achieved.146 Derivatives of cysmethynil indole core have been developed that 
offer improved antiproliferative properties.147 Collectively, these works have shown the 
utility of the indole class of Icmt inhibitors, and establish a new drug design platform for 
highly specific inhibition of Icmt. 
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High-throughput screening has also identified small molecule Icmt inhibitors 
isolated from natural products. The first natural product inhibitor, spermatinamine 1.29 
(Figure 1.8), was discovered form the Australian marine sponge, Pseudoceratina sp. 
Spermatinamine is a symmetrical polyamine alkaloid compound with a bromotyrosyl-
spermine-bromotyrosyl sequence. Inhibition studies with Icmt afforded an IC50 of 1.9 
µM.148 Additionally, other milder natural product Icmt inhibitors have been found: 
Aplysamine 6 1.30 (Figure 1.9),149 a bromotyrosine like structure similar to 
spermatinamine from Pseudoceratina sp, and a series of prenylated b-hydroxychalcone 
from Hovea parvicalyx root extract.150 The inhibition potency for spermatinamine and 
aplysamine 6 led to their total synthesis,151,152 which would later be improved upon for 
spermatinamine.153 It will be interesting to see what future studies on these natural 
products will expose for Icmt. 
 
Figure 1.9. Non-isoprenylcysteine Icmt inhibitors: Cysmethynil 1.28, spermatinamine 
1.29, aplysamine 6 1.30. 
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1.3.4 Icmt Photoactive Probes 
Structural characterization of Icmt has been limited due to its membrane-bound 
nature and low cellular abundance. To generate a model of Icmt and gain insight into its 
structural features, photoaffinity labeling has been explored. The first reported 
photolabeling study on human and yeast Icmt worked with isoprenoid analogues that 
incorporated the photoreactive group benzophenone. A variety of compounds were 
utilized ranging from small molecule derivatives of AFC that incorporated benzophenone 
in the isoprenoid structure 1.31, or in the peptide backbone with noncanonical amino acid 
Bpa 1.32, to more complex a-factor based peptides prenylated with different 
benzophenone-containing isoprenoid analogues 1.33 (Figure 1.10).154 Using an in vitro 
methyltransferase vapor diffusion assay, all of the probes tested as substrates for Ste14p 
with Km’s comparable to that of AFC. Similar results for Icmt were obtained for 1.31 and 
1.32; however, the a-factor probes tested as inhibitors to the enzyme, with the most 
potent, 1.33, having an IC50 value of 13.7 µM. Most importantly, all of the compounds 
were shown to crosslink to both Ste14p and Icmt, as confirmed by neutravidin–agarose 
capture, SDS–PAGE resolution, and immunoblot identification. Although labeling 
efficiencies varied amongst the analogues, they will be invaluable tools in future efforts 
to identify and define the substrate binding sites for both yeast and human Icmt. 
The most recent photocrosslinking study showed an enhancement in the ability to 
label Icmt.155 The improvement in crosslinking efficacy was afforded by the development 
of a new isoprenoid analogue that contained the diazirine photoactive motif. Using a-
factor as a scaffold, a trifunctional Icmt labeling probe was designed incorporating biotin, 
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a fluorophore, and the diazirine isoprenoid analogue 1.34 (Figure 1.10). Substrate testing 
with Ste14p showed an increase in the binding efficiency of the diazirine probe compared 
to a trifunctional benzophenone version (Km 12.2 µM vs 27.8 µM, respectively), and 
crosslinking to Ste14p was improved by 100%. As compared to the benzophenone 
analogues, the diazirine version better resembles the natural farnesyl structure and 
generates a more reactive carbene intermediate than the diradical intermediate produced 
from the benzophenone photophore. Competition experiments with the wild type 
farnesylated version of a-factor showed a decrease in Ste14 labeling, indicating that the 
probe was labeling the binding site. The addition of the fluorophore also simplified the 
detection of crosslinked products. Given the increase in photolabeling and ease of 
analysis obtained, the diazirine isoprenoid mimic should facilitate the identification of the 
active-site residues in Ste14p. 
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Figure 1.10. Photocrosslinking probes for Icmt: N-Biotin-S-C10-Benzopheone-Cysteine 
1.31, Biotin-Bpa-farnesylcysteine 1.32, a-factor-C10-Benzophenone 1.33, a-factor-C10-
Diazirine 1.34. 
1.3.5 Perspective and Conclusion 
Given the adverse consequences associated with inhibiting the prenylation 
endoproteases, advancement of chemical tools to study and control Icmt activity has been 
a growing target in oncogenesis research. Beginning with simple compounds like AFC, 
the scientific field has developed a wide range of effective inhibitors based on product-
substrate design, to natural product discovery. While no crystal structure has been solved 
for Icmt, the improvement in photoaffinity labeling compounds, in combination with 
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enhancement in analysis techniques, should afford a better structural model to Icmt, and 
aid in future inhibitor design. 
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Chapter 2: Evalulation of Substrate and Inhibitor Binding to Yeast and Human 
Isoprenylcysteine Carboxyl Methyltransferases (Icmts) using Biotinylated 
Benzophenone-containing Photoaffinity Probes 
Isoprenylcysteine carboxyl methyltransferases (Icmts) are a class of integral 
membrane protein methyltransferases localized to the endoplasmic reticulum (ER) 
membrane in eukaryotes. The Icmts from human (hIcmt) and S. cerevisae (Ste14p) 
catalyze the α-carboxyl methyl esterification step in the post-translational processing of 
CaaX proteins, including the yeast a-factor mating pheromones and both human and 
yeast Ras proteins.  Herein, we evaluated synthetic analogues of two well-characterized 
Icmt substrates, N-acetyl-S-farnesyl-L-cysteine (AFC) and the yeast a-factor mating 
pheromone, that contained photoactive benzophenone moieties in either the lipid or 
peptide portion of the molecule.  The AFC modified compounds were substrates for both 
hIcmt and Ste14p, whereas the a-factor analogues were only substrates for Ste14p.  
However, the a-factor analogues were found to be micromolar inhibitors of hIcmt.  
Photocrosslinking and neutravidin-agarose capture experiments revealed that both hIcmt 
and Ste14p were specifically photolabeled with all of the analogues tested to varying 
degrees Together, these data suggest that the Icmt substrate binding site is dependent 
upon features in both the isoprenyl moiety and downstream amino acid composition and 
that hIcmt and Ste14p have overlapping, yet distinct, substrate specificities. 
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2.1 Introduction 
Many eukaryotic proteins are initially synthesized with a C-terminal amino acids 
CAAX motif that signals a series of post-translational modifications including 
isoprenylation of the cysteine (C) by either a farnesyl or geranylgeranyl moiety, 
proteolysis of the –aaX residues and α-carboxyl methyl esterification of the newly 
exposed cysteine residue.27,100,101 CAAX proteins include the Ras superfamily of small 
GTPases,156,157  Rheb, the nuclear lamins, the Rho family of GTPases and the γ subunits 
of heterotrimeric G proteins.3,18,98,101  
The only enzymes known to methyl esterify the α-carboxylate group of CAAX 
proteins are the isoprenylcysteine carboxyl methyltransferases (Icmts), a family of 
integral membrane proteins localized to the endoplasmic reticulum (ER).18,88,101,158-160  
Ste14p from S. cerevisiae, the founding member of the Icmt family of enzymes, is a 26-
kDa integral membrane protein with six putative transmembrane helices.29,89  The human 
enzyme, hIcmt, which shares 41% identity and 63% similarity with Ste14p, is a 33-kDa 
membrane protein with putative eight transmembrane helices.85,90,130  Interestingly, hIcmt 
functionally complements the mating defect of a Δste14 strain by methylating the a-factor 
peptide, suggesting that the enzymes have overlapping substrate specificities.85  In 
addition to CAAX proteins and peptides, numerous small molecules such as N-acetyl-S-
farnesyl-L-cysteine (AFC), N-acetyl-S-geranylgeranyl-L-cysteine (AGGC), and farnesyl 
thioproionic acid (FTP) have been shown to be substrates for both human and yeast 
Icmts,112,113 while other compounds have shown specificity for the yeast enzyme.130   
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Aside from these few examples, little is known about the differences in substrate 
specificity between the yeast and human enzymes, nor is it known how and where 
substrate binds to these Icmts.  A recent 3.4 Å crystal structure of the prokaryotic Icmt 
ortholog Ma-Icmt has been published that revealed important well-conserved structural 
features of the binding pocket for the co-substrate S-adenosyl-L-methionine (SAM).161  
The structure also showed a conserved access tunnel for lipidated substrates that is 
comprised of residues both in the C-terminal SAM-binding domain and those in the N-
terminal half of the protein.161  The N-terminal half of the protein is thought to confer 
substrate specificity for lipid substrates.  However, poor sequence conservation between 
Ma-Icmt and the eukaryotic Icmts in the N-terminal half precluded a definitive analysis 
of residues important for binding the isoprene moieties and thus, different approaches 
must be taken to identify these key amino acids. 
Benzophenone-modified substrate analogues have been used previously to 
interrogate the protein binding sites for farnesyl and geranylgeranyl moieties.  The utility 
of this approach was first demonstrated in experiments designed probe the interaction 
between the CAAX protein Rho and its regulator RhoGDI.  In this study, an isoprenoid 
containing cysteine analogue bearing the benzophenone label in the lipid itself was used 
to demonstrate that the isoprene group itself specifically interacts with RhoGDI.162  Most 
recently, a series of benzophenone-modified peptide analogues based on the yeast a-
factor sequence was developed and used to examine the activity of yeast CAAX protease 
Ras converting enzyme 1 (Rce1p).  These experiments demonstrated that yeast Rce1p 
recognized the modified analogues as substrates and each analogue specifically 
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photoaffinity labeled the protein.56,78  Similarly, carboxyl methylated, photoactive 
analogues of the a-factor mating pheromone peptide were shown to functionally interact 
with the a-factor receptor, Ste3p.163   
In this study, we synthesized and examined several analogues of AFC and 
farnesylated a-factor peptides that contained both a biotin tag and a photoactive 
benzophenone moiety, either in the isoprene unit or in the peptide region, for their ability 
to bind and act as substrates or inhibitors of hIcmt and Ste14p.  The benzophenone group 
allowed for specific photoaffinity labeling of the substrate binding site and the biotin 
moiety allowed for isolation of the labeled protein from a crude membrane mixture.  
Using kinetic studies, we determined that the AFC analogues were substrates for both 
enzymes.  The a-factor analogues were only substrates for Ste14p but were competitive 
inhibitors of hIcmt.  Furthermore, using photocrosslinking experiments followed by 
isolation with neutravidin-agarose beads, we determined that both Ste14p and hIcmt were 
labeled by all of the analogues tested, albeit to varying degrees, under saturating 
conditions.   
 
2.2 Results and Discussion 
2.2.1 Probe synthesis. All of the photoactive probes used in the studies described here 
were prepared via solid phase synthesis (Figure 2.1).  For the preparation of the AFC 
analogues, the compounds were assembled starting with Fmoc-Cys(S-t-Bu)-OH that had 
been immobilized on 2-chlorotrityl resin.  Side chain deprotection followed by S-
alkylation was used to install either a farnesyl group (for 2.2) or a benzophenone-based 
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photolabel (for 2.3).  Photolabel 2.3 was based on a previously described AFC 
analogue.162   Fmoc deprotection and subsequent chain elongation using standard solid 
phase synthetic procedures followed by cleavage under mild acidic conditions afforded 
the desired probes.  For the preparation of the a-factor-based analogues, the biotinylated 
peptide 2.4 was first prepared via standard solid phase synthetic procedures.  That 
compound was then alkylated with the short chain benzophenone-functionalized 
isoprenoids 2.5a or 2.5b to yield 2.7a or 2.7b, respectively; similarly, alkylation of 2.4 
with 2.6a or 2.6b yielded 2.7a or 2.7b, respectively. 
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Figure 2.1.  Structures of Photoactive Analogues of AFC and the a-factor peptide from S. 
cerevisiae. 
 
2.2.2 All photoaffinity analogues were substrates of His-Ste14p.  We first examined 
the ability of the benzophenone-labeled AFC (2.1) analogues (2.2 and 2.3) and a-factor 
mimetics (2.7a, 2.7b, 2.8a and 2.8b) (Figure 2.1) to act as substrates for yeast 
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His10myc3N-Ste14p (His-Ste14p) using an in vitro methyltransferase vapor diffusion 
assay.  We determined the Km and Vmax values for each analogue using crude membrane 
preparations from yeast expressing His-Ste14p (5µg), using AFC as the positive 
control.130 The small molecule photoaffinity compounds based on AFC (2.2 and 2.3), 
demonstrated similar Km values to that of AFC (Table 2.1).
130  The a-factor peptide 
photoaffinity analogues with the benzophenone substituted in the meta position (2.7a and 
2. 8a) also demonstrated similar Km values to AFC (Table 2.1).  Interestingly, the Km 
values for the a-factor analogues containing a para-substituted benzophenone moiety 
(2.7b and 2.8b) were 2 – 3 times lower than the meta-substituted analogues.  These data 
suggest that 2.7b and 2.8b interact with the His-Ste14p binding site with higher affinity, 
possibly as a result of the increased linear and aromatic hydrophobicity of the analogues.  
AFC and the small molecule AFC-based analogues substrates may demonstrate greater 
Km values than the a-factor analogues because they lack favorable downstream amino 
acid contacts with the His-Ste14p substrate binding site.  Together, these data suggest 
that features of both the lipid moiety and the peptide sequence affect binding to His-
Ste14p.  However, it is important to note that while the isoprene moiety is absolutely 
essential for recognition by His-Ste14p and other Icmts, the peptide sequence is 
dispensable,98 and may serve as a more subtle recognition factor for the selection of 
substrates in vivo. 
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Table 2.1.  Kinetic Parameters for AFC and a-Factor Photoaffinity Analogues as 
Substrates for His-Ste14p. 
 
Compound Km(app)a, b, c Vmaxc 
 µM pmol methyl groups 
transferred/min/mg 
2.1 15.9 ± 0.9130   869.6 ± 14.9 
2.2 17.9 ± 0.5 2072 ± 112 
2.3 18.3 ± 0.4 362 ± 4.2 
2.7a 14.6 ± 0.3 762 ± 28 
 
2.7b 6.1 ± 0.6 320 ± 16 
 
2.8a 15 ± 0.2 
 
473 ± 8 
 
2.8b 5.1 ± 0.6 240 ± 3.8 
a Km values are apparent because the hydrophobic nature of the substrates precluded 
accurate determinations of their exact concentrations. 
bData are the average of three experiments performed in duplicate ± standard deviation  
cValues were determined by fitting data to classical (Michaelis-Menten) enzyme-
catalyzed curve data using GraphPad Prism 4. 
 
Although the Km values for 2.2, 2.3, 2.7a and 2.8a were similar for His-Ste14p, 
the Vmax values varied greatly (Table 2.1).  Analogue 2.2, which contains a photoactive a 
p-benzoyl-L-phenylalanine upstream of the cysteine residue, demonstrated the greatest 
Vmax (2072 pmol/min/mg).  This value was more than 2-fold greater than that of AFC 
(869 pmol/min/mg), the compound defined as the minimal substrate for Icmts that 
contains peptide character.98  These data suggest that His-Ste14p can turn over a substrate 
containing a bulky hydrophobic moiety next to the lipidated cysteine residue more 
quickly and may point to a mechanism in which product release is rate limiting.  
Analogue 2.3 demonstrated the lowest Vmax, 362 pmol/min/mg, with analogues 2.7a and 
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2.8a showing midrange Vmax values of 473 and 762 pmol/min/mg, respectively (Table 
2.1).  Analogues 2.7b and 2.8b, which had the lowest Km values, showed the lowest Vmax 
values of all the substrates tested against His-Ste14p.  This reduction is substrate turnover 
may be a result of the lower Km or a decreased ability to release product following the 
reaction.  
 
2.2.3 AFC photoaffinity analogues were substrates for His-hIcmt but the a-factor 
photoaffinity peptide analogues were inhibitors. We next examined the ability of these 
analogues to act as substrates for His10myc3N-hIcmt (His-hIcmt).  We performed kinetic 
analyses to determine the Km and Vmax values for each of the analogues and to establish if 
differences in substrate specificity existed between the yeast and human enzymes (Table 
2.2).  We found that 2.2 is a substrate for His-hIcmt with a Km lower than that for AFC 
and a Vmax that was only slightly decreased.  However, 2.3, which contains the modified 
isoprenyl group, was not a substrate for His-hIcmt to any measurable extent and thus, the 
Km value is not particularly relevant (Table 2.2).  Furthermore, even though the native a-
factor peptide is a substrate for His-hIcmt,85 none of the modified a-factor analogues 
displayed any measurable activity (data not shown).  However, all of a-factor peptides 
were inhibitors of His-hIcmt, to varying degrees (Table 2.2).  Analogues 2.7a and 2.7b, 
which have a shorter 5-carbon isoprene spacer, were poor inhibitors of His-hIcmt (IC50 
>100 M) whereas 2.8a and 2.8b, which have a 10-carbon isoprene spacer, were 
relatively potent, displaying IC50 values of 25.7 ± 1.6 µM and 13.7 ± 0.8 M, 
respectively (Table 2.2).  The calculated Ki values for 2.8a and 2.8b using the Cheng – 
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Prusoff method were 13.0 ± 0.8 M and 7.0 ± 0.4 M, respectively.164  These marked 
differences between the activities of these photoaffinity analogues and His-Ste14p and 
His-Icmt highlight previously unappreciated substrate specificity differences between the 
different Icmts.  Furthermore, these data suggest that the hIcmt binding site is less 
tolerant of changes in the isoprene architecture than is Ste14p.   
Table 2. Kinetic Parameters for AFC and a-Factor Photoaffinity Analogues as 
Substrates for His-hIcmt. 
 
Compound Km(app)a, b, c Vmaxc IC50d 
 µM pmol methyl groups 
transferred/min/mg 
µM 
2.1 10.3 ± 0.5130 884 ± 49 N. A. 
2.2 5.9 ± 0.5 504 ± 27 N. A. 
2.3 3.4 ± 0.3 24 ± 2 N. A. 
2.7a N. D. N. D. > 100 
2.7b N. D. N. D. > 100 
2.8a N. D. N. D. 25.7 ± 1.6 
 
2.8b N. D. N. D. 13.7 ± 0.8 
a Km values are apparent because the hydrophobic nature of the substrates precluded 
accurate determinations of their exact concentrations. 
bData are the average of three experiments performed in duplicate ± standard deviation  
cValues were determined by fitting data to classical (Michaelis-Menten) enzyme-
catalyzed curve data using GraphPad Prism 4. 
dValues were found by fitting data to variable slope sigmoidal dose-response curve using 
GraphPad Prism 4. 
 
2.2.4 His-Ste14p specifically interacted with each of the benzophenone-modified 
analogues. To evaluate the ability of His-Ste14p to be labeled with the analogues, we 
performed photoaffinity labeling studies.  Crude membranes expressing His-Ste14p (100 
µg) were incubated with saturating concentrations of each substrate, based on kinetic 
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parameters, and photocrosslinked with UV light (365 nm) for 40 min.56  The crosslinked 
proteins were isolated by neutravidin-agarose capture exploiting the biotin tag on each 
analogue and resolved by SDS-PAGE.  Incubation with AFC served as the negative 
control and membrane preparations from a Δste14 deletion strain served as the control for 
non-specific binding.  The proteins were visualized by enhanced chemiluminescence 
(ECL) following immunoblot analysis.  The signal corresponded to the amount of 
analogue covalently crosslinked to His-Ste14p (Figure 2.2A).  Although His-Ste14p was 
labeled with all of the analogues, it is of note that 2.2 and 2.7a crosslinked to the protein 
less efficiently than the other compounds, which labeled His-Ste14p with approximately 
equal efficiency.  Paradoxically, 2.2 was the best substrate for His-Ste14p enzymatically, 
suggesting that the benzophenone moiety was not in an ideal position in the binding 
pocket for efficient labeling.   
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Figure 2.2. Immumoblot of His-Ste14p (A) or His-hIcmt (B) photocrosslinked with 
benzophenone-containing analogues.  (100 µg) of crude membrane protein were 
incubated with each substrate for 40 min on ice under UV irradiation (365nm).  The 
samples were extracted and re-solubilized in RIPA/10% SDS before enrichment using 
neutravidin-agarose beads.  Proteins were eluted, resolved by 10% SDS-PAGE, and 
visualized as described in Materials and Methods.  A: His-Ste14p: lane 1: 200 µM 2.1, 
lane 2:100 µM 2.2, lane 3:100 µM 2.3, lane 4: 50 µM 2.7b, lane 5: 100 µM 2.7a, lane 6: 
50 µM probe 2.8b, lane 7: 100 µM 2.8a, lane 8: empty vector (Δste14) + 100 µM 2.2.  B: 
His-hIcmt: lane 1: 200 µM 2.1, lane 2: 50 µM 2.2, lane 3: 50 µM 2.3, lane 4: 200 µM 
2.7b, lane 5: 200 µM 2.7a, lane 6: 200 µM 2.8b, lane 7: 200 µM 2.8a, lane 8: empty 
vector (Δste14) + 50 µM 2.2. 
 
2.2.5 Crosslinking experiments of modified substrates exhibit the ability to 
covalently crosslink to His-hIcmt. To determine if His-hIcmt interacted similarly with 
the analogues, crude membrane extracts expressing His-hIcmt (100 µg) were incubated 
with saturating concentrations of each of the photoactive reagents (200 µM).  Samples 
with His-hIcmt expressing membranes incubated with AFC were used as the negative 
control and the membrane preparation from the Δste14 strain was used as a non-specific 
binding control.  All of the samples were crosslinked, enriched, and resolved under the 
same conditions as described above for His-Ste14p.  The amount of each crosslinked 
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protein was determined by immunoblot analysis followed by visualization by ECL 
visualized by ECL (Figure 2.2B).  These data indicated that all of the analogues labeled 
the protein but that the degree of crosslinking varied with the structure of these 
molecules.  Analogue 2.2 crosslinked more efficiently than 2.3, possibly due to the fact 
that 2.3 was a poor substrate for His-hIcmt (Table 2.2).  For the peptide analogues, 2.8a 
labeled His-hIcmt most efficiently followed by 2.7b, 2.8b and 2.7a.  In an effort to 
determine the nature of inhibition demonstrated by the a-factor analogues, we performed 
competition experiments with His-Icmt and 2.8b (200 µM) using increasing 
concentrations of the substrate AFC.  The intensity of photolabeling of His-Icmt with 
2.8b decreased with increasing AFC concentration, suggesting that 2.8b acted as a 
competitive inhibitor (data not shown).  These data suggest that the a-factor analogues 
interact and specifically label residues within the His-Icmt binding pocket 
 
2.3 Conclusion 
It is clear from our data that the labeling efficiencies for the benzophenone-
containing substrate analogues did not correlate completely to the kinetic data.  For 
example, the a-factor peptide that photolabeled His-hIcmt most efficiently was one of the 
poorest inhibitors (Table 2.2 and Figure 2.2B).  Thus, care must be taken not to 
overinterpret crosslinking data.  Since variables such as proximity and orientation of the 
moiety to the residues in the binding pocket affect the ability to efficiently label a 
protein,165,166 the observed variances in crosslinking to His-Ste14p and His-Icmt may be 
due to the position of the photolabel in the substrate binding site rather than a measure of 
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their affinity for the enzymes.  However, these analogues will be invaluable tools in our 
future efforts to define the substrate binding sites for both yeast and human Icmts. 
 
2.4 Materials and Methods 
2.4.1 Materials. All solvents and reagents used for the solid-phase peptide synthesis of 
the photoactivatable peptides were of analytical grade and purchased from Peptides 
International (Louisville, KY), NovaBioChem® (Nohenbrunn, Germany), or Sigma-
Aldrich (St.Louis, MO).  N-acetyl-S-farnesyl-L-cysteine (AFC) was synthesized in the 
Gibbs laboratory (Purdue University) as previously described.167  High performance 
liquid chromatography grade acetonitrile (CH3CN), dichloromethane (DCM), N,N-
dimethylformamide (DMF), trifluoroacetic acid (TFA), and H2O were purchased from 
Fisher Scientific (Springfield, NJ), OmniSolv® (Charlotte, NC), or Sigma-Aldrich. NHS-
PEG4-Biotin was obtained from Thermo Scientific (Waltham, MA). The benzophenone-
containing isoprenoid bromides; C5-meta-Bp-Br (2.5a) or C5-para-Bp-Br (2.5b) [(E)-(3-
((4-bromo-2-methylbut-2-enyloxy)methyl)phenyl)(phenyl)-methanone] and C10-meta-
Bp-Br (2.6a) or C10-para-Bp-Br (2.6b) [(3-(((2E,6E)-8-bromo-2,6-dimethylocta-2,6-
dienyloxy)-methyl)phenyl)-(phenyl)methanone] were prepared as previously 
described.76,162,168-170 HPLC analysis was performed using a Beckman-Coulter system 
employing series 126 pumps and a series 168 detector. Analytical separations were 
performed using a Varian (Microsorb-MV C18, 4.6 x 250 mm) column while preparative 
separations employed either a Phenomenex (Luna C18, 10 x 250 mm) column or a 
Higgins Analytical (Proto 200 C4, 250 X 10 mm) column. ESI-MS analysis was 
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performed using a BioTOFII (Bruker) mass spectrometer. S-adenosyl-L-[14C-methyl] 
methionine ([14C]-SAM) was purchased from Perkin Elmer (Waltham, MA).  α-myc 
monoclonal antibody, goat α-mouse IgG and goat α -rabbit IgG were purchased from 
Invitrogen (Carlsbad, CA).  The α -Ste14 polyclonal antibody was a gift from Dr. S. 
Michaelis (The Johns Hopkins University School of Medicine).  The neutravidin coated 
agarose beads and SuperSignal West Pico enhanced chemiluminescence (ECL) was 
purchased from Pierce (Rockford, IL).   
 
2.4.2 Am-bpBFC BPA Analogue (2.2). The synthesis of the photoactive analogue 2.2 
was performed using an adaptation of a solid phase synthetic method developed for the 
preparation of other AFC analogues.171 Briefly, Fmoc-Cys(S-tBu)-OH was coupled to 2-
chlorotrityl chloride resin using collidine in DMF. was capped with 1% collidine in a 
solution of 90:10 DCM/MeOH. After the S-t-butyl protecting group was removed using 
dithiothreitol (DTT) and diisopropylethyl amine (DIEA), the free thiol was alkylated with 
farnesyl bromide using DIEA as a base. The Fmoc protecting group was then removed 
with 20% piperidine in DMF followed by coupling with Fmoc-BPA-OH with HOBt, 
HBTU, and DIEA in DMF. The Fmoc protecting group was then removed with 20% 
piperdine in DMF followed by coupling with 2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic 
acid with HOBt, HBTU, and DIEA in DMF. Deprotection with 20% piperidine in DMF 
followed by coupling of D-biotin with HOBt, HBTU, and DIEA in DMF and subsequent 
resin-cleavage with 0.5% TFA in DCM yielded the desired analogue, which was purified 
by C18 RP-HPLC. ESI-MS: calcd for for C50H69N5O9S2 [M+H]
+: 948.45, found: 946.30  
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2.4.3 F-bpBFC AFC Analogue (2.3). The synthesis of the photoactive analogue 2.3 was 
performed using an adaptation of a solid phase synthetic method developed for the 
preparation of other AFC analogues as noted above and was based on a previously 
described photoaffinity analogue of AFC.162  Briefly, Fmoc-Cys(S-tBu)-OH was coupled 
to 2-chlorotrityl chloride resin using collidine in DMF. The resin was capped with 1% 
collidine in a solution of 90:10 DCM/MeOH. After the S-t-butyl protecting group was 
removed using dithiothreitol (DTT) and diisopropylethyl amine (DIEA), the photoactive 
isoprenoid (3-(((2E,6E)-8-bromo-2,6-dimethylocta-2,6-dien-1-yl)oxy)phenyl)-
(phenyl)methanone172 was coupled with the free thiol using DIEA as a base. The Fmoc 
protecting group was then removed with 20% piperdine in DMF followed by coupling 
with 2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid with HOBt, HBTU, and DIEA in 
DMF. Deprotection with 20% piperdine in DMF followed by coupling of D-biotin with 
HOBt, HBTU, and DIEA in DMF and subsequent resin-cleavage with 0.5% TFA in 
DCM yielded the desired analogue which was purified by C18 RP-HPLC. 
1H NMR 
(CDCl3, 500 MHz) 1.43 (m, 2 H), 1.70 (m, 9 H), 2.08 (t, 2 H), 2.22 (m, 4 H), 2.70 (d, 2 
H), 2.88 (m, 2 H), 3.00 (dd, 1 H), 3.18 (m, 3 H), 3.33 (m, 1 H), 3.61 (m, 4 H), 3.71 (s, 2 
H), 3.97 (d, 1 H), 4.12 (d, 1 H), 4.35 (m, 1 H), 4.42 (s, 2 H), 4.53 (m, 1 H), 4.82 (qt, 1 H), 
5.20 (t, 1 H), 5.51 (t, 2 H), 6.71 (s, 1 H), 7.03 (s, 1 H), 7.14 (d, 1 H), 7.34 (m, 3 H), 7.47 
(t, 2 H), 7.52 (d, 1 H), 7.58 (t, 1 H), 7.79 (d, 2 H); 13C NMR (CDCl3, 500 MHz) 13.92, 
16.13, 25.51, 26.12, 27.72, 27.96, 29.77, 33.23, 35.71, 38.99, 40.40, 51.19, 55.34, 60.31, 
62.13, 69.66, 69.78, 70.20, 71.03, 74.15, 115.49, 119.61, 119.94, 122.76, 128.23, 128.63, 
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129.16, 130.01, 130.97, 132.40, 137.59, 138.76, 139.59, 158.89, 164.78, 170.15, 173.64, 
174.57; ESI-MS: calcd for for C42H56N4O9S2Na [M+Na]
+: 847.3386, found: 847.3396. 
 
 
2.4.4 Biotin-Peg4-YIIKGVFWDPAC (2.4). Peptide synthesis was carried out using an 
automated solid-phase peptide synthesizer (PS3, Protein Technologies Inc, Memphis, 
TN) employing standard Fmoc/HCTU based chemistry. Synthesis began on preloaded 
Fmoc-Cys(Trt)- Wang resin (0.25 mmol) and the peptide chain was elongated using 
HCTU/N-Methylmorpholine-catalyzed, single coupling steps with 4 equivalents of both 
protected amino acids and HTCU for 30 min. Following complete chain elongation, the 
N-terminal amine was deprotected with 10% piperidine in DMF (v/v) and the presence of 
the resulting free amine was confirmed by ninhydrin analysis.173 The resin containing the 
peptide was washed with DCM, dried in vacuo overnight, weighed, and divided into three 
portions for further synthesis on a reduced scale. Using 83.0 µmol of peptide, the free 
amino terminus was biotinylated in DMF (5 mL) with NHS-PEG4-Biotin (49 mg, 83 
µmol,) catalyzed by DIEA (14 µL, 8.3 µmol) for 16 h. After acylation, the resin bound 
peptide was washed thoroughly with DCM and dried in vacuo for 4 h.  The peptide was 
cleaved from the resin along with simultaneous side chain deprotection by treatment with 
reagent K containing TFA (10 mL), crystalline phenol (0.5 g), 1,2-ethanedithiol (0.25 
mL), thioanisole (0.5 mL), and H2O (0.5 mL) for 2 h at room temperature.  The released 
peptide was collected and combined with TFA washes of the resin before precipitation of 
the peptide in chilled Et2O (100 mL). The crude solid peptide was collected by 
centrifugation, the supernatant was removed, and the resulting pellet was washed 2 times 
  51 
with cold Et2O (50 mL) repeating the centrifugation and supernatant removal steps each 
time.  The crude peptide was purified using a semipreparative C18 RP-HPLC column with 
detection at 214 nm and eluted with a gradient of Solvent A (H20/0.1% TFA, v/v) and 
Solvent B (CH3CN/0.1% TFA, v/v). The crude peptide (150 mg) was dissolved in a 
DMF/H2O solution (1:5 v/v, 25 mL), applied to the column equilibrated in Solvent A, 
and washed with 15% Solvent B for 15 min. The peptide was eluted using a linear 
gradient of (15-55% Solvent B over 1.5 h at a flow-rate of 5 mL/min). Fractions collected 
were analyzed using an analytical C18 RP-HPLC column employing a linear gradient (0-
100% Solvent B over 60 min at a flow-rate of 1 mL/min) and detected at 214 nm.  
Fractions containing peptide product of at least 90% purity were pooled and concentrated 
by lyophilization to yield 55 mg (37% yield) of a white solid. A small amount  (< 1mg) 
of the resulting purified peptide was dissolved in 10 µl of 0.1% TFA/CH3CN and diluted 
1:50 in a mixture of CH3CN/H2O (1:1 v/v) prior to MS analysis. MS was performed 
using a 50 µL injection and collecting 3000 scans. ESI-MS: calcd [M+2H]+2: 942.97, 
found 943.00. 
 
2.4.5 Biotin-Peg4-YIIKGVFWDPAC(C5-meta-Bp) (2.7a). Biotin-Peg4-
YIIKGVFWDPAC (2.4) (10 mg, 5.3 µmol) was dissolved in DMF/n-Butanol/H2O 
containing 0.10% TFA (3:1:1 v/v/v, 6 mL). To purify the C5-meta-Bp-Br (2.5a) [(E)-(3-
((4-bromo-2-methylbut-2-enyloxy)methyl) phenyl) (phenyl)methanone]76,168 isoprenoid 
before reaction, the bromide (8.6 mg, 24 μmol) was dissolved in 0.50 mL of DMF and 
loaded onto a C18 SepPack® column that had been equilibrated with Solvent A 
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containing 5% Solvent B. The column was washed with additional Solvent A containing 
5% Solvent B (5 mL), followed by Solvent A containing 30% Solvent B (10 mL). The 
purified bromide, C5-meta-Bp-Br (5a), was then eluted from the column with 3.0 mL 
DMF directly into the reaction flask that contained the dissolved peptide. 
Zn(OAc)2·2H2O (5.4 mg, 25 μmol) was then added to initiate the alkylation reaction.  
After 2 h at room temperature, 2-mercaptoethanol (100 µL, 1.4 mmol) was added to 
quench the reaction, which was then allowed to stir for an additional 4 h. The reaction 
was analyzed by analytical RP-HPLC, purified by semipreparative C18 RP-HPLC, and 
identified via ESI-TOF MS. This reaction yielded 2.5 mg (22 %) of the desired alkylated 
peptide (2.7a). Purity by HPLC: 91 %, ESI-MS: calcd [M+2H]+2: 1082.32, found 
1082.36. 
 
2.4.6 Biotin-Peg4-YIIKGVFWDPAC(C5-para-Bp) (2.7b). Biotin-Peg4-
YIIKGVFWDPAC (2.4) (10 mg, 5.3 µmol) was alkylated with isoprenoid bromide C5-
para-Bp-Br (2.5b), [(E)-(4-((4-bromo-2-methylbut-2-enyloxy)methyl) phenyl) 
(phenyl)methanone]76,168 (8.6 mg, 24 μmol) using the reaction conditions described above 
for the preparation of 2.7a. This reaction yielded 2.7 mg (24 %) of the desired alkylated 
peptide (2.7b). Purity by HPLC: 91 %, ESI-MS: calcd [M+2H]+2: 1082.32, found 
1082.34 
 
2.4.7 Biotin-Peg4-YIIKGVFWDPAC(C10-meta-Bp) (2.8a). Biotin-Peg4-
YIIKGVFWDPAC (2.4) (10 mg, 5.3 µmol) was alkylated with C10-meta-Bp-Br (2.6a), 
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[(3-(((2E,6E)-8-bromo-2,6-dimethylocta-2,6-dienyloxy)methyl)phenyl)-(phenyl)meth-
anone]162,169,170 (10.2 mg, 24 μmol) using the reaction conditions described above for the 
preparation of 2.7a. To separate the product from unreacted bromide (2.6a), the peptide 
was suspended in EtOAc (5 mL), recovered by centrifugation, and purified by RP-HPLC 
(C4 column). This reaction yielded 3.2 mg (27 %) of the desired alkylated peptide (2.8a). 
Purity by HPLC: 95%, ESI-MS: calcd [M+2H]+2: 1116.57, found 1116.58.  
 
2.4.8 Biotin-Peg4-YIIKGVFWDPAC(C10-para-Bp) (2.8b). Biotin-Peg4-
YIIKGVFWDPAC (2.4) (10 mg, 5.3 µmol) was alkylated with C10-para-Bp-Br (2.6b), 
[(4-(((2E,6E)-8-bromo-2,6-dimethylocta-2,6-dienyloxy)methyl)phenyl)-(phenyl)meth-
anone]162,169,170 (10.2 mg, 24 μmol) using the reaction conditions described above for the 
preparation of 2.7a.  Purification of the alkylated product was performed as described for 
2.8a. This reaction yielded 2.9 mg (25 %) of the desired alkylated peptide (2.8b). Purity 
by HPLC: 94 %, ESI-MS: calcd [M+2H]+2: 1116.57, found 1116.56. 
 
2.4.9 Yeast strains and crude membrane preparations from yeast cells. His10myc3N-
Ste14p (His-Ste14p) and His10myc3N-hIcmt (His-hIcmt) yeast strains were cloned and 
expressed as previously described.88,130  Crude membranes were prepared as described 
previously with minor modifications.88  After centrifugation at 100,000 x g, the 
membrane pellet was resuspended in 10 mM Tris-HCl, pH 7.5, aliquoted, flash frozen in 
liquid N2 and stored at -80ºC.   
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2.4.10 In Vitro Methyltransferase Vapor Diffusion Assay.  Reactions were performed 
as described previously.174  All inhibition studies were completed as detailed earlier.130 
Crude membranes preparations derived from a Δste14 strain transformed with an empty 
vector were used as the negative control for these experiments. 
 
2.4.11 Photocrosslinking and neutravidin-agarose pull-down assays. 
Photocrosslinking assays were performed as described previously, with minor 
modifications.56  Briefly, 100 µg of crude membrane preparation expressing either His-
Ste14p or His-hIcmt in 100 mM Tris-HCl, pH 7.5 were incubated in the presence of 
saturating concentrations of the photoaffinity analogues and incubated at 4ºC for 10 min.  
After incubation, the samples were irradiated with UV light (365 nm) in 96-well plates 
for 40 min on ice.  Following photocrosslinking, unreacted analogue was removed by 
chloroform/methanol extraction.175   The resulting protein samples were solubilized in 
400 µL of radioimmumoprecipitation assay (RIPA) buffer (25mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1% triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecylsulfate) 
/10% SDS and incubated with 50 µL of a 50% neutravidin/RIPA bead slurry for 2 h at 
room temperature.  Following incubation, the beads were centrifuged at 13,000 x g for 1 
min and washed three times with RIPA/10% SDS.  The crosslinked protein was eluted 
from the neutravidin beads by the addition of 50 µL of 2X SDS sample buffer (0.5 M 
Tris-HCl, pH 6.8, 30% sucrose (w/v), 10% sodium dodecylsulfate (w/v), 3.5 M 2-
mercaptoethanol and 0.1% bromophenol blue (w/v)).  The His-Ste14p samples were 
heated for 30 min at 65ºC and the His-hIcmt samples were incubated at room temperature 
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overnight.  The proteins were separated by 10% SDS-PAGE and transferred to 
nitrocellulose (0.22 µm).  The nitrocellulose membrane was blocked at room temperature 
for 2 h in 20% (w/v) non-fat dry milk in phosphate-buffered saline with Tween-20 (137 
mM NaCl, 2.7 mM KCl, 4 mM Na2HPO4, 1.8 mM KH2PO4 and 0.05% (v/v) Tween-20, 
pH 7.4) (PBST).  The blocked membrane was then incubated for 2 h at room temperature 
with primary antibody (1:1,000 α-Ste14p) or (1: 10,000 α-myc) in 5% (w/v) non-fat dry 
milk in PBST for His-Ste14p or His-hIcmt, respectively.  The membrane was washed in 
PBST three times and then incubated for 1 h at room temperature with secondary 
antibody (1:10,000 goat α-rabbit IgG-HRP for α-Ste14p or 1:4000 goat α-mouse IgG-
HRP for α-myc) in 5% (w/v) dry milk in PBST.  The membrane was washed three times 
with PBST and the proteins were visualized using ECL. 
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2.5 Supporting Information 
2.5.1 Characterization of Biotin-Peg4-YIIKGVFWDPAC (2.4) 
 
 
Figure 2.3. Mass spectrum and analytical RP-HPLC chromatogram for peptide 2.4. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
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2.5.2 Characterization of Biotin-Peg4-YIIKGVFWDPAC(C5-meta-Bp) (2.7a) 
 
Figure 2.4. Mass spectrum and analytical RP-HPLC chromatogram for peptide 2.7a. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
 
 
 
 
 
 
 
 
 
  58 
2.5.3 Characterization of Biotin-Peg4-YIIKGVFWDPAC(C5-para-Bp) (2.7b) 
 
 
Figure 2.5. Mass spectrum and analytical RP-HPLC chromatogram for peptide 2.7b. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
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2.5.4 Characterization of Biotin-Peg4-YIIKGVFWDPAC(C10-meta-Bp) (2.8a) 
 
Figure 2.6. Mass spectrum and analytical RP-HPLC chromatogram for peptide 2.8a. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
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2.5.5 Characterization of Biotin-Peg4-YIIKGVFWDPAC(C10-meta-Bp) (2.8b) 
 
Figure 2.7. Mass spectrum and analytical RP-HPLC chromatogram for peptide 2.8b. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
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2.5.6 Characterization of Am-bpBFC BPA Analogue (2.2) 
 
Figure 2.8. Mass spectrum of compound 2.2.  
2.5.7 Characterization F-bpBFC AFC Analogue (2.3) 
 
Figure 2.9. Mass spectrum of compound 2.3. 
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Chapter 3: A Diazirine-Containing Photoactivatable Isoprenoid: Synthesis and 
Application in Studies with Isoprenylcysteine Carboxyl Methyltransferase 
 
Photoaffinity labeling is a useful technique employed to identify protein-ligand and 
protein-protein noncovalent interactions.  Photolabeling experiments have been 
particularly informative for probing membrane-bound proteins where structural 
information is difficult to obtain.  The most widely used classes of photoactive 
functionalities include aryl azides, diazocarbonyls, diazirines and benzophenones.  
Diazirines are intrinsically smaller than benzophenones and generate carbenes upon 
photolysis that react with a broader range of amino acid side chains compared with the 
benzophenone-derived diradical; this makes diazirines potentially more general 
photoaffinity labeling agents.  In this report, we describe the development and application 
of a new isoprenoid analogue containing a diazirine moiety that was prepared in six steps 
and incorporated into an a-factor-derived peptide produced via solid phase synthesis. In 
addition to the diazirine moiety, fluorescein and biotin groups were also incorporated into 
the peptide to aid in the detection and enrichment of photocrosslinked products.  This 
multifuctional diazirine-containing peptide was a substrate for Ste14p, the yeast homolog 
of the potential anticancer target Icmt, with KM (6.6 µM) and Vmax (947 nmol/min/mg) 
values comparable or better than a-factor peptides functionalized with benzophenone-
based isoprenoids.  Photocrosslinking experiments demonstrated that the diazirine probe 
photocrosslinked to Ste14p with observably higher efficiency than benzophenone-
containing a-factor peptides.   
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3.1 Introduction 
 
Photoaffinity labeling is a useful technique employed to identify noncovalent 
interactions between molecules, including protein-ligand and protein-protein complexes.  
The utility of photoreactive probes to study such interactions is highly dependent upon 
three criteria, including how closely the photolabeling moiety mimics the native 
structure, what type of reactive intermediates are formed, and the spatial relationship 
between the two interacting molecules.  The most widely used classes of photoactive 
functionality include aryl azides, diazocarbonyls and diazirines, and benzophenones, 
which give rise to nitrenes, carbenes and diradicals, respectively, upon photolysis.176  
Prenylated proteins are a class of membrane-associated polypeptides that employ 
a farnesyl, or geranylgeranyl isoprenoid (sometimes two in the latter case) to anchor the 
proteins into membranes.  A three-step process consisting of prenylation, proteolysis and 
carboxymethylation is frequently required to produce the final mature active proteins.  
Prenylation is performed by farnesyl- or geranylgeranyltransferases and proteolysis is 
carried out by Rce1 or Ste24 while carboxymethylation is catalyzed by Icmt, a SAM-
dependent enzyme.101  Attachment of the hydrophobic isoprenoid causes membrane 
association,
4 and is essential for membrane-associated functions involving protein-protein 
interactions,11 signal transduction,25,174 and cellular homeostasis regulation.88   Due to the 
fact that Ras prenylation is required for its proper cellular localization and function,69 
numerous human clinical trials have been conducted to inhibit this critical signal 
transduction event that is particularly relevant to cancer.177,178  Importantly, an area of 
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growing interest is developing inhibitors for the other enzymes in the processing pathway 
including Icmt, which is localized to the membrane of the endoplasmic reticulum. 
Photoactive analogues of farnesyl diphosphate have been used extensively to 
study the interactions between soluble proteins and their ligands, including isoprenoids 
and prenyltransferases.  This class of photoprobes includes molecules containing aryl 
azides,179 diazoesters,180-183 and benzophenones,77,168,169,184,185 with the latter being the 
most commonly employed.  Peptides containing these photoactive isoprenoids have also 
been used to study the interactions between prenylated proteins and their cognate 
receptors.162 Recently, we used peptides functionalized with benzophenone-containing 
isoprenoids in photocrosslinking experiments with membrane-associated proteins that 
also recognize isoprene moieties, including the Ras coverting enzyme Rce1 and the 
isoprenylcysteine carboxyl methyltransferase, Icmt, two enzymes involved in the CaaX 
protein posttranslational processing pathway.56,154  Although we showed that those 
enzymes could be successfully photolabeled, the yield of crosslinking was not sufficient 
to generate quantities of material adequate for mass spectrometric sequencing.  In 
addition, the benzophenone-containing peptides were generally poorer substrates than 
those incorporating a natural farnesyl group, likely due to the larger size of the 
benzophenone moiety.  To address this size question and potentially increase the yield of 
crosslinked protein, we wanted to explore the use of smaller isoprene unit surrogates.  
While a number of diazoester-containing isoprenoid analogues have been previously 
reported,168,180,181,185 their synthesis is complicated by the need to use phosgene gas and 
trifluorodiazoethane.186 In contrast, diazirines are much simpler to prepare from ketones.  
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Since diazirines are intrinsically smaller than benzophenones and more closely 
approximate the size and shape of an isoprene unit, they should be effective isoprenoid 
mimics; moreover, because they generate carbenes upon photolysis, they also have the 
potential to react with a wider range of amino acid side chains thereby, increasing 
photocrosslinking efficiency.  
Herein, we describe the synthesis of a diazirine-containing isoprenoid unit (3.1) 
(Figure 3.1) and its incorporation into a biotinylated and fluorescently labeled a-factor 
peptide analogue (3.16) (Figure 3.2); the dodecapeptide, a-factor, is a naturally occuring 
farnesylated peptide found in yeast and known to be generated via methylation by 
Icmt.187  The ability of this multifunctional photoactive peptide to bind and serve as a 
substrate for Icmt was then evaluated using Ste14p, the Icmt from the yeast S. cerevisiae 
as a model enzyme. The diazirine-containing a-factor analogue demonstrated an 
increased Vmax and lower KM relative to benzophenone-containing probes.  Crosslinking 
studies showed that the efficiency of photolabeling achieved with the diazirine-based 
probe was greater than that of benzophenone-containing probes.  In contrast to previous 
work where antibody-based methods were necessary for detection of crosslinked protein, 
in-gel fluorescence via a fluorophore incorporated into the peptide was used here to 
successfully detect the crosslinked purified enzyme.  These results suggest that such 
multifunctional diazirine-containing peptides should be useful for identifying active-site 
residues in Icmts and potentially other enzymes involved in the processing of prenylated 
proteins. 
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Figure 3.1. Photoactivatable isoprenoid analogues: Left image; Farnesol, Diazirine 3.1, 
Benzophenone 3.2, DATFP 3.3. Right image: Space filling models of the isoprenoid 
analogues. Hydrogen atoms omitted for clarity. Color Scheme: Carbon (green), Oxygen 
(red), Nitrogen (blue) and Fluorine (white). Spheres are shown at 0.6 VDW radii for 
clarity. 
 
3.2 Results and Discussion  
3.2.1 Design and synthesis of diazirine containing isoprenoid.  To prepare the desired 
multifunctional a-factor peptide for in vitro kinetic and photocrosslinking analyses of 
Ste14p, the initial strategy was to first design an isoprenoid moiety containing a diazirine 
group.  Compound 3.1 was selected as the target based on the overall similarity in size of 
the analogue compared with farnesyl diphosphate (FPP).  Comparison of 3.1 with 
benzophenone- and DATFP-containing FPP analogues (3.2 and 3.3) reveals that 3.1 is 
closest in size to FPP (Figure 3.1).  While potentially less stable than ether-linked 
analogues such as 3.2, the ester analogue 3.1 was chosen for ease of synthesis.  A 
convergent strategy was used to prepare 3.1 based on previously published routes for the 
production of the isoprenoid building block, 3.9,185 and the diazirine derivative pentanoic 
acid 3.6 (Scheme 3.1).188  Coupling of 3.9 and 3.6 in the presence of DIC and DMAP 
afforded the ester (3.10).  Removal of the THP protecting group was performed with 
PPTS in EtOH, followed by conversion of the free alcohol, 3.11, to the corresponding 
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bromide, 3.12, by reaction with CBr4 and PPh3. Purification of the bromide was carried 
out using a small reversed-phase cartridge to minimize decomposition of the allylic 
bromide on silica gel.  The reversed-phase purification also appears to remove colored 
impurities that interfere with the subsequent peptide alkylation; while this process does 
not remove unreacted alcohol starting material, that compound does not interfere with the 
subsequent alkylation chemistry. 
 
Scheme 3.1. Synthesis of a diazirine-containing analogue of a farnesyl group 
 
 
3.2.2 Synthesis of prenylated a-factor.  We incorporated the isoprenoid analogue 3.12 
into a peptide based on the structure of the farnesylated dodecapeptide mating pheromone 
a-factor, an in vivo substrate for Ste14p that is produced via the same three step process 
as larger prenylated proteins (Scheme 3.2).187  This peptide (3.16) contains a free C-
terminal carboxylate to serve as the methyl acceptor in the enzymatic reaction. 
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Scheme 3.2. Synthesis of prenylated a-factor precursor peptide 3.16 
 
 
Solid phase peptide synthesis was used to construct peptide 3.13 utilizing standard 
Fmoc/HCTU coupling conditions.  An additional N-terminal lysine residue was added to 
the a-factor sequence to provide an additional handle (via the side chain) for fluorophore 
attachment.  After the peptide was elongated, its free N-terminus was biotinylated to yield 
3.14.  Biotin-Peg4-NHS was chosen for installation of the biotin label due to its efficient 
reaction kinetics and inexpensive cost.  After specific on-resin cleavage of the Dde 
protecting group from the side chain ε-amino group of the N-terminal lysine with a 10% 
hydrazine/DMF solution, the resulting free amine was acylated with 5-
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carboxylfluorescein succinimidyl ester (5-Fam) in the presence of DIEA to give the 
fluorescently labeled peptide on resin.  5-Fam was chosen as the fluorescent reporter 
because of its reactivity with primary amines via the succinimidyl ester and its 
convenient emission wavelength that makes it easy to detect using most commercially 
available fluorescence scanners.  Cleavage from the resin and acidic deprotection was 
carried out simultaneously by treatment with Reagent K to afford an orange peptide 3.15, 
with a C-terminal cysteine bearing a free thiol.  It is interesting to note that previous 
reports have noted that some epimerization of C-terminal cysteine residues can occur 
when Cys-functionalized Wang resin and Reagent K cleavage conditions are used;189 
however, after RP-HPLC purification, no evidence for epimerization was observed.  
MS/MS analysis (see Supporting Information) revealed a large ensemble of b-type and y-
type fragments consistent with the proposed structure for 3.15. Alkylation of the free 
thiol was performed using the bromide 3.12 (1.5 equiv) in the presence of Zn(OAc)2 (0.1 
equiv) in acidic DMF to yield the prenylated peptide 3.16 whose identity was determined 
via ESI-MS and purity confirmed by analytical RP-HPLC (see Figure 3.16).  As was 
observed for 3.15, MS/MS analysis of 3.16 (see Figure 3.15 and 3.17) showed the 
presence of a variety of b-type and y-type fragments consistent with the proposed 
structure for 3.16. Fragmentation via loss of the farnesyl group was also observed as has 
been previously reported for prenylated peptides.56,190  The farnesylated control peptide 
3.17 and benzophenone-containing peptide 3.19 were prepared by a similar procedure 
while 3.18 was prepared as previously described.  
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Figure 3.2. a-factor-based peptides for the in vitro study of Icmt. 
 
3.2.3 Diazirine-modified a-factor is a substrate for His-Ste14p.  To assess the ability 
of 3.16 to act as a substrate for Icmt, we used a recombinant form of yeast Icmt (Ste14p) 
that incorporates both a His10 tag for purification and a triply iterated myc tag to facilitate 
detection by immunoblot analysis (His-Ste14p).88  The ability of 3.16 to act as a substrate 
for His-Ste14p was determined using an in vitro methyltransferase vapor diffusion assay. 
The KM and Vmax values (Table 3.1) for 3.16 were measured using crude membrane 
fractions prepared from yeast expressing His-Ste14p using N-acetyl-S-farnesyl-L-
cysteine (AFC) as a positive control.  Comparison of the kinetic parameters obtained for 
the diazirine 3.16 and the benzophenone-containing analogues 3.18154 (previously 
reported) and 3.19 reveal that of those three probes containing photoactive isoprenoids, 
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the diazirine manifests the highest Vmax value and lowest KM value making it the most 
efficient substrate.  Although the Vmax for 3.16 was lower than that for a farnesylated 
analogue of a-factor precursor, 3.17, 3.16 demonstrated a lower KM value making the 
catalytic efficiency of 3.16 (Vmax/KM = 143) comparable to that of 3.17 (Vmax/KM = 157).  
Both of these values are higher than those obtained for benzophenone-based probes 3.18 
and 3.19 (Vmax/KM = 52 and 7.0, respectively) suggesting that the smaller diazirine 
moiety is a superior mimic of an isoprene unit. 
 
Table 3.1. In vitro reaction kinetics for a-factor peptides methylated by His-Ste14p. 
 
Compound Vmaxa 
(pmol•min-
1 •mg-1) 
KM(app)b 
(µM) 
 
Vmax/KMa,b 
(pmol•min-1•mg-
1•µM-1) 
 
AFC154 870 ± 15 15.9 ± 0.9 54  
3.16 947 ± 4 6.6 ± 0.2 143 
3.17 1919 ± 30 12.2 ± 0.1 157 
3.18154 762 ± 28 14.6 ± 0.3 52 
3.19  217 ± 3 27.8 ± 1 7.0 
     a Reported as pmol methyl groups transferred to substrate. 
     b Since these experiments were performed at a single concentration of SAM  
        and the biphasic nature of the membrane suspension makes the concentration  
     of the peptide substrate unknown (due to partitioning into the lipid membranes),  
     these experiments provide only apparent values for KM. 
 
 
 
3.2.4 His-Ste14p crosslinking with the diazirine-modified a-factor.  The ability of His-
Ste14p to be covalently modified with the diazirine- and benzophenone-modified a-factor 
peptides was assessed via photoaffinity labeling studies (Figure 3.3).  Purified His-Ste14p 
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(0.25 μg) was incubated with 50 µM of each peptide, irradiated with UV light (365 nm) 
for 30 min on ice and the crosslinked material was resolved by SDS-PAGE.  The identity 
of the Ste14p-a-factor conjugate was determined by three different methods: detection of 
the biotin moiety with NeutrAvidin HRP (Figure 3.3B); detection of His-Ste14 using an 
α-Ste14p antibody (Figure 3.3C); and ultimately through direct fluorescence detection of 
the 5-Fam fluorophore (Figure 3.3A).   
 
 
Figure 3.3. Analysis of crosslinking reactions containing purified His-Ste14p and 
different photoactive probes. (A) Fluorescent imaging; (B) immunoblot analysis with 
NeutrAvidin HRP; (C) immunoblot analysis with α-Ste14. Experiments were performed 
with 3.16, 3.18 and 3.19.  For this experiment, purified His-Ste14p (0.25 µg) was 
incubated with the probes indicated (50 µM) and irradiated on ice for 30 min followed by 
fractionation via SDS-PAGE. The resulting gel was visualized using (A) a fluorescence 
scanner or transferred to a nitrocellulose membrane and visualized using (B) NeutrAvidin 
HRP or (C) an α-Ste14 antibody. The data shown is from one of three replicates of this 
experiment. 
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Following separation of the reaction mixture by SDS-PAGE, immunoblot analysis 
with an α-Ste14p antibody demonstrated that His-Ste14p was present in each lane at the 
expected molecular weight (~36 kDa) (Figure 3.3C).  UV-dependent photocrosslinking of 
the probes to His-Ste14p was visualized using NeutrAvidin HRP.  Biotinylated His-
Ste14p was only present in samples subjected to UV light (Figure 3.3B, lanes 3, 5 and 7).  
The strongest signal was obtained with the diazirine-containing peptide 3.16, suggesting 
that this compound photolabeled His-Ste14p with the highest efficiency.  Additionally, 
UV-dependent fluorescent labeling was also observed using 3.16 and 3.19 (Figure 3.3A, 
lanes 5 and 7).  Probe 3.18 does not contain a 5-Fam moiety and hence could not be 
visualized in a similar manner.  Furthermore, the increased labeling efficiency with 3.16 
observed with NeutrAvidin HRP detection was recapitulated with the fluorescence data.  
This increased labeling, that can be readily visualized via direct fluorescence scanning of 
the gel, suggests that a larger number of enzyme molecules are crosslinked.  These results 
are in contrast to those previously reported for Rce1 with benzophenone-based probes56,78 
and bode well for future experiments that will be aimed at identifying the site(s) of 
crosslinking.  Moreover, the experimental simplicity of following the crosslinking 
reactions via fluorescence scanning in lieu of more complicated western blotting or 
NeutrAvidin HRP detection should greatly facilitate optimization of experimental 
conditions.  Overall, the presence of both a biotin for enrichment and a fluorescent label 
for direct visualization should make these new probes particularly useful.  In addition to 
the direct analysis of crosslinking reactions shown in Figure 3.3, pull-down experiments 
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with 3.16 and 3.19 were also performed (see Figure 3.20) showing that the biotin handle 
could be used to recover the crosslinked products from the reaction mixture.   
Comparing the efficiency of crosslinking of His-Ste14p to 3.16, 3.18 or 3.19, it is 
clear that the diazirine probe is the more efficient photoaffinity labeling reagent.  Since 
the crosslinkling experiments were performed with a concentration of each probe that 
was ~2 – 8 times greater than their individual KM values, the increase in labeling is likely 
not attributable to differences in affinities between the different probes.  Rather, it must 
be due either to the increased reactivity of the carbene intermediate generated from 
diazirine 3.16 compared to the diradical intermediate produced from the benzophenone 
photophores of 3.18 and 3.19 or greater proximity or more favorable geometry of the 
peptide in the active site.  Currently, additional diazirine- and benzophenone-containing 
probes are being prepared and we will determine whether the former types always yield 
higher levels of crosslinking.  
Finally, in addition to confirming the formation of the crosslinked protein, the 
specificity of the photolabeling of His-Ste14p with 3.16 was examined in a competition 
experiment (Figure 3.4).  A biotinylated a-factor precursor peptide, 3.17, was chosen as a 
competitor, as it was a substrate for His-Ste14p (Table 3.1) and closely mimicked the 
structure of 3.16 (Figure 3.2).  Crude membranes prepared from a Δste14 deletion strain 
overexpressing His-Ste14p were incubated with 3.16 in the presence or absence of 
increasing concentrations of the competitor 3.17 in the presence of UV light (Figure 3.4).  
Following incubation, the samples were enriched for biotinylated proteins via 
neutravidin-agarose beads and the proteins were separated by SDS-PAGE.  Immunoblot 
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analysis with an α-Ste14p antibody revealed that the amount of crosslinked His-Ste14p 
decreased as the concentration of the competitor, 3.17, was increased from 5 µM (Figure 
3.4, lane 3) to 200 µM (Figure 3.4, lane 8).  These data suggest that 3.16 is labeling the 
substrate binding site of His-Ste14p.   
 
 
Figure 3.4. Competition of photolabeling of His-Ste14p by 3.16 using a biotinylated a-
factor precursor peptide 3.17.  For this experiment, His-Ste14p crude membrane protein 
(100 µg) was mixed with 3.16 and 3.17 at the concentrations indicated and irradiated on 
ice for 30 min followed by enrichment with neutravidin-agarose beads.  The samples are 
then eluted and resolved via SDS-PAGE. The resulting gel was blotted to a nitrocellulose 
membrane and visualized using an α-Ste14 antibody. The data shown is from one of two 
replicates of this experiment. 
 
3.3 Conclusion 
Herein, we have described the development and application of a new class of 
isoprenoid analogue containing a photoexcitable diazirine moiety. The photoactive 
farnesyl mimic was prepared in 6 steps and incorporated into a multifunctional peptide 
produced via solid phase synthesis.  Kinetic analyses with His-Ste14p showed that the 
diazirine-containing peptide was an efficient substrate for the enzyme compared to 
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similar peptides functionalized with benzophenone-based isoprenoids.  The diazirine-
based probe crosslinked to His-Ste14p upon UV irradiation with an observable increase 
in efficiency compared to benzophenone-containing peptides.  Finally, the incorporation 
and use of this diazirine-modified isoprenoid in a peptide probe equipped with a 
fluorophore greatly simplified the detection of crosslinked products.  The greater yield of 
photocrosslinked His-Ste14p coupled with the ease of analysis obtained with this new 
class of isoprenoid mimics should facilitate the identification of active site residues in 
His-Ste14p.   Such experiments are currently underway for this important membrane 
protein target.  Given their improved features compared with other types of photoactive 
isoprenoid probes, this new class of analogues should be useful for a variety of studies of 
enzymes that act on terpene-derived molecules. 
 
3.4 Materials and Methods 
3.4.1 General. All solvents and reagents used for the synthesis of the diazirine isoprenoid 
analogue and solid-phase peptide synthesis of the photoactivatable peptides were of 
analytical grade and purchased from Peptides International (Louisville, KY), 
NovaBioChem® (Nohenbrunn, Germany), or Sigma-Aldrich (St.Louis, MO). NHS-
PEG4-Biotin was obtained from Thermo Scientific. The benzophenone-containing 
isoprenoid bromides; C10-meta-Bp-Br (3.2) was prepared as previously 
described.77,168,169,185 HR-ESI-MS analysis was performed using a Bio-TOF-II (Bruker) 
mass spectrometer 
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3.4.2 Synthesis of compound 3.5: 3-(3-methyldiaziridin-3-yl)propanoic acid. 
Levulinic acid 3.4 (1.61 g, 13.8 mmol, 1 eq) was dissolved in 7 N NH3 in CH3OH (13.5 
mL, 91.0 mmol, 7 eq). The resulting solution was stirred under N2 on ice for 3 h. A 
solution of hydrolxylamine-O-sulfonic acid (1.80 g, 15.9 mmol, 1.2 eq) in CH3OH (12 
mL) was added dropwise at a rate of 1 s-1. The reaction mixture was stirred for 20 h and 
allowed to warm to rt. N2 was bubbled through the solution for 1 h to remove NH3 gas. 
Vacuum filtration and concentration resulted in a yellow oil that was used in the next step 
without purification. 
 
3.4.3 Synthesis of coumpound 3.6: 3-(3-methyl-3H-diazirin-3-yl)propanoic acid. The 
diaziridine 3.5 was redissolved in CH3OH (10 mL) and stirred on ice for 5 min in a tin 
foil covered flask. Triethylamine (3.00 mL, 21.5 mmol) was added and allowed to stir for 
5 min. Slowly, chips of I2 were added until the solution remained a brown-red color for 
longer than 5 min after the last addition. The reaction solution was diluted with EtOAc, 
washed with 1 M HCl, and with aqueous 10% sodium thiosulfate until the organic layer 
was colorless. The aqueous layer was further extracted with EtOAc (2x 20 ml). The 
organic layers were combined, dried over MgSO4, and concentrated to afford the 
diazirine acid 3.5 as a brown residue (0.785 g, 45%). 1H NMR (300 MHz, CDCl3) δ: 1.05 
(s, 3H), 1.73 (t, 2H, J = 6.8 Hz), 2.23 (t, 2H, J = 6.8 Hz); 13C NMR (75.0 MHz, CDCl3) 
δ: 20.4, 29.2, 30.0, 72.3, 179.1; HR-ESI-MS; calcd for C5H8N2O2 [M-H]– 127.0513, 
found 127.0493. 
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 3.4.4 Synthesis of compound 3.8: (E)-2-((3,7-dimethylocta-2,6-dien-1-
yl)oxy)tetrahydro-2H-pyran. This compound was prepared via a modification of a 
previously described procedure.185 To a solution of geraniol 3.7 (3.11 g, 20.2 mmol, 1 eq) 
in CH2Cl2 (3.5 mL) were added DHP (2.54 g, 30.3 mmol, 1.5 eq) and PPTS (0.502 g, 2.0 
mmol. 0.1 eq), and the resulting solution was stirred overnight at rt. The reaction mixture 
was quenched with saturated aqueous NaH  and extracted with CH2Cl2. The organic 
layer was dried over MgS  and concentrated to afford 3.8 as a clear oil (4.79 g, 99% ). 
1H NMR (300 MHz, CDCl3) δ 1.58 (s, 3H), 1.65 (s, 6H), 1.48 – 1.85 (m, 6H ), 2.04 – 
2.22 (m, 4H), 3.47 – 3.54 (m, 1H), 3.85 – 3.92 (m, 1H), 3.98 – 4.05 (dd, 1H, J = 7.2, 12 
Hz), 4.21 – 4.27 (dd, 1H, J = 6.3, 12 Hz), 4.62 (t, 1H, J = 2.7 Hz ), 5.16 (t, 1H, J = 6.3 
Hz), 5.39 (t, 1H, J = 6.2 Hz). HR-ESI-MS; calcd for C15H26O2 [M+H]
+1  239.1919, found 
239.1932 
 
3.4.5 Synthesis of compound 3.9: (2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-
yl)oxy)octa-2,6-dien-1-ol. This compound was prepared via a modification of a 
previously described procedure.185 The protected geraniol 3.8 was dissolved in CH2Cl2 
(28 mL). In turn, 70% t-Bu-OOH in H2O (8.5 mL, 60.9 mmol, 3eq), salicylic acid (0.279 
g, 2.02 mmol, 0.1 eq), and SeO2 (0.205 g, 2.03 mmol, 0.1eq) were added, and the 
resulting solution was stirred overnight at rt. The reaction mixture was quenched with 
saturated aqueous NaHCO3, extracted with CH2Cl2, and dried over MgSO4. After 
concentration, the residue was purified by flash chromatography (Hexanes: Et2O, 3:2, 
v/v) on silica gel to obtain 2.36 g (46%) of alcohol 3.9 as a clear oil. 1H NMR (300 MHz, 
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CDCl3) δ 1.65 (s, 6H), 1.48 – 1.85 (m, 6H), 2.04 – 2.22 (m, 4H), 3.47 – 3.54 (m, 1H), 
3.85 – 3.92 (m, 1H), 3.91 (s, 2H), 3.98 – 4.05 (dd, 1H, J = 7.2, 12 Hz), 4.21 – 4.27 (dd, 
1H, J = 6.3, 12 Hz), 4.62 (t, 1H, J = 2.7 Hz ), 5.16 (t, 1H, J = 6.3 Hz), 5.39 (t, 1H, J = 6.2 
Hz). HR-ESI-MS; calcd for C15H26O3Na [M+Na]
+1 277.1790, found 277.1763 
 
3.4.6 Synthesis of compound 3.10: (2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-
yl)oxy)octa-2,6-dien-1-yl3-(3-methyl-3H-diazirin-3-yl)propanoate. To a solution of 
protected alcohol 3.9 (1.94 g, 7.60 mmol,1 eq) and DMAP (92.8 mg, 0.76 mmol, 0.1 eq) 
in CH2Cl2 (7 mL) was added a solution of the diazirine acid 3.6 (0.97 g, 7.60 mmol, 1 eq) 
in CH2Cl2 (10 mL). DIC (0.959 g, 7.6 mmol0, 1eq) was added and the resulting solution 
was stirred at rt for 16 hours. The reaction mixture was filtered and concentrated. 
Purification by flash chromatography (hexanes: EtOAc, 5:1) afforded 1.07 g (57%) of 
diazirine 3.10 as a clear oil. 1H NMR (300 MHz, CDCl3) δ: 1.03 (s, 3H), 1.48 – 1.85 (m, 
14H), 2.04 – 2.22 (m, 6H), 3.47 – 3.54 (m, 1H), 3.85 – 3.92 (m, 1H), 3.98 – 4.05 (dd, 1H, 
J = 7.2, 12 Hz), 4.21 – 4.27 (dd, 1H, J = 6.3, 12 Hz), 4.46 (s, 2H), 4.62 (t, 1H, J = 2.7 
Hz), 5.36 (t, 1H, J = 6.3 Hz), 5.44 (t, 1H, J = 6.2 Hz); 13C NMR (75.0 MHz, CDCl3) δ: 
13.16, 16.4, 20.5, 23.7, 25.1, 26.6, 30.6, 32.9, 39.7, 44.2, 63.3, 65.6, 69.3, 72.3, 105.5, 
118.5, 130.4, 130.7, 141.8, 173.1. IR (NaCl, cm-1): 2940.69 (s), 2870.41 (m), 1737.07 (s), 
1669.76 (w), 1587.67 (w), 1447.34 (m), 1385.74 (m), 1175.14 (m), 1117.30 (m), 1023.15 
(m). HR-ESI-MS: calcd for C20H32N2O4Na [M+Na]
+
 : 387.2260, found 387.2234. 
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3.4.7 Synthesis of compound 3.11: (2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dien-1-yl 
3-(3-methyl-3H-diazirin-3-yl)propanoate. To a solution of 3.10 (99 mg, 0.271 mmol, 1 
eq) in EtOH (1.60 mL) was added PPTS (6.81 mg, 271 µmol, 0.1 eq). The reaction flask 
was fitted with a septum and stirred at 60 °C for 4 h. The reaction mixture was 
concentrated in vacuo and purified by flash chromatography (hexanes: EtOAc, 2:1) to 
afford 75 mg (99%) of diazirine alcohol 3.11 as a clear oil. 1H-NMR (300 MHz, CDCl3) 
δ: 1.03 (s, 3H), 1.58 – 1.75 (m, 8H), 2.05 – 2.22 (m, 6H), 4.15 (t, 2H, J = 6.0 Hz), 4.47 (s, 
2H), 5.38 – 5.45 (m, 2H); 13C NMR (75.0 MHz, CDCl3): δ 13.6, 16.4, 23.5, 26.4, 32.9, 
39.7, 44.2, 58.9, 69.3, 72.1, 124.6, 130.4, 130.7, 141.8, 173.1. IR (NaCl, cm-1): 3395.58 
(br) 2925.24 (s), 2870.41 (m), 1735.59 (s), 1669.76 (w), 1587.67 (w), 1447.34 (m), 
1385.74 (m), 1176.09 (m), 1000.73 (m). HR-ESI-MS: calcd for C15H24N2O3Na [M+Na]
+
 : 
303.1685, found 303.1649. 
 
3.4.8 Synthesis of compound 3.12: (2E,6E)-8-bromo-2,6-dimethylocta-2,6-dien-1-yl 
3-(3-methyl-3H-diazirin-3-yl)propanoate.  The diazirine alcohol 3.11 (69.5 mg, 0.247 
mmol, 1 eq) was converted to the corresponding bromide in the presence of resin-bound 
PPh3 (250 mg, 1.08 mmol, 4 eq) and CBr4 (350 mg, 1.08 mmol, 4 eq) dissolved in CHCl3 
(6 mL). The resulting solution was allowed to stir for 2 h at rt. After the reaction was 
complete, excess CBr4 and resin bound PPh3 were removed from the mixture by passing 
the reaction through a C18 sep-pak column. Removal of the solvent afforded 68.1 mg 
(80%) of diazirine bromide 3.12 as a clear oil. 1H-NMR (300 MHz, CDCl3) δ: 1.03 (s, 
3H), 1.58 – 1.75 (m, 8H), 2.05 – 2.22 (m, 6H), 3.99 (d, 2H, J = 8.4 Hz), 4.47 (s, 2H), 5.39 
  81 
(t, H, J = 6 Hz) 5.51 (t, 2H, J = 6.1 Hz); 13C NMR (75.0 MHz, CDCl3) δ: 13.6, 15.4, 23.5, 
26.4, 30.8, 32.9, 38.3, 44.2, 69.3, 72.1, 123.3, 130.4, 130.7, 143.2, 173.1. IR (NaCl, cm-
1): 2925.24 (m), 2870.41 (m), 1736.18 (s), 1656.35 (w), 1586.54 (w), 1446.66(m), 
1385.30 (m), 1173.27(m). HR-ESI-MS: calcd for C15H23BrN2O2Na [M+Na]
+
 :
 366.1941, 
found 366.1952. 
 
3.4.9 Synthesis of Biotin-Peg4-K(5-Fam)YIIKGVFWDPAC-OH (3.15). Peptide 
synthesis was carried out using an automated solid-phase peptide synthesizer (PS3, 
Protein Technologies Inc, Memphis, TN) employing standard Fmoc/HCTU based 
chemistry. Synthesis began on preloaded Fmoc-Cys(Trt)- Wang resin (0.25 mmol) and 
the peptide chain was elongated using HCTU/N-Methylmorpholine-catalyzed, single 
coupling steps with 4 eq of both protected amino acids and HTCU for 30 min. Following 
complete chain elongation, the peptide’s N-terminus was deprotected with 10% 
piperidine in DMF (v/v) and the presence of the resulting free amine was confirmed by 
ninhydrin analysis. The resin containing the peptide was washed with CH2Cl2, dried in 
vacuo overnight, weighed, and divided into three portions for further synthesis on a 
reduced scale. Using 83.0 µmol of peptide, the free amino terminus was biotinylated in 
DMF (5 mL) with NHS-PEG4-Biotin (0.49 mg, 83.0 µmol, 1eq) catalyzed by DIEA (14.4 
µL, 8.3 µmol, 0.1 eq) for 16 h. After acylation, the resin bound peptide was washed 
thoroughly with CH2Cl2 and dried in vacuo for 4 h. The peptide was then reacted with 
5% hydrazine in DMF (5 mL, v/v) to orthogonally remove they Dde protected side chain. 
After verifying the deprotection was complete by ninhydrin analysis, the peptide was 
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washed with CH2Cl2, dried, and then reacted 5-FAM SE (45 mg, 86.0 µmol, 1 eq) 
catalyzed by DIEA (14.4 µL, 8.3 µmol, 0.1 eq) overnight. The peptide was cleaved from 
the resin along with simultaneous side chain deprotection by treatment with Reagent K 
containing TFA (10 mL), crystalline phenol (0.5 g), 1,2-ethanedithiol (0.25 mL), 
thioanisole (0.5 mL), and H2O (0.5 mL) for 2 h at rt. The released peptide was collected 
and combined with TFA washes of the resin before precipitation of the peptide in chilled 
Et2O (100 mL). The crude solid peptide was collected by centrifugation, the supernatant 
was removed, and the resulting pellet was washed 2 times with cold Et2O (50 mL) 
repeating the centrifugation and supernatant removal steps each time. The crude peptide 
was purified using a semipreparative C18 RP-HPLC column with detection at 280 nm and 
eluted with a gradient of Solvent A (H20/0.1% TFA, v/v) and Solvent B (CH3CN/0.1% 
TFA, v/v). The crude peptide (150 mg) was dissolved in a DMF/H2O solution (1:5 v/v, 
25 mL), applied to the column equilibrated in Solvent A, and washed with 15% Solvent 
B for 15 min. The peptide was eluted using a linear gradient of (15-65% Solvent B over 
1.5 h at a flow-rate of 5 mL/min). Fractions were analyzed using an analytical C18 RP-
HPLC column employing a linear gradient (0-100% Solvent B over 60 min at a flow-rate 
of 1 mL/min) and detected at 214 nm. Fractions containing peptide product of at least 
90% purity were pooled and concentrated by lyophilization to yield 55 mg (37% yield) of 
a yellow solid. A small amount (< 1mg) of the resulting purified peptide was dissolved in 
10 µl of 0.1% TFA/CH3CN and diluted 1:50 in a mixture of CH3CN/H2O (1:1 v/v) prior 
to MS analysis. MS was performed using a 50 µL injection and collecting 3000 scans. 
ESI-MS: calcd for C117H155N19O30S2 [M+2H]
+2
:  1186.0334, found 1186.0453. 
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3.4.10 Synthesis of Biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C10-Diazirine)-OH 
(3.16). Peptide 3.15 (20 mg, 5.3 µmol, 1 eq) was dissolved in DMF/n-Butanol/H2O 
(0.10% TFA) (3:1:1 v/v/v, 6 mL). The isoprenoid bromide 3.12 (15 mg, 54.5 μmol, 10 
eq) was dissolved in 0.50 mL of DMF and loaded onto a C18 SepPack® column that had 
been equilibrated with 5% CH3CN in aq. 0.10% TFA. The column was washed with 5% 
CH3CN (5 mL), followed by 30% CH3CN (10 mL). The purified bromide was then eluted 
from the column with 3.0 mL DMF directly into the reaction flask that contained the 
dissolved peptide. Zn(OAc)2·2H2O (5.4 mg, 25 μmol, 5 eq) was then added to initiate the 
alkylation reaction. After 4 h the reaction was analyzed by analytical RP-HPLC, purified 
by semipreparative C18 RP-HPLC, and identified via ESI-TOF MS. This reaction yielded 
5.1 mg (21 %) of the desired alkylated peptide 3.16. Purity by HPLC: 96.1 %, ESI-MS: 
calcd for C132H177N21O32S2 [M+2H]
+2
: 1317.1223, found 1317.1172. 
 
3.4.11 Synthesis of Biotin-Peg4-YIIKGVFWDPAC(Fr)-OH (3.17). Solid phase 
peptide synthesis and purification was carried out in the same fashion as described above.  
Following complete chain elongation, the peptide’s N-terminus was deprotected with 
10% piperidine in DMF (v/v) and the presence of the resulting free amine was confirmed 
by ninhydrin analysis. Using 83.0 µmol of peptide, the free amino terminus was 
biotinylated in DMF (5 mL) with NHS-PEG4-Biotin (0.49 mg, 83.0 µmol, 1 eq) catalyzed 
by DIEA (14.4 µL, 8.3 µmol, 0.1 eq) for 16 h. After Reagent K cleavage and HPLC 
purification the free thiol-containing peptide (20 mg, 13 μmol, 1 eq) was prenylated with 
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farnesyl bromide (10 mg, 65 μmol, 5 eq) using the same conditions as 3.16. Purity by 
HPLC: 92.4 %, ESI-MS: calcd for C105H157N17O23S2 [M+2H]
+2
: 1045.0551, found 
1045.0499 
 
3.4.12 Synthesis of Biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C5-m-BP)-OH (3.19). 
Starting with 3.15, as previously described, the peptide was prenylated using the same 
conditions and quantities as used for 3.16 with replacement of the isoprenoid analogue 
3.12 with C5-meta-Bp-Brthat that was prepared as previously described. 
162,168 Purity by 
HPLC: 94.2 %, ESI-MS: calcd for C136H173N19O32S2 [M+2H]
+2 1325.0951, found 
1325.0994. 
 
3.4.13 Protein Isolation and in vitro Methyltransferase Vapor Diffusion Assays.  For 
experiments using crude protein, membrane preparations from the yeast strain CH2704 
overexpressing His-Ste14p were prepared as previously described, with minor 
modifications.88,130  Following centrifugation at 100,000 x g for 1 h, the membrane pellet 
was resuspended in 10 mM Tris-HCl, pH 7.5, aliquoted, flash frozen in liquid N2 and 
stored at -80ºC.  In vitro assays for methyltransferase activity were performed using 
crude membranes as previously described.154  In brief, reactions contained crude 
membrane preparations, 200 µM AFC, 20 µM S-adenosyl-L-[methyl-14C]methionine 
([14C]SAM) (50–60 mCi/mmol), and 100 mM Tris-HCl, pH 7.5, in 60 µL. The reactions 
were incubated at 30 °C for 30 min and terminated by the addition of 50 µL of 1 M 
NaOH, 1% SDS (v/v). Each reaction (100 µL) was then spotted onto a filter paper that 
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was wedged into the neck of a vial containing 10 mL of scintillation fluid and allowed to 
diffuse at rt for 2.5 h. The filters were discarded, and the base labile [14C]methyl groups 
transferred were measured via liquid scintillation counting.  For experiments performed 
with purified His-Ste14p, His10myc3N-Ste14p (His-Ste14p) was expressed in a ste14 
deletion strain130 and purified as previously described.88  
 
3.4.14 Photocrosslinking and neutravidin-agarose pull-down assays in crude 
membranes.  Photocrosslinking assays were performed as described previously, with 
minor modifications.154,169 100 µg of crude membrane preparation expressing His-Ste14p 
in 10 mM Tris-HCl, pH 7.5 were pre-incubated with increasing concentrations of the 
competition peptide before addition of the photolabeling reagent and incubated at 4 ºC for 
5 min.  The samples were irradiated at 365 nm in 96-well plates for 30 min on ice.  The 
resulting protein samples were solubilized in 800 µL of radioimmunoprecipitation assay 
(RIPA) buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% sodium dodecylsulfate)/10% SDS and incubated with 50 µL of a 
50% neutravidin/RIPA bead slurry for 2 h at 4ºC.  The beads were centrifuged at 13,000 
x g for 1 min and washed three times with RIPA/10% SDS.  The crosslinked protein was 
eluted from the neutravidin beads by the addition of 50 µL of 2X SDS sample buffer (0.5 
M Tris-HCl, pH 6.8, 30% sucrose (w/v), 10% sodium dodecylsulfate (w/v), 3.5 M 2-
mercaptoethanol and 0.1% bromophenol blue (w/v)). Samples were heated for 30 min at 
65ºC and subjected to 12% SDS-PAGE and immunoblot analysis.   
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3.4.15 Photocrosslinking of purified His-Ste14p.  5 µg of purified His-Ste14p in 138 
mM MOPS and 1 mM DTT were incubated in the presence of the photoaffinity 
analogues and incubated at 4ºC for 10 min. The samples were irradiated (365 nm) in 96-
well plates for 30 min on ice. Following photocrosslinking, 40 µL of 5X SDS sample 
buffer (0.5 M Tris-HCl, pH 6.8, 30% sucrose (w/v), 10% sodium dodecylsulfate (w/v), 
3.5 M 2-mercaptoethanol and 0.1% bromophenol blue (w/v)) was added directly to the 
samples. Samples were heated for 30 min at 65ºC and subjected to 12% SDS-PAGE.   
 
3.4.16 Fluorescence Imaging. SDS-PAGE gels were imaged using GE Healthcare Life 
Sciences Typhoon Trio scanner.  Excitation was performed at 488 nm and emission 
observed with a 520 nm band-pass emission filter (520 BP 40).  The images were 
collected with a pixel size of 50 µm at normal sensitivity with a PMT voltage of 400 V. 
 
3.4.17 Immunoblot Analysis.  Proteins from SDS-PAGE gels were transferred to 
nitrocellulose membranes (0.22 µm) and the membranes were blocked at rt for 2 h in 
20% (w/v) non-fat dry milk in phosphate-buffered saline with Tween-20 (137 mM NaCl, 
2.7 mM KCl, 4 mM Na2HPO4, 1.8 mM KH2PO4 and 0.05% (v/v) Tween-20, pH 7.4) 
(PBST). The blocked membrane was incubated for 2 h at rt with an α-Ste14p (1:500-
crude or 1:10,000-pure protein) antibody in 5% (w/v) non-fat dry milk in PBST.  The 
membrane was washed in PBST three times and incubated for 1 h at rt with goat α-rabbit 
IgG-HRP (1:10,000) in 5% (w/v) dry milk in PBST.  Incubation of the membrane with 
NeutrAvidin HRP (1:5000) was performed in 5% (w/v) BSA in PBST for 3 
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3.5 Supporting Information 
3.5.1 Characterization of compound 3.10 
 
Figure 3.5. 1H NMR spectrum of compound 3.10. 
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Figure 3.6. 13C NMR spectrum of compound 3.10. 
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Figure 3.7. IR spectrum of compound 3.10. 
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3.5.2 Characterization of compound 3.11 
 
Figure 3.8. 1H NMR spectrum of compound 3.11. 
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Figure 3.9. 13C NMR spectrum of compound 3.11. 
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Figure 3.10. IR spectrum of compound 3.11. 
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3.5.3 Characterization of compound 3.12 
 
Figure 3.11. 1H NMR spectrum of compound 3.12. 
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Figure 3.12. 13C NMR spectrum of compound 3.12. 
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Figure 3.13. IR spectrum of compound 3.12. 
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3.5.4 Characterization of Biotin-Peg4-K(5-Fam)YIIKGVFWDPAC-OH (3.15) 
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Figure 3.14. Mass spectrum and analytical RP-HPLC chromatogram for peptide 3.15. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
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Table 3.2. Summary of the ESI-MS-MS fragmentation for peptide 3.15: -b, loss of 5-
((4R)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanal (C10H16N2O2S); -p loss of  
N-(15-oxo-3,6,9,12-tetraoxapentadecyl)-5-((4R)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (C21H37N3O7S); -h loss of H2O.  
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Figure 3.15. MS/MS spectrum of peptide 3.15.  
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3.5.5 Characterization of Biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C10-Diazirine)-
OH (3.16) 
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Figure 3.16. Mass spectrum and analytical RP-HPLC chromatogram for peptide 3.16. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
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Table 3.3. Summary of the ESI-MS-MS fragmentation for peptide 3.16:-f, (2E,6E)-3,7-
dimethyl-8-((3-(3-methyl-3H-diazirin-3-yl)propanoyl)oxy)octa-2,6-dien-1-ylium 
(C15H23N2O2
+) -b, loss of 5-((4R)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanal (C10H16N2O2S
+); -p, loss of  N-(15-oxo-3,6,9,12-tetraoxapentadecyl)-5-((4R)-
2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (C21H37N3O7S
+); -h, loss of 
H2O. 
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Figure 3.17. MS/MS spectrum of peptide 3.16.  
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3.5.6 Characterization of Biotin-Peg4-YIIKGVFWDPAC(Fr)-OH (3.17) 
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Figure 3.18. Mass spectrum and analytical RP-HPLC chromatogram for peptide 3.17. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm.  
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3.5.7 Characterization of Biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C5-m-BP)-OH 
(3.19) 
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Figure 3.19. Mass spectrum and analytical RP-HPLC chromatogram for peptide 3.19. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 214 nm. 
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3.5.8 Pull-down experiments with 3.16 and 3.19 
 
 
Figure 3.20. Analysis of crosslinking reactions containing purified His-Ste14p and 
photoactive probes 3.16 and 3.19 after pull-down with streptavidin. For this experiment, 
crude membrane proteins (100 µg) isolated from yeast were incubated with the probes 
indicated (50 µM) and irradiated on ice for 30 min followed by pull-down with 
streptavidin coated agarose beads.  After washing the beads, the bound proteins were 
eluted in SDS loading buffer and fractionated via SDS-PAGE. The resulting gel was 
transferred to a membrane and visualized using an α-Ste14 antibody.  Lane 1: 
Crosslinking reaction with membranes containing His-Ste14p and 3.19; Lane 2: 
Crosslinking reaction with membranes containing His-Ste14p and 3.16; Lane 3: 
Crosslinking reaction with membranes lacking His-Ste14p (deletion strain) and 3.19. 
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Chapter 4: Synthesis of Peptides for Evaluating the Activity of Ste24p 
 
4.1 Introduction 
 
Yeast (Saccharomyces cerevisiae) is known for its unique mating pattern, 
accomplished by the secretion of bioactive signaling molecules, fungal pheromones that 
are divided into two types, a-factor and α-factor.191 These two pheromones are translated 
as precursor peptides that require multi-step enzymatic processing to progress to their 
active forms. Due to the presence of a CAAX box motif and an upstream N-terminal 
cleavage site, studies on a-factor provide important information on the posttranslational 
processing of yeast CAAX proteins.3 
Similar to the processing of prelamin A found in mammalian cells, a-factor is 
post-translationally modified by the prenylation pathway.51 As seen in Figure 4.1, a-
factor undergoes prenylation, endoproteolysis, methyl esterification, and then is 
subsequently cleaved to reveal the active form of the pheromone. 
 
Figure 4.1. Post-translational processing of a-factor. 
  104 
It is interesting that Ste24p is predicted to cleave at two different sites, first at the C-
terminal tripeptide and then again upstream in the N-terminal extension. This dual 
cleavage role suggests that Ste24p’s active site can allow for the recognition of two 
unrelated peptide sequences. It also raises the question of whether the reaction kinetics 
vary between the different cleavage positions, a concept that has yet to be explored. 
Having a better grasp of the dual cleavage role performed by Ste24p may help with 
understanding mammalian Ste24, as it also multiply cleaves its substrate, prelamin A. 
The desire to inhibit Rce1 and Ste24 function has led to the development of many 
assays to monitor the cleavage of the tripeptide from CAAX bearing substrates. 
Monitoring of Ste24p function in yeast has been largely dominated by coupled assays 
with Ste14p, using either bioassays to detect the active form of a-factor,163 or a vapor 
diffusion assay detecting radiolabeled methyl esters.154 Novel fluorescence based assays 
have also been developed which can directly monitor proteolysis by Ste24p; however, 
they are designed to mimic the C-terminal domain of K-RasB4. In order to make a more 
relevant comparison between Ste24p’s proteolysis rate of the two cleavage sites, donor-
quencher peptides were designed using a-factor as a template. By incorporating 2-
aminobenzoic acid (Abz) and 2,4-dinitrophenol (Dnp) at positions across the scissile 
bonds, direct proteolysis rates can be measured by observing the increase in fluorescence 
over time. Here we show the synthesis and application of the donor-quencher peptides to 
study Ste24p. 
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4.2 Results and Discussion 
 
4.2.1 Design and synthesis of CAAX cleavage probe. The design for a CAAX box 
cleavage probe started with determining what position in the a-factor sequence was 
suitable to incorporate the fluorescent moiety, Abz, and the quencher, Dnp, which would 
no longer be attached to the same peptide after Ste24p cleavage. Previous work with 
Ste24p has shown that Abz-KSKTKCVIQL-OH is a suitable substrate with a KM of 10.9 
M, and displays a measurable increase in fluorescence upon tripeptide cleavage.65 When 
aligned next to the a-factor sequence, (Figure 4.2), the attachment of the Abz group falls 
between the amino acids Val and Phe. This position has been shown to maintain a-factor 
activity upon mutagenesis,51 making it an attractive location for Abz incorporation. 
Additionally, placement of Dnp-lysine (QL) at the A2 or X amino acid in the K-Ras4B 
peptide were shown to be processed by Ste24, with the X position being a superior 
substrate. With these factors in mind peptide, 4.1 (Figure 4.2), was developed. 
 
Figure 4.2. Design of fluorescence assay CAAX cleavage probe: CAAX cleavage probe 
4.1, short cleavage standard 4.2. 
 
Synthesis of peptide 4.1 started with the loading of Fmoc-Lys(Dnp) onto wang 
resin using DIC and DMAP to facilitate the ester bond formation, 4.3 (Scheme 4.1). After 
determining the loading of the resin by quantitative-Fmoc analysis, solid phase peptide 
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synthesis (SPPS) was used to construct the peptide utilizing standard Fmoc/HCTU 
coupling conditions. The N-terminus was deprotected by treatment with 20% piperidine 
in DMF, and the free amine was detected by ninhydrin testing. Cleavage from the resin 
and acidic deprotection was carried out simultaneously by treatment with Reagent K to 
afford a yellow peptide, 4.4, with a cysteine bearing a free thiol. After purification of the 
crude peptide by preparative RP-HPLC, 4.4 was chemically alkylated with farnesyl 
bromide (3 equiv) in the presence of Zn(OAc)2 (3 equiv) in acidic DMF to yield the 
prenylated peptide, 4.1, whose identity was determined via ESI-MS and purity confirmed 
by analytical RP-HPLC (See Figure 4.8). The cleaved peptide, 4.2, to be used as a 
standard in HPLC based assays was prepared similarly; however, Fmoc-Cys(Trt)-Wang 
resin was used in SPPS as well as an increase in farnesyl bromide and Zn(OAc)2 to afford 
chemical prenylation. 
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Scheme 4.1. Synthesis of CAAX cleavage probe  
 
 
 
4.2.2 Design and synthesis of N-terminal cleavage probe. Determining the design of 
the N-terminal cleavage probe once again hinged on the placement of donor-quencher 
moieties while maintaining recognition by Ste24p. For the sake of synthetic simplicity, 
the Abz group was chosen to be appended to the N-terminus of the a-factor precursor 
peptide, seven amino acids upstream of the site of cleavage. Placement of the Dnp 
quencher on the side chain of the furthest upstream lysine residue satisfied the 
requirement for fluorescence evolution upon proteolysis while also taking advantage of 
commercially available Lys(Dnp) during peptide synthesis. Moreover, mutational studies 
have shown that precursor a-factor with derivatization at the chosen lysine residue is still 
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processed by Ste24p.51 Although the distance between the donor and quencher was 
extended by two amino acids compared to the known K-RasB4 fluorescence peptide, 
efforts to synthesize and evaluate the designed peptide, 4.6 (Figure 4.3), were still taken. 
 
 
Figure 4.3. Design of fluorescence assay N-terminal cleavage probes: wild type a-factor 
4.5, N-terminal cleavage probe 4.6, long C-terminal HPLC standard 4.7, long N-terminal 
HPLC standard 4.8. 
 
SPPS synthesis began on Fmoc-Cys(Wang)-OMe resin that was made as 
previously described,192,193 and utilized standard Fmoc/HCTU coupling conditions for 
chain elongation (Scheme 4.2). Upon determination of the free amino N-terminus by 
ninhydrin testing, the peptide was cleaved and deprotected by treatment with Reagent K. 
Interestingly, previous reports have noted that some epimerization of C-terminal cysteine 
residues can occur when Cys-functionalized Wang resin and Reagent K cleavage 
conditions are used,194 but after RP-HPLC purification, no evidence for epimerization 
was observed using the thiol anchoring methodology. Preparative RP-HPLC and 
subsequent ESI-MS identification yielded a yellow peptide, 4.9, with a C-terminal 
cysteine bearing a free thiol and a methyl ester. Alkylation of the thiol was with farnesyl 
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bromide (3 equiv) in the presence of Zn(OAc)2 (3 equiv) in acidic DMF yielded the 
prenylated peptide, 4.6, whose identity was determined via ESI-MS and purity confirmed 
by analytical RP-HPLC (Figure 4.10). The wild type a-factor peptide, 4.5, and long C-
terminal standard peptide, 4.7, used for a comparative HPLC assay with Ste24p were 
synthesized in the same fashion, while the Abz containing peptide fragment, 4.9, started 
with Fmoc-Thr(Boc)-Wang resin. 
 
Scheme 4.2. Synthesis of fluorescence assay N-terminal cleavage 
probes
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4.2.3 CAAX and N-terminal cleavage probes are substrates for Ste24p. To determine 
if probes 4.1 and 4.6 were substrates for Ste24p we used an assay that was adapted from 
an established fluorescence assay with K-Ras quenched substrate.2,3 Ste24p membranes 
from yeast (5 μg) was incubated with varying concentrations of quenched substrate, 4.1 
or 4.6, and the fluorescence in the samples was measured at 420 nm every 30 sec for 20 
min at 30°C (Figure 4.3). The kinetic values were determined by fitting saturation curve 
data to Michaelis-Menten equation using Graphpad Prism 4 (Figure 4.4). The fluorescent 
extinction coefficient was determined by the standard curve of cleavage products, 4.2 and 
4.8 (Figure 4.5).   
 
Figure 4.4. Monitoring Ste24p reaction in real time using: Left graph, 4.1; Right graph, 
4.6. Linear increase in fluorescence measured by Bio-Tek Synergy H4 fluorimeter at 
320/420 nm from dequenched peptide was detected. 15 μM of each probe was incubated 
with yeast Ste24p membranes (5 μg) for 20 min at 30 °C (). Control reaction with 
CH2740 membranes (no Ste24p) showed no increase in fluorescence (■). 
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Figure 4.5. Saturation curves for Ste24p proteolysis of 4.1 and 4.6: Left graph, 4.1; Right 
graph, 4.6. The activity of Ste24p measured from substrate concentrations ranging from 0 
to 40 μM. The fluorescent extinction coefficient was determined by the standard curve of 
cleavage product, 4.2 and 4.8 (Figure 4.6.). Kinetic values were determined by fitting 
data to Michaelis-Menten equation using Graphpad Prism 4.  
 
 
 
Figure 4.6. Representative calibration curve using 4.2 and 4.8 as standards. 
Concentrations ranged from (0-10 µM). 
As see in figure 4.3, it is clear that in the presence of Ste24p the reaction mixture 
increases in fluorescence over time, suggesting that peptides 4.1 and 4.6 are recognized 
and processed by Ste24p. Additionally, in the presence of yeast membrane lacking 
Ste24p, there is no significant increase in fluorescence, providing evidence that 
proteolysis of the two quenched peptides is dependent upon Ste24p activity, and not 
another cellular protease. Comparison of the kinetic parameters obtained for CAAX 
cleavage probe 4.1 and N-terminal cleavage probe 4.6 reveal that both assay peptides 
bind equally as well with Ste24p with similar KM values (Figure 4.4); however, peptide 
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4.6 is processed at a faster rate than 4.1, as shown by a Vmax value that is nearly an order 
of magnitude greater (Figure 4.4. It is also surprising that the extinction coefficients of 
the two cleaved products differ, 4.8 being two-fold greater than 4.2 (Figure 4.5), 
suggesting that aromatic residues in close proximity to the Abz moiety alter its molar 
absorptivity. 
 
4.3 Conclusion 
 
In this work we described the synthesis and application of fluorescence assay 
peptides to monitor the dual cleavage role of Ste24p in the processing of precursor a-
factor. The quenched a-factor mimics were prepared in 4 steps via solid phase peptide 
synthesis on non-commercially available resin.  Kinetic analyses with Ste24p showed that 
the CAAX cleavage peptide was comparable to previously reported K-Ras quenched 
substrate. Kinetic parameters obtained with the N-terminal cleavage probe are the first to 
be reported that quantify the secondary cleavage rate of precursor a-factor by Ste24p, and 
showed an enhanced reaction rate over CAAX proteolysis. Monitoring fluorescence of 
the cleaved standards also revealed a change in the fluorescent extinction coefficient of 
the Abz fluorophore that appears to be dependent on adjacent aromatic amino acid 
residues. Given the success in defining the kinetics associated with both cleavage 
reactions catalyzed by Ste24p, the new class of fluorescence assay peptides should 
provide a starting platform for the development of similar peptides to study mammalian 
Ste24. 
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4.4 Materials and Methods 
4.4.1 General. All solvents and reagents used for the synthesis of the fluorescent assay 
peptides and cleaved products were of analytical grade and purchased from Peptides 
International (Louisville, KY), NovaBioChem® (Nohenbrunn, Germany), or Sigma-
Aldrich (St. Louis, MO). Fmoc-Cys(Wang Resin)-OMe was prepared as previously 
outlined.192,193 HR-ESI-MS analysis was performed using a Bio-TOF-II (Bruker) mass 
spectrometer. 
 
4.4.2 Synthesis of Fmoc-Lys(Dnp)-Wang resin (4.3). Fmoc-Lys(Dnp)-OH (QL) (2.0 g, 
3.74 mmol, 2 eq) was dissolved in anhydrous CH2Cl2 (5 mL) along with Cl-HOBt (0.63 
g, 3.74 mmol, 2 eq), DMAP (0.12g, 0.935 mmol, .5 eq), and DIC (0.47 g, 3.74 mmol, 2 
eq) in a fritted 6 mL syringe. The resulting solution was allowed to mix on a rotisserie for 
10 mins. Wang resin with a (1.62 g, 1.87 mmol, 1 eq) was then added and the resulting 
mixture was tumbled on a rotisserie overnight. The reaction solution was removed from 
the syringe by vacuum filtration, and the remaining resin was washed with CH2Cl2 and 
dried in vacuo overnight. Loading of Fmoc-Lys(Dnp)-OH onto the resin (0.68 mmol/g) 
was determined via Fmoc-quantitative analysis. 
 
4.4.3 Synthesis of Abz-FWDPACVIQL-OH (4.4). Peptide synthesis was carried out 
using an automated solid-phase peptide synthesizer (PS3, Protein Technologies Inc, 
Memphis, TN) employing standard Fmoc/HCTU based chemistry. Synthesis began on 
preloaded QL-Wang resin (0.1 mmol) and the peptide chain was elongated using 
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HCTU/N-Methylmorpholine-catalyzed, single coupling steps with 4 eq of both protected 
amino acids and HTCU for 30 min. Following complete chain elongation, the peptide’s 
Fmoc-Abz N-terminus was deprotected with 20% piperidine in DMF (v/v) and the 
presence of the resulting free amine was confirmed by ninhydrin analysis. The peptide 
was cleaved from the resin along with simultaneous side chain deprotection by treatment 
with Reagent K containing TFA (10 mL), crystalline phenol (0.5 g), 1,2-ethanedithiol 
(0.25 mL), thioanisole (0.5 mL), and H2O (0.5 mL) for 2 hat rt. The released peptide was 
collected and combined with TFA washes of the resin before precipitation of the peptide 
in chilled Et2O (100 mL). The crude solid peptide was collected by centrifugation, the 
supernatant was removed, and the resulting pellet was washed 2 times with cold Et2O (50 
mL), repeating the centrifugation and supernatant removal steps each time. The crude 
peptide was purified using a semipreparative C18 RP-HPLC column with detection at 220 
and 280 nm and eluted with a gradient of Solvent A (H20/0.1% TFA, v/v) and Solvent B 
(CH3CN/0.1% TFA, v/v). The crude peptide (136 mg) was dissolved in a DMF (10 mL), 
applied to the column equilibrated in Solvent A, and washed with 15% Solvent B until no 
absorbance was detected at 220 nm. The peptide was eluted using a linear gradient of 
(15-85% Solvent B over 1.5 h at a flow-rate of 5 mL/min). Fractions containing the 
desired mass determined by MS analysis were checked for purity by analytical C18 RP-
HPLC column employing a linear gradient (0-100% Solvent B over 60 min at a flow-rate 
of 1 mL/min) and detected at 214 nm. Fractions containing peptide product of at least 
90% purity were pooled and concentrated by lyophilization to yield a yellow powder 48 
mg (35% yield). ESI-MS: calcd for C65H83N14O17S [M+H]
+  1363.5781, found 1363.5753 
  115 
 
4.4.4 Synthesis of Abz-FWDPAC(Fr)VIQL-OH (4.1). Peptide 4.4 (25 mg, 18.3 µmol, 1 
eq) was dissolved in DMF/H2O (0.10% TFA) (9:1 v/v, 10 mL) after which farnesyl 
bromide (14 mg, 92 μmol, 5 eq) and Zn(OAc)2·2H2O (20 mg, 92 μmol, 5 eq) was then 
added to initiate the alkylation reaction. After 12 h the reaction was purified by 
semipreparative C18 RP-HPLC in the same fashion as previously stated, and identified via 
ESI-TOF MS. This reaction yielded 6.3 mg (22 %) of the desired alkylated peptide. 
Purity by HPLC: 94.1 %, ESI-MS: calcd for C80H106N14O17S [M+H]
+ : 1567.7659, found 
1567.7598. 
 
4.4.5 Synthesis of Abz-FWDPAC(Fr)-OH (4.2). Peptide synthesis began on Fmoc-
Cys(Trt)-Wang resin (0.05 mmol) and followed the same SPPS and purification condition 
as described above. After Reagent K cleavage and HPLC purification, the free thiol-
containing peptide (20 mg, 13 μmol, 1 eq) was prenylated with farnesyl bromide (20 mg, 
130 μmol, 10 eq) and Zn(OAc)2·2H2O (28.1 mg, 130 μmol, 10 eq) with the same reaction 
conditions previously described. This reaction yielded 3.3 mg (24.5%) of the desired 
alkylated peptide. Purity by HPLC: 97.2 %, ESI-MS: calcd for C57H72N8O10S [M+H]
+ : 
1061.5180, found 1061.5153. 
 
4.4.6 Synthesis of Abz-MQPSTATAAPK(Dnp)EKTSSEKKDNYIIKGVFWDPAC-
OMe (4.9). Peptide synthesis begin on Fmoc-Cys(Wang)-OMe resin (0.1 mmol) which 
was prepared as previously described,192,193 and followed the same SPPS and purification 
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as described above. Fractions that contained the desired mass and were above 90% pure 
were pooled and lyophilized giving a yellow powder 138 mg (35% yield). ESI-MS: calcd 
for C175H262N44O56S2 [M+3H]
+3: 1314.2894, found 1314.2854. 
 
4.4.7 Synthesis of Abz-MQPSTATAAPK(Dnp)EKTSSEKKDN-
YIIKGVFWDPAC(Fr)-OMe (4.6). Peptide 4.9 (75 mg, 19 µmol, 1 eq) was dissolved in 
DMF/H2O (0.10% TFA) (9:1 v/v, 15 mL) after which farnesyl bromide (14.5 mg, 95 
μmol, 5 eq) and Zn(OAc)2·2H2O (20.6 mg, 95 μmol, 5 eq) were added and the reaction 
was mixed for 12 hours. The reaction was purified by semipreparative C18 RP-HPLC 
purification in the same fashion as previously stated, and identified via ESI-TOF MS. 
This reaction yielded 19.7 mg (25%) of the desired alkylated peptide. Purity by HPLC: 
95.2 %, ESI-MS: calcd for C190H286N44O56S2 [M+3H]
+3: 1382.3521, found 1382.3482. 
 
4.4.8 Synthesis of MQPSTATAAPKEKTSSEKKDNYIIKGVFWDPAC(Fr)-OMe 
(4.5). Peptide synthesis begin on Fmoc-Cys(Wang)-OMe resin (0.05 mmol) which was 
prepared as previously described,192,193 and followed the same SPPS and purification as 
described above. After Reagent K cleavage and HPLC purification the free thiol-
containing peptide (30 mg, 9.6 μmol, 1 eq) was prenylated using the same conditions as 
seen with 4.6. This reaction yielded 6.7 mg (21%) of the desired alkylated peptide. Purity 
by HPLC: 96.4 %, ESI-MS: calcd for C177H282N41O51S2 [M+3H]
+3 1287.3391, found 
1287.3354. 
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4.4.9 Synthesis of AAPK(Dnp)EKTSSEKKDNYIIKGVFWDPAC(Fr)-OMe (4.7). 
Peptide synthesis begin on Fmoc-Cys(Wang)-OMe resin (0.05 mmol) which was 
prepared as previously described,192,193 and followed the same SPPS and purification as 
described above. After Reagent K cleavage and HPLC purification the free thiol-
containing peptide (30 mg, 9.6 μmol, 1 eq) was prenylated using the same conditions as 
seen with 4.6. This reaction yielded 6.7 mg (21%) of the desired alkylated peptide. Purity 
by HPLC: 93.4 %, ESI-MS: calcd for C154H233N35O44S [M+3H]
+3 1103.9008, found 
1103.8942. 
 
4.4.10 Synthesis of Abz-MQPSTAT-OH (4.8). Peptide synthesis begin on Fmoc-
Thr(tBu)-Wang resin (0.05 mmol) and followed the same SPPS and purification as 
described above. Reagent K cleavage and HPLC purification the yield a white solid 22.3 
mg (53% yield) Purity by HPLC: 92.8 %, ESI-MS: calcd for C36H55N9O13S [M+1H]
+ 
854.3718, found 854.3702.  
 
4.4.11 Crude membrane preparation of yeast Ste24p. Crude membranes containing 
yeast Ste24p were prepared as previously described.88 Briefly, late-log phase yeast cells 
(3-5 A600/ml) were cultured in SC-URA medium at 30°C and harvested by centrifugation 
at 3,750 × g for 5 minutes at 4°C. The cell pellets were resuspended in lysis buffer (300 
mM sorbitol, 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1% aprotinin, 2 
mM 4-(2-aminoethyl)benzenesulfonyl fluoride and 1 mM dithiothreitol) and incubated on 
ice for 15 minutes. The cells were frozen in liquid nitrogen and thawed at room 
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temperature twice prior to being lysed by passing through a French press twice at 18,000 
psi. The lysates were centrifuged at 500 × g for 10 minutes at 4°C. The resulting 
supernatant was then centrifuged at 100,000 × g for 1 hour at 4°C to pellet membrane 
fraction. The pellet was resuspended in 10 mM Tris-HCl, pH 7.5, aliquoted, flash-frozen 
in liquid nitrogen and stored at -80°C. 
 
4.4.12 In vitro fluorescence-based C- or N-terminal cleavage assays for yeast Ste24p. 
The assay was adapted from an established fluorescence-based assay with K-Ras 
sequence based quenched substrate.65,195 Here we modified the substrates based on a-
factor sequence to monitor C- or N-terminal proteolysis activity of yeast Ste24p. In brief, 
yeast Ste24p membranes from yeast (5 μg) and quenched substrates FLQ-CaaX or FLQ-
Nterm (various concentrations) were mixed in a 96-well plate with 100 mM Tris-HCl, pH 
7.5 and protease inhibitors (10 μg/μl chymostatin, 10 μg/μl leupeptin, 1% aprotinin and 2 
mM AEBSF). The fluorescence in the samples was measured at 420 nm every 30 sec for 
20 min at 30°C using Bio-Tek Synergy H4 fluorimeter. The collected data were exported 
and initial linear slopes were graphed and determined by Microsoft Excel. The saturation 
curves and kinetic values were determined by fitting data to Michaelis-Menten equation 
using Graphpad Prism 4. 
 
4.4.13 Calibration curve of Abz-FWDPAC(Fr) or Abz-MQPSTAT. The calibration 
curves were determined by measuring Abz-released fluorescence with 320/420 nm from 
C- or N-terminal cleavage products, Abz-FWDPAC(Fr) or Abz-MQPSTAT (0 to 10 μM) 
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in 100 mM Tris-HCl, pH 7.5. The fluorescent extinction coefficients were obtained from 
standard curves of relative fluorescent units and fixed substrate concentrations for each 
substrate. 
4.5 Supporting Information 
4.5.1 Characterization of Abz-FWDPACVIQL-OH (4.4) 
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Figure 4.7. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.4. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min then 100% CH3CN (0.1%TFA) 
for 5 min, detected at 214 nm. 
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4.5.2 Characterization of Abz-FWDPAC(Fr)VIQL-OH (4.1) 
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Figure 4.8. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.1. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min then 100% CH3CN (0.1%TFA) 
for 5 min, detected at 214 nm. 
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4.5.3 Characterization of Abz-FWDPAC(Fr)-OH (4.2) 
0
0.2
0.4
0.6
0.8
1
1.2
400 600 800 1000 1200 1400
Abz-FWDPAC(Fr)-OH 4.2
In
te
n
s
it
y
, 
c
o
u
n
ts
m/z, amu
[M+H]
+
 = 1061.5153
 
0
0.2
0.4
0.6
0.8
1
1.2
0 10 20 30 40 50 60
A
b
s
o
rb
a
n
c
e
 (
A
2
1
4
)
Time (min)
Abz-FWDPAC(Fr)-OH 4.2
 
Figure 4.9. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.2. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min, detected at 214 nm. 
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4.5.4 Characterization of Abz-MQPSTATAAPK(Dnp)EKTSSEKKDN-
YIIKGVFWDPAC-OMe (4.9) 
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Figure 4.10. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.9. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min then 100% CH3CN (0.1%TFA) 
for 5 min, detected at 214 nm. 
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4.5.5 Characterization of Abz-MQPSTATAAPK(Dnp)EKTSSEKKDN-
YIIKGVFWDPAC(Fr)-OMe (4.6) 
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Figure 4.11. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.6. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min then 100% CH3CN (0.1%TFA) 
for 5 min, detected at 214 nm. 
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4.5.6 Characterization of MQPSTATAAPK(Dnp)EKTSSEKKDN-
YIIKGVFWDPAC(Fr)-OMe (4.5) 
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Figure 4.12. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.5. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min, detected at 214 nm. 
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4.5.7 Characterization of AAPK(Dnp)EKTSSEKKDNYIIKGVFWDPAC(Fr)-OMe 
(4.7) 
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Figure 4.13. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.7. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min then 100% CH3CN (0.1%TFA) 
for 5 min, detected at 214 nm. 
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4.5.8 Characterization of Abz-MQPSTAT-OH (4.8) 
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Figure 4.14. Mass spectrum and analytical RP-HPLC chromatogram for peptide 4.8. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 30 min then 100% CH3CN (0.1%TFA) 
for 5 min, detected at 214 nm. 
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Chapter 5: Synthesis and Evaluation of FPP and GGPP Analogues that Incorporate 
Photoactive Diazirines 
5.1 Introduction  
Farnesyl diphosphate (5.1, FPP, figure 5.1) is an important biological compound 
that is found in all living organisms. The biosynthesis of farnesyl diphosphate is a well-
established metabolic pathway that begins with two 5-carbon isoprene units that cascade, 
via electrophilic addition followed by elimination, into isoprenoids of varying length.196 
FPP plays a central role as a precursor in the metabolism of an array of essential 
compounds found in nature. Examples include biopolymers like latex or dolichol,197,198 
sesquiterpene natural products,199 and side chains to cofactors.200 Protein prenylation is a 
post-translational modification that also uses FPP, and the longer isoprenoid 
geranylgeranyl diphosphate (GGPP), as the lipid donors.20 Since the discovery that 
prenylation of mutant Ras proteins is required for transformation,201 the prenyltransferase 
enzymes have been a target for anti-cancer drugs.5,202,203 Given the plethora of important 
products and the impact that enzymes who use FPP as a substrate have in disease 
proliferation and prevention,101 development of chemical tools to study these enzymes is 
an important area of inquiry. One class of FPP analogue that has had considerable use in 
this pursuit exploits the technique known as photoaffinity labeling. 
Photoaffinity labeling is a technique used to identify noncovalent interactions 
between molecules, including protein-protein and protein-ligand complexes. Several 
photoaffinity analogues of isoprenoid diphosphates have been developed to study the 
enzymes that synthesize FPP, as well as the prenyltransferases that employ FPP as a 
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substrate. These studies used the photoactive moieties diazotrifluoropropionate,181-
183,186,204-211 or benzophenone,76,77,168,169,212-215 incorporated into the isoprenoid chain to 
act as a substitute for FPP. While successful in their intended application, each of the 
analogues has limitations. DATFP-containing analogues, although good structural 
mimics of FPP, require prolonged short wavelength UV irradiation for photoactivation 
and their synthesis is complicated by the need to use phosgene gas and 
trifluorodiazoethane. Benzophenone-containing analogues are attractive because they are 
relatively stable and activated by long wavelength UV irradiation; however, enzyme 
binding efficiency is reduced by their longer and bulkier shape compared to FPP. The 
benzophenone photophore must also adopt a coplanar arrangement for efficient light 
absorption, which can be restricted when bound, and produce a diradical upon photolysis 
that only reacts with a limited group of amino acid side chains. Compounds that utilize 
the diazirine as the photoactive group proved to be an attractive alternative for several 
reasons. Diazirines are simple to prepare from ketone precursors, their structure closely 
approximates the size and shape of an isoprene unit, and when activated by long 
wavelength UV radiation they produce a carbene intermediate that reacts with a wide 
range of amino acid side chains. Additionally, work from the Distefano and Hrycyna labs 
showed that a prenylated a-factor peptide, incorporating a diazirine-containing 
isoprenoid, had increased binding and crosslinking efficiency over a benzophenone 
variant with the isoprenylcysteine recognition-dependent enzyme, Ste14p.154,155  
While wild type allylic diphosphate analogues of FPP have been successful 
substrates, several photoaffinity analogues have been developed that contain 
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phosphonates.216-218 The advantage of incorporating a phosphonophosphate to mimic the 
allyilc diphosphate is that the phosphonophosphate moiety is more stable under acid 
conditions, affording a longer half-life in vivo.185 The phosphonate linkage is unable to be 
cleaved by enzymes that use FPP as a substrate. Thus their incorporation produces 
analogues that act as inhibitors, which may afford increased labeling efficiency or 
identification of unknown binding partners. Work by Zhao et al. extended the utility of 
photocrosslinking phosphonophosphate analogues by adding an azide functionality to the 
phosphate end, allowing for the biorthogonal click reaction with functionalized alkynes to 
detect or enrich crosslinked product. Upon irradiation of the bifunctional 
phosphonophosphate analogue in the presence of crude extract from S. cerevisae a 
number of labeled proteins were observed after a pull-down with a click installed biotin 
handle. Such an approach has pronounced potential for proteomic applications. 
Herein, we describe the synthesis of the diazirine functionalized farnesyl 
diphosphate analogue 5.2 (Figure 5.1) and phosphonophosphate analogues (5.7 & 5.9) 
(Figure 5.2), as well as GGPP phosphonophosphate analogues (5.8 & 5.10) (Figure 5.2). 
Kinetics of compound 5.2 were studied using yeast and mammalian protein 
farnesyltransferase validating the new FPP analogue as an alternative substrate. Inhibition 
kinetics with analogues 5.7 and 5.8, were also determined with yeast PFTase, and will 
serve as a baseline for saturation conditions in labeling studies to follow. Crosslinking 
experiments with PFtase and resulting identification of the beta subunit demonstrated the 
ability of photoaffinity labeling compounds 5.9 and 5.10 to selectively label isoprenoid 
binding sights. In addition, photolysis experiments with SmgGDS splice variant proteins, 
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SmgGDS-607 and SmgGDS-558, that promote prenylation and trafficking of GTPases,219 
validated the capability of compounds 5.9 and 5.10 at identifying proteins that recognize 
but don’t utilize isoprenoid diphosphates as substrates. 
 
Figure 5.1. Photoactivatable isoprenoid diphosphate analogues: FPP 5.1, Diazirine 5.2, 
Benzophenone 5.3, DATFP 5.4.  
 
 
Figure 5.2. Photoactivatable isoprenoid phosphonophosphate analogues: Benzophenone-
phosphonate 5.5, Benzophenone-phosphonophosphate -azide 5.6, Diazirine- 
phosphonophosphate -alkyne 5.7 & 5.8, Diazirine- phosphonophosphate-click-biotin 5.9 
& 5.10. 
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5.2 Results and Discussion 
5.2.1 Design and synthesis of diazirine containing isoprenoid diphosphate. To design 
a more efficient FPP analogue for photoaffinity labeling studies, the diazirine motif was 
selected due to its similarity in size to an isoprene unit. Comparison of 5.2 with 
benzophenone- and DATFP-containing FPP analogs (5.3 and 5.4) reveals that 5.2 is 
closest in size to FPP (Figure 5.1). Although crystal structure studies have shown that 
ether linkages are the most structurally similar to farnesyl diphosphate, 5.3,168 an ester 
linkage was chosen for ease of synthesis. 5.2 was prepared based on the previously 
published route to compound 5.18155 that utilized a convergent strategy of established 
compounds 5.16215 and 5.13.188 Conversion of the free alcohol, 5.18, to the corresponding 
bromide was performed by reaction with PBr3. Without subsequent purification, the 
bromide was then converted to the diphosphate, 5.19, by displacement with TTBHPP. 
The final product was obtained by ionic exchange to the NH4
+ salt and purified by HPLC. 
Scheme 5.1. Synthesis of Diazirine-containing FPP analogue 
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5.2.2 Diazirine analogue is a substrate for PFTase. Initially, a continuous fluorescence 
assay was used to assess the potential of the new photoaffinity analogue 5.2 as an 
alternative substrate for yeast protein farnesyltransferase (yPFTase).220 Incubation of the 
substrate peptide N-dansyl-GCVIA with FPP and yPFTase resulted in a rapid increase in 
the dansyl fluorescence (Figure 5.3) due to the increase in hydrophobicity upon 
prenylation 5.20 (Figure 5.4). When analogue 5.2 replaced FPP in the assay, a similar 
time-dependent increase in fluorescence resulted (Figure 5.3), indicating that the 
analogue acted as a substrate for yPFTase. Although both assays were performed at the 
same substrate and enzyme concentrations, the maximum fluorescence differs between 
the two prenylated products 5.20 and 5.21 due to their differing hydrophobicity. More 
importantly, the fluorescence increased 12 times slower with 5.2 than FPP, and required a 
longer reaction time for the complete conversion of the peptide substrate (Figure 5.3). 
Additionally, the formation of product 5.21, was verified by large scale enzymatic 
prenylation followed by MS detection. The prenylated peptide was purified by step 
chromatography on a Sep Pak cartridge, and high resolution electrospray ionization mass 
spectrometry (HR-ESI-MS) detected the presence of the prenylated peptide 
[C46H69N8O12S2]
+ at 957.4345 m/z, which corresponded closely to the calculated mass of 
957.4573 m/z for 5.21. Having determined that compound 5.2 acts as an alternative 
substrate for yPFTase, reaction kinetics with the mammalian homologue were pursued. 
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Scheme 5.2. yPFTase prenylation of substrate peptide N-dansyl-GCVIA  
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Figure 5.3. Evaluation of diazirine 5.2 as an alternative substrate S. cerevisiae protein 
farnesyltransferase (yPFTase). N-dansyl-GCVIA (2.0 µM), yPFTase (70 nM) and FPP 
(solid line) or 5.2 (●) (10 µM) were used with excitation at 340nm and detection at 
504nm. 
The kinetic parameters for 5.2 with mammalian PFtase, obtained from the rat 
(rPFTase), were calculated using the continuous fluorescence assay developed to study 
human PFTase by Pompliano et al.221. 50 nM of rPFTase was incubated with N-dansyl 
GCVLS (2.0 µM) and varying concentrations of 5.2. The fluorescence assay was 
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performed in triplicate and the initial velocity was calculated using Microsoft Excel 
(Figure 5.4). Kinetic values were determined by fitting data to the Kinetic values 
obtained: Vmax (1.159 nM/s), KM (0.254 µM), and Kcat (0.0272 s-1). The KM value is 
approximately 2-fold higher than that of farnesyl diphosphate. This is likely due to the 
structure of the diazirine group; although 5.2 is more similar to FPP than previous 
photoaffinity analogues (5.3 and 5.4), it still does not perfectly superimpose the natural 
substrate. Moreover, pervious kinetics studies with mammalian PFTase using DATFP- 
and benzophenone-containing FPP substrates failed to produce detectable product 
formation at the concentration used in the fluorescence assay, requiring large scale 
prenylation reactions coupled with HPLC detection to quantify prenylated product.182,207 
Given that product formation with compound 5.2 was detectable at the assay 
concentration, suggests that the smaller diazirine moiety is a superior mimic of an 
isoprene unit. 
 
Figure 5.4. Initial reaction rate of rPFTase with 5.2. rPFTase (50 nM) was incubated with 
N-dansyl GCVLS (2.0 µM) and varying concentrations of 5.2. Kinetic values were 
determined by fitting data to the Michaelis-Menten equation. 
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5.2.3 Design and synthesis of phosphonophosphate analogues. Having confirmed the 
ability of the diazirine analogue 5.2 to act as an alternative substrate for FPP with yeast 
and mammalian PFTases, phosphonate analogues were pursued for their application in 
protein identification experiments. Pervious phosphonophosphate analogues, 5.5 and 5.6 
(Figure 5.2), displayed a substantial increase in stability to acidic hydrolysis, while 
maintaining the ability to be recognized and photolabel PFTase.185 Due to the 
replacement of the phosphoester bond with a phosphonate at the C-1 position, proteins 
are unable to hydrolyze the C-P bond producing analogues that act as inhibitor, allowing 
for isoprenoid interacting partners to be identified as reported with 5.6.75 With these 
favorable attributes in mind, phosphonophosphate analogues 5.7 and 5.8 were designed. 
Similar to 5.6, compounds 5.7 and 5.8 are envisioned as bifunctional FPP and GGPP 
derivatives that incorporate the diazirine motif in the isoprenoid structure, and an alkyne 
functionality across the phosphonophosphate bond.  
Synthesis of analogue 5.7 was based on previously published routes for the 
production of the isoprenoid building block 5.28185 and the diazirine derivative 5.13 
(Scheme 5.3).222 Coupling of 5.28 and 5.13 in the presence of DIC and DMAP afforded 
the ester (5.30). Treatment with (CH3)3SiCH2CHCH2 and(CH3)3SiBr resulted in clean 
deprotection of the phosphonate esters to produce 5.32. Activation with CID followed by 
addition of phosphate 5.23 produced the coupled phosphonophosphate 5.7. Purification 
of 5.7 was performed using RP-HPLC yielding a white powder upon lyophilization. 
Synthesis of the longer version, 5.8, followed the same synthetic steps as 5.7, but began 
with farnesyl bromide 5.26 in place of geranyl bromide 5.25. A copper-catalyzed click 
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reaction with azide 5.35 converted 5.7 and 5.8 into the biotinylated compounds 5.9 and 
5.10, respectively, which isolated by RP-HPLC. 
Scheme 5.3. Synthesis of phosphonophosphate analogues 
 
 
5.2.4 Phosphonophosphate analogues are inhibitors of PFTase. Given the inherent 
stability of the C−P bond at position C-1, phosphonophosphate 5.7 and 5.8 was tested as 
a competitive inhibitor of yPFTase. The rate of yPFTase-catalyzed farnesylation of N-
dansyl-GCVIA was measured in the presence of a fixed concentration of FPP and 
varying concentrations of 5.7 and 5.8. An IC50 value of 16.99 µM was calculated for 5.7, 
and 13.67 µM for 5.8 (Figure 5.3). Comparison with the previously reported 
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benzophenone-containing phosphonate FPP analogue 5.5, the bifunctional analogues 
showed a reduction in the inhibition yPFTase activity (Table 5.1). Given the 
improvement of diazirine-containing diphosphate analogue 5.2 to act as an alternative 
yPFTase substrate over the benzophonone-containing analogue 5.3, the decrease in the 
inhibitor potency for 5.7 and 5.8 must be related to the addition of the alkyne 
functionality to their phosphate end. 
Figure 5.5. Inhibition of yPFTase activity by compounds 5.7 (left) and 5.8. Inhibition 
was evaluated using a fluorescence based assay using N-dansyl-GCVIA (2.4 μM), FPP 
(5.0μM), yPFTase (2.0μM) and varying concentrations of compound 5.7 and 5.8. IC50 
values were calculated from a plot of the enzymatic rate versus concentration. 
 
Table 5.1. Values for inhibition of yPFTase by diazirine- and benzophenone-based 
phosphonate isoprenoid diphosphate analogues. 
 
Compound IC50 (µM) 
5.7 16.99 
5.8 13.67 
5.5185 0.96 
 
5.2.5 Photolabeling of SmgGDS-607, SmgGDS-558, and rPFTase. The ability of 
phosphonophosphate 5.9 and 5.10 to crosslink isoprenoid binding proteins was assessed 
by photoaffinity labeling studies (figure 5.4). Recombinant SmgGDS-607 and SmgGDS-
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558 (10 µg) was incubated with compound 5.9 or 5.10 (10 µg) for 10 mins, and then 
irradiated with UV light (365 nm) for 30 min at a distance of 3 cm. Additionally, rPFtase 
was also treated with the same conditions and quantities to serve as a positive control. 
Crosslinked material was isolated with streptavidin beads, precipitated, and resolved by 
SDS-Page. The identification of the labeled proteins was determined by immunoblotting 
with antibodies to SmgGDS and the beta-subunit of rPFtase. 
 
Figure 5.6. Analysis of crosslinking reactions containing rPFtase, SmgGDS-607, 
SmgGDS-558, and compounds 5.9 and 5.10. (A) analogue 5.9; (B) analogue 5.10; (C) 
total protein. For this experiment, rPFTase, SmgGDS-607, and SmgGDS-558 (10 µg) 
was incubated with compound 5.9 or 5.10 (10 µg) for 10 mins, and then irradiated with 
UV light (365 nm) for 30 min in a cold room. Crosslinked material was isolated with 
streptavidin beads, precipitated, and resolved by SDS-Page. The resulting gel was 
transferred to a nitrocellulose membrane and visualized using antibodies to SmgGDS and 
the alpha-subunit of rPFtase. 
 
Following SDS-PAGE resolution, immunoblot analysis with the respective 
protein antibody demonstrated that each protein was present in the specified lane, and at 
the expected molecular weight; beta-subunit of yPFtase near 42 kDa, SmgGDS proteins 
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near 65 kDa (Figure 5.4C). Pull down of each protein with streptavidin beads was 
dependent upon UV exposure (Figure 5.4, lane 4). Detection of only the beta-subunit of 
rPFtase suggest that 5.9 and 5.10 are crosslinking the substrate binding site (Figure 5.4, 
lane 1). Successful labeling and enrichment of the prenylated GTPases recognizing 
protein, SmgGDS-558, highlighted the ability of the phosphonophosphate analogues to 
identify non-prenyltransferase isoprenoid binding partners (Figure 5.4, lane 3). Given that 
SmgGDS-607 is thought to recognize nonprenylated GTPases, it is surprising that both 
5.9 and 5.10 displayed the capability to crosslink SmgGDS-607 (Figure 5.4, lane 2). 
Comparing the intensity of the SmgGDS-607 band in lane 2, it is clear that 5.10 labeled 
more efficiently, suggesting that SmgGDS-607 has a greater capability to bind GGPP 
over FPP. The enhancement in GGPP recognition corralets with the finding that 
SmgGDS-607 forms more stable complexes with nonprenylated GTPases that will 
become geranylgeranylated than with nonprenylated GTPases that will become 
farnesylated.219 
5.3 Conclusion 
Herein, we have described the development and application of isoprenoid 
diphosphate analogues containing a photoexcitable diazirine moiety and phosphate or 
phosphonate linkages. The diphosphate analogue of FPP was synthesized in seven steps 
and was shown an alternative substrate for both yeast and mammalian PFTase enzymes. 
The phosphonophosphate analogues of FPP and GGPP were prepared over nine steps and 
are competitive inhibitors of PFTase with KI’s in the low micromolar range. Photolysis of 
yPFTase in the presence the phosphonophosphate analogues resulted in preferential 
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labeling of the β subunit, suggesting that the analogues interact with isoprenoid 
recognition site. Additionally, the phosphonophosphate analogues successfully labeled 
SmgGDS proteins, demonstrating their ability to identify isoprenoid binding partners 
other than enzymes that use isoprenoid diphosphates as substrates. These analogues 
should be valuable tool in identifying binding sights of know isoprenoid interacting 
proteins, and aid in the discovery of unknown isoprenoid binding proteins. 
 
5.4 Materials and Methods 
5.4.1 General. All solvents and reagents used for the synthesis of the diazirine isoprenoid 
analogues were of analytical grade and purchased from Sigma-Aldrich (St.Louis, MO). 
NHS-PEG4-Biotin was obtained from Thermo Scientific. Flash chromatography was 
performed with silica gel (60-120 mesh) was obtained from E. M. Science. Preparative 
HPLC separations were performed with a Rainin Dynamax Microsorb C18 column (2.14 
× 25 cm) while analytical separations employed a Varian c18 resin (Microsorb-MW 5 
μm, 4.6 × 250 mm). 1H NMR spectra were obtained at 300 or 500 MHz and 31P NMR 
spectra were obtained at 121 MHz.,. HR-ESI-MS analysis was performed using a Bio-
TOF-II (Bruker) mass spectrometer. Concentrations of FPP and the varius analogues 
were determined by phosphate analysis as described by Reed and Rilling employing 
KH2PO4 as a standard.
223 OD600 of cells was taken with a DU 720 UV/vis 
spectrophotometer (Beckman Coulter). Protein concentration was determined using a 
standard Bradford assay with a DTX 880 Multimode Detector plate reader (Beckman 
Coulter) 
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5.4.2 Synthesis of compound 5.12: 3-(3-methyldiaziridin-3-yl)propanoic acid. 
Levulinic acid 5.11 (1.61 g, 13.8 mmol, 1 eq) was dissolved in 7 N NH3 in CH3OH (13.5 
mL, 91.0 mmol, 7 eq). The resulting solution was stirred under N2 on ice for 3 h. A 
solution of hydrolxylamine-O-sulfonic acid (1.80 g, 15.9 mmol, 1.2 eq) in CH3OH (12 
mL) was added dropwise at a rate of 1 s-1. The reaction mixture was stirred for 20 h and 
allowed to warm to rt. N2 was bubbled through the solution for 1 h to remove NH3 gas. 
Vacuum filtration and concentration resulted in a yellow oil that was used in the next step 
without purification. 
 
5.4.3 Synthesis of compound 5.13 : 3-(3-methyl-3H-diazirin-3-yl)propanoic acid. The 
diaziridine 5.12 was redissolved in CH3OH (10 mL) and stirred on ice for 5 min in a tin 
foil covered flask. Triethylamine (3.00 mL, 21.5 mmol) was added and allowed to stir for 
5 min. Slowly, chips of I2 were added until the solution remained a brown-red color for 
longer than 5 min after the last addition. The reaction solution was diluted with EtOAc, 
washed with 1 M HCl, and with aqueous 10% sodium thiosulfate until the organic layer 
was colorless. The aqueous layer was further extracted with EtOAc (2x 20 ml). The 
organic layers were combined, dried over MgSO4, and concentrated to afford the 
diazirine acid 5 as a brown residue (0.785 g, 45%). 1H NMR (300 MHz, CDCl3) δ: 1.05 
(s, 3H), 1.73 (t, 2H, J = 6.8 Hz), 2.23 (t, 2H, J = 6.8 Hz). HR-ESI-MS; calcd for 
C5H8N2O2 [M-H]
–: 127.0513, found 126.0493. 
 
  142 
5.4.4 Synthesis of compound 5.15: (E)-2-((3,7-dimethylocta-2,6-dien-1-
yl)oxy)tetrahydro-2H-pyran. This compound was prepared via a modification of a 
previously described procedure.76 To a solution of geraniol 5.14 (3.11 g, 20.2 mmol, 1 
eq) in CH2Cl2 (3.5 mL) were added DHP (2.54 g, 30.3 mmol, 1.5 eq) and PPTS (0.502 g, 
2.0 mmol. 0.1 eq), and the resulting solution was stirred overnight at rt. The reaction 
mixture was quenched with saturated aqueous NaH  and extracted with CH2Cl2. The 
organic layer was dried over MgS  and concentrated to afford 8 as a clear oil (4.79 g, 
99% ). 1H NMR (300 MHz, CDCl3) δ 1.58 (s, 3H), 1.65 (s, 6H), 1.48 – 1.85 (m, 6H), 2.04 
– 2.22 (m, 4H), 3.47 – 3.54 (m, 1H), 3.85 – 3.92 (m, 1H), 3.98 – 4.05 (dd, 1H, J = 7.2, 12 
Hz), 4.21 – 4.27 (dd, 1H, J = 6.3, 12 Hz), 4.62 (t, 1H, J = 2.7 Hz ), 5.16 (t, 1H, J = 6.3 
Hz), 5.39 (t, 1H, J = 6.2 Hz). HR-ESI-MS; calcd for C15H26O2 [M+H]
+: 239.1919, found 
239.1932 
 
5.4.5 Synthesis of compound 5.16: (2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-
yl)oxy)octa-2,6-dien-1-ol. This compound was prepared via a modification of a 
previously described procedure.76 The protected geraniol 5.15 was dissolved in CH2Cl2 
(28 mL). In turn, 70% t-Bu-OOH in H2O (8.5 mL, 60.9 mmol, 3eq), salicylic acid (0.279 
g, 2.02 mmol, 0.1 eq), and SeO2 (0.205 g, 2.03 mmol, 0.1eq) were added, and the 
resulting solution was stirred overnight at rt. The reaction mixture was quenched with 
saturated aqueous NaHCO3, extracted with CH2Cl2, and dried over MgSO4. After 
concentration, the residue was purified by flash chromatography (Hexanes: Et2O, 3:2, 
v/v) on silica gel to obtain 2.36 g (46%) of alcohol 9 as a clear oil. 1H NMR (300 MHz, 
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CDCl3) δ 1.65 (s, 6H), 1.48 – 1.85 (m, 6H ), 2.04 – 2.22 (m, 4H), 3.47 – 3.54 (m, 1H), 
3.85 – 3.92 (m, 1H), 3.91 (s, 2H), 3.98 – 4.05 (dd, 1H, J = 7.2, 12 Hz), 4.21 – 4.27 (dd, 
1H, J = 6.3, 12 Hz), 4.62 (t, 1H, J = 2.7 Hz ), 5.16 (t, 1H, J = 6.3 Hz), 5.39 (t, 1H, J = 6.2 
Hz). HR-ESI-MS; calcd for C15H26O3Na [M+Na]
+1 
: 277.1790, found 277.1763 
 
5.4.6 Synthesis of compound 5.17: (2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-
yl)oxy)octa-2,6-dien-1-yl3-(3-methyl-3H-diazirin-3-yl)propanoate. This compound 
was prepared via a modification of a previously described procedure.155 To a solution of 
protected alcohol 5.16 (1.94 g, 7.60 mmol,1 eq) and DMAP (92.8 mg, 0.76 mmol, 0.1 eq) 
in CH2Cl2 (7 mL) was added a solution of the diazirine acid 5.13 (0.97 g, 7.60 mmol, 1 
eq) in CH2Cl2 (10 mL). DIC (0.959 g, 7.6 mmol0, 1eq) was added and the resulting 
solution was stirred at rt for 16 hours. The reaction mixture was filtered and concentrated. 
Purification by flash chromatography (hexanes: EtOAc, 5:1) afforded 1.07 g (57%) of 
diazirine 5.17 as a clear oil. 1H NMR (300 MHz, CDCl3) δ: 1.03 (s, 3H), 1.48 – 1.85 (m, 
14H), 2.04 – 2.22 (m, 6H), 3.47 – 3.54 (m, 1H), 3.85 – 3.92 (m, 1H), 3.98 – 4.05 (dd, 1H, 
J = 7.2, 12 Hz), 4.21 – 4.27 (dd, 1H, J = 6.3, 12 Hz), 4.46 (s, 2H), 4.62 (t, 1H, J = 2.7 
Hz), 5.36 (t, 1H, J = 6.3 Hz), 5.44 (t, 1H, J = 6.2 Hz); HR-ESI-MS: calcd for 
C20H32N2O4Na [M+Na]
+: 387.2260, found 387.2234. 
 
5.4.7 Synthesis of compound 5.18: (2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dien-1-yl 
3-(3-methyl-3H-diazirin-3-yl)propanoate. This compound was prepared via a 
modification of a previously described procedure.155  To a solution of 5.17 (99 mg, 0.271 
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mmol, 1 eq) in EtOH (1.60 mL) was added PPTS (6.81 mg, 271 µmol, 0.1 eq). The 
reaction flask was fitted with a septum and stirred at 60 °C for 4 h. The reaction mixture 
was concentrated in vacuo and purified by flash chromatography (hexanes: EtOAc, 2:1) 
to afford 75 mg (99%) of diazirine alcohol 5.18 as a clear oil. 1H NMR (300 MHz, 
CDCl3) δ: 1.03 (s, 3H), 1.58 – 1.75 (m, 8H), 2.05 – 2.22 (m, 6H), 4.15 (t, 2H, J = 6.0 Hz), 
4.47 (s, 2H), 5.38 – 5.45 (m, 2H). HR-ESI-MS: calcd for C15H24N2O3Na [M+Na]+: 
303.1685, found 303.1649. 
5.4.8 Synthesis of compound 5.19: (2E,6E)-3,7-Dimethyl-8-((3-(3-methyl-3H-
diazirin-3-yl)propanoyl)oxy)octa-2,6-dien-1-yl diphosphate. To a solution of diazirine 
alcohol 5.18 (69.5 mg, 247 µmol) in Et2O (4 mL) was added PBr3 (73 mg, 270 µmol, 1.2 
eq). The resulting solution was allowed to stir in an ice bath for 30 min. The mixture was 
concentrated and redissolved in CH3CN. TTBHPP (0.445 g, 494 µmol, 2.0 eq) was 
added, and the solution was stirred for 16 hat RT. The reaction solution was concentrated 
and applied to an ion exchange column (Dowex 50WX8-100 Resin) equilibrated with 25 
mM NH4HCO3 /isopropanol (49:1, v/v). The column was eluted with 25 mM 
NH4HCO3/isopropanol (49:1, v/v), and the fractions containing the desired mass were 
lyophilized for 48 h to obtain a white powder. Additional purification by reverse-phase 
HPLC with a gradient of 0 to 40% CH3CN in 25 mM NH4HCO3 over 50 min at a flow 
rate of 5 mL/min resulted in the elution of desired diphosphate 8 at 12.8 – 14.4% CH3CN. 
The fractions containing the desired mass were lyophilized to afford 21 mg (18%) of a 
white solid. 1H NMR (300 MHz, D2O) δ: 1.03 (s, 3H), 1.58 – 1.75 (m, 8H), 2.05 – 2.22 
(m, 6H), 4.31 (t, 2H, J = 6.6 Hz), 4.38 (s, 2H), 5.31 (t, 1H, J = 6.3 Hz), and 5.39 (t, 1H, J 
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= 6.3 Hz); 31P NMR (300 MHz, D2O) δ -5.83 (d, 1P, J = 54.6 Hz), and -9.83 (d, 1P, J = 
54.6 Hz). HR-ESI-MS: calcd for C15H24N2O9P2 [M-H]
-: 439.1041, found 439.1160. 
5.4.9 Synthesis of compound 5.23: 1-Bromo-6-(prop-2-yn-1-yloxy)hexane. Propargyl 
alcohol 5.22 (0.840 g, 15.0 mmol, 1 eq) was dissolved in anhydrous THF (15 mL) under 
nitrogen atmosphere. N-butyllithium in hexane (2.5 M, 15.0 mmol, 1 eq) was added and 
the resulting solution was stirred for 90 min while cooling on an ice bath. 1,6 
dibromohexane (7.32 g, 30 mmol, 2 eq) and tetrabutylammonium iodide (0.55 g, 1.5 
mmol, 0.1 eq) were added, and the mixture was stirred at 50 °C for 16 h. Purification by 
flash chromatography (hexanes: Et2O 20:1) afforded compound 5.23 as clear oil (1.043g, 
32%). 1H-NMR (300 MHz, CDCl3) δ 1.37 – 1.51 (m, 4H), 1.57 – 1.66 (m, 2H), 1.82 – 
1.91 (m, 2H), 2.42 (m, 1H), 3.41 (t, 2H, J = 6.6 Hz), 3.52 (t, 2H J = 6.6 Hz), and 4.14 (s, 
2H). Compound was unable to be visualized by ESI-MS.   
5.4.10 Synthesis of compound 5.24 6-(prop-2-yn-1-yloxy)Hexyl dihydrogen 
phosphate. Bromide 5.23 (0.504 g, 2.30 mmol) and Bu4NH4PO4 (2.34 g, 6.88 mmol, 3.0 
eq) were dissolved in anhydrous CH3CN (30 mL) and stirred at 40 °C for 48 h. The 
reaction solution was concentrated and applied to an ion exchange column (Dowex 
50WX8-100 Resin) equilibrated with 25 mM NH4HCO3/isopropanol (49:1, v/v). The 
column was eluted with 25 mM NH4HCO3/isopropanol (49:1, v/v), and the fractions 
containing the desired mass were lyophilized for 48 hours. Additional purification by 
reverse-phase HPLC (25 mM NH4HCO3) and lyophilization resulted in phosphate 5.24 
(0.216 g, 40%).  1H NMR (300 MHz, D2O) δ:  1.21 (m, 4H), 1.44 (m, 4H), 3.46(t, 2H, J 
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= 6.6 Hz), 3.57(q, 2H, J = 6.9 Hz), and 4.04 (s, 2H); 31P NMR (300 MHz, D2O) δ: 4.504 
(s, 1P). HR-ESI-MS: calcd for C9H16O5P [M-H]
-: 235.0694, found 235.0741.  
5.4.11 Synthesis of compound 5.27: (E)-Dimethyl (3,7-dimethylocta-2,6-dien-1-
yl)phosphonate. This compound was prepared via a modification of a previously 
described procedure.185 A solution of geranyl bromide 5.25 (7.66 g, 35.3 mmol, 1.0 eq) in 
P(OCH3)3 (4.60 ml, 38.8 mmol 1.2 eq) was heated to reflux for 16 h. The reaction 
mixture was purified by flash chromatography (hexanes: EtOAc, 1:3) on silica gel to 
obtain 5.27 (5.85 g, 67.3%) as a clear oil. 1H NMR (300 MHz, CDCl3) δ: 1.56 (s, 3H), 
1.65 (m, 6H), 2.04 (m, 4H), 2.57 (dd, 2H, J = 7.8 Hz, 22.2 Hz), 3.72 (d, 6H, J = 12.6 Hz), 
5.06 (t, 1H, J = 4.2 Hz), and 5.16 (m, 1H); 31P NMR (300 MHz, CDCl3) δ 31.883 (s, 1P). 
HR-ESI-MS: calcd for C12H23O3PNa [M+Na]
+: 269.1277, found 269.2143. 
 
5.4.12 Synthesis of compound 5.29: Dimethyl ((2E,6E)-8-hydroxy-3,7-dimethylocta-
2,6-dien-1-yl) phosphonate. This compound was prepared via a modification of a 
previously described procedure.185 Phosphonate 5.27 (5.85 g, 23.8 mmol, 1.0 eq) was 
then dissolved in CH2Cl2 (32 mL). In turn, 70% tBu-OOH in H2O (10.9 mL, 76.0 mmol, 
2.5 eq), salicylic acid (0.328 g, 2.38 mmol, 0.1 eq), and SeO2 (0.261 g, 2.38 mmol, 0.1 
eq) were added, and the resulting solution was stirred at rt for 22 h. The reaction mixture 
was quenched with saturated NaHCO3 (30 mL), extracted thrice with CH2Cl2 (30 mL), 
and dried over MgSO4. After concentration, the residue was purified by flash 
chromatography (CH3OH:CH2Cl2, 1:10) on silica gel to obtain 5.29 (1.53 g, 24.6%) as a 
clear oil. 1H NMR (300 MHz, CDCl3) δ: 1.68 (m, 6H), 2.12 – 2.19 (m, 4H), 2.55 (dd, 2H, 
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J = 7.8 Hz, 21.6 Hz), 3.72 (d, 6H, J = 12.6 Hz), 3.96 (s, 2H), 5.15 (m, 1H), and 5.30 (m, 
1H); 31P NMR (300 MHz CDCl3) δ 32.033 (s, 1P); HR-ESI-MS: calcd for C12H23O4PNa 
[M+Na]+: 285.1226, found 285.1068. 
5.4.13 Synthesis of compound 5.31: (2E,6E)-8-(dimethoxyphosphoryl)-2,6-
dimethylocta-2,6-dien-1-yl 3-(3-methyl-3H-diazirin-3-yl)propanoate. To a solution of 
5.29 (0.900 g, 3.44 mmol, 1.0 eq) and DMAP (42 mg, 0.34 mmol, 0.1 eq) in CH2Cl2 (5 
mL) was added a solution of the diazirine acid 5.13 (0.55 g, 4.3 mmol, 1.5 eq) in CH2Cl2 
(6 mL). DIC (0.510 mL, 3.44 mmol, 1.0 eq) was added and the resulting solution was 
stirred at rt for 18 h. The reaction mixture was filtered and concentrated. Purification by 
flash chromatography (EtOAc) afforded diazirine 5.31 as clear oil (0.79 g, 61%). 1H 
NMR (300 MHz, CDCl3) δ: 1.03 (s, 3H), 1.64 (m, 6H), 1.74 (t, 2H, J = 5.4 Hz), 2.04 (m, 
4H), 2.19 (t, 2H, J = 5.4 Hz)  2.57 (dd, 2H, J = 7.8 Hz, 22.2 Hz), 3.73 (d, 6H, J = 12.6 
Hz), 4.45 (s, 2H), 5.20 (m, 1H), and 5.42 (t, 1H, J = 6.6 Hz); 31P NMR (300 MHz, 
CDCl3) δ: 31.760 (s, 1P). Compound was unable to be visualized by ESI-MS 
5.4.14 Synthesis of compound 5.33: ((2E,6E)-3,7-Dimethyl-8-((3-(3-methyl-3H-
diazirin-3-yl)propanoyl)oxy)octa-2,6-dien-1-yl)phosphonic acid. Compound 5.31 
(0.77 g, 2.0 mmol, 1.0 eq) was dissolved in anhydrous CH2Cl2 (28mL). In turn, 
(CH3)3SiCH2CHCH2 (0.491 mL, 3.09 mmol, 1.5 eq) and (CH3)3SiBr (0.815 mL, 6.18 
mmol, 3.0 eq) were added. The resulting solution was stirred for 40 h at RT. The reaction 
mixture was then concentrated and quenched with 25 mM NH4HCO3 (20 mL). After 
lyophilization, purification by reverse-phase HPLC with a gradient of 0 to 40% CH3CN 
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in 25 mM NH4HCO3 over 50 min at a flow rate of 5 mL/min resulted in the elution of the 
desired phosphonate 5.33 at 20-26% CH3CN. Lyophilization yielded a white solid (0.502 
g, 73.2%). HR-ESI-MS: calcd for C12H24N2O5P [M-H]
-: 343.1428, found 343.1297. 
5.4.15 Synthesis of compound 5.7:  ((2E,6E)-3,7-Dimethyl-8-((3-(3-methyl-3H-
diazirin-3-yl)propanoyl)oxy)octa-2,6-dien-1-yl)phosphonic(6-(prop-2-yn-1-
yloxy)hexyl phosphoric) anhydride. Phosphonate 5.33 (47.1 mg, 0.137 mmol, 1.0 eq) 
and DIEA (17.7 mg, 0.137 mmol, 1.0 eq) were dissolved in dry DMF (3 mL) and stirred 
at room temperature for 30 min. CDI (111 mg, 0.684 mmol, 5.0eq) was added and the 
resulting solution was stirred for 3.5 h. CH3OH (35 mg, 1.11 mmol, 8.0 eq) was added 
and stirred for 30 min to decompose excess CDI. Phosphate 5.24 (40.5 mg, 0.172 mmol 
1.2 eq) was added and stirred for 16 h. The reaction mixture was quenched with 25 mM 
NH4HCO3 (7 mL).  Purification by reverse-phase HPLC with a gradient of 0 to 50% 
CH3CN in 25 mM NH4HCO3 over 50 min at a flow rate of 5 mL/min resulted in the 
elution of the desired product 5.7 at 30-34% CH3CN. Lyophilization yielded a white solid 
(6 mg, 7.8%). 1H NMR (300 MHz, D2O) δ:  0.89 (s, 3H), 1.25 (m, 6H), 1.45 (m, 8 H) 
1.61 (t, 2H, J = 5.2 Hz), 2.4 (m, 4H), 2.19 (t, 2H, J = 7.2 Hz), 2.41 (dd, 2H, J = 7.8 Hz, 
21.9 Hz), 3.47 (t, 2H, J = 6.6 Hz), 3.77 (m, 2H), 4.05 (s, 2H), 4.40 (s, 2H), 5.15 (q, 1H, J 
= 7.5 Hz), and 5.43 (t, 1H, J = 6.3 Hz); 31P NMR (300 MHz, D2O) δ: 16.65 (d, 1P), -
10.28 (d, 1P). HR-ESI-MS: calcd for C24H40N2O9P2 [M-H]
-: 561.2136, found 561.2033. 
5.4.16 Synthesis of compound 5.35: N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-
1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-
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3,6,9,12-tetraoxapentadecan-15-amide. Commercial available NHS-PEG4-Biotin (148 
mg, 0.252 mmol, 1eq), N3-Peg2-NH2 (55 mg, 0.252 mmol, 1eq) and DIEA (1 mL, 25.2 
µmol, 0.1 eq) were dissolved in anhydrous DMF (5 mL) and stirred at rt for 12 h. The 
reaction was filtered and concentrated. Purification by reverse-phase HPLC with a 
gradient of 0 to 40% CH3CN in H2O (0.1% TFA) over 60 min at a flow rate of 5 mL/min 
resulted in the elution of the desired product 5.35 at 19-21% CH3CN. Lyophilization 
yielded a white solid (128 mg, 73.6%). 1H NMR (300 MHz, CDCl3) δ: 1.36 (m, 2H), 1.43 
(m, 4H), 1.59 (t, 2H, J = 7.9 Hz), 2.19 (t, 2H, J = 7.5 Hz), 2.45 (t, 2H, J = 6.0 Hz), 2.72 
(d, 1H, 12.9 J = Hz), 2.86 (dd, 1H, J = 4.5 Hz, 12.9 Hz), 3.08 (q, 1H, J = 7.5 Hz), 3.36 
(dt, 4H, J = 4.5 Hz, 7.5 Hz), 3.52 (t, 2H, J = 5.1 Hz), 3.61 (m, 24H), 3.71 (t, 2H, J = 6.0 
Hz), 4.28 (dd, 1H, J = 4.5 Hz ,7.5 Hz), 4. 46 (dd, 1H, J = 4.5 Hz ,7.5 Hz), 5.69 (s, 1H), 
6.38 (s, 1H), 6.91 (t, 1H, J = 4.5 Hz) 7.02 (t, 1H, J = 4.5 Hz). HR-ESI-MS: calcd for 
C29H53N7O10S [M+H]
+ : 692.3653, found 692.3598 
 
5.4.17 Synthesis of compound 5.9: 5.(6-((1-(13,29-dioxo-33-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9,16,19,22,25-heptaoxa-12,28-
diazatritriacontyl)-1H-1,2,3-triazol-4-yl)methoxy)hexyl phosphoric) ((2E,6E)-3,7-
dimethyl-8-((3-(3-methyl-3H-diazirin-3-yl)propanoyl)oxy)octa-2,6-dien-1-
yl)phosphonic anhydride. Phosphonophosphate 5.7 (3.5 mg, 6.18 µmol, 1 eq) was 
dissolved with azide 5.35 (5.1 mg, 7.37 µmol, 1.2 eq) in 25 mM NH4HCO3 (3 mL). In 
turn, CuSO4 (77.1 µg, 3.09 µmole, 0.5 eq), TCEP (77.2 µg, 3.09 µmol, 0.5 eq), and 
TBTA (22.8 µg, 0.43 µmol, .07 eq) was added to the solution and stirred at rt for 5 h. 
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Purification by reverse-phase HPLC with a gradient of 0 to 50% CH3CN in 25 mM 
NH4HCO3 over 50 min at a flow rate of 5 mL/min resulted in the elution of the desired 
product 5.9 at 23-25% CH3CN. Lyophilization yielded a white solid (7.4 mg, 9.5%). 
1H 
NMR (300 MHz, D2O) δ: 0.84 (s, 3H), 1.25 (m, 6H), 1.45 – 1.55 (m, 16 H), 1.90 – 2.20 
(m, 10H), 2.32-2.41 (m, 4H,), 2.58 (d, 1H, J = 13.2 Hz), 2.80 (dd, 1H, J = 4.8 Hz, 13.2 
Hz), 3.14 (q, 1H, J = 6.0 Hz) 3.21 (t, 4H, J = 5.1 Hz), 3.37-3.48 (m, 24H), 3.61 (t, 2H, J = 
6.3 Hz), 3.71 (q, 2H, J = 6.6 Hz), 3.79 (t, 2H, J = 5.1 Hz), 4.24 (dd, 1H, J = 4.5 Hz ,7.5 
Hz) 4.33 (s, 2H), 4.42 (dd, 1H, J = 4.5 Hz ,7.5 Hz), 4.46 (s, 2H), 5.15 (q, 1H, J = 7.5 Hz), 
5.34 (t, 1H, J = 6.3 Hz), and 7.89 (s, 1H). HR-ESI-MS: calcd for C53H92N9O19P2S [M-H]
- 
:1252.5711, found 1252.5695 
 
5.4.18 Synthesis of compound 5.28: Dimethyl ((2E,6E)-3,7,11-trimethyldodeca-
2,6,10-trien-1-yl)phosphonate. Compound 5.28 was synthesized using the same 
conditions and quantities as used for 5.27 with replacement of geranyl bromide 5.25 with 
farnesyl bromide 5.26. 1H NMR (500 MHz, CDCl3) δ: 1.59 (s 3H), 1.61 (s, 3H), 1.67(s, 
6H), 2.04 (m, 8H), 2.57 (dd, 2H, J = 7.8 Hz, 22.2 Hz), 3.73 (d, 6H, J = 12.6 Hz), 5.08 (m, 
2H,), and 5.17 (q, 1H, J = 6.6 Hz); 31P NMR (300 MHz, CDCl3) δ 32.235 (s, 1P). HR-
ESI-MS: calcd for C17H31O3PNa [M+Na]
+:337.1909, found 337.1894 
 
5.4.19 Synthesis of compound 5.30 Dimethyl ((2E,6E,10E)-12-hydroxy-3,7,11-
trimethyldodeca-2,6,10-trien-1-yl)phosphonate. Compound 5.30 was synthesized 
using the same conditions and quantities as used for 5.29. 1H NMR (500 MHz, CDCl3) δ: 
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1.59 (s 3H), 1.65 (s, 6H), 2.06 (m, 8H), 2.58 (dd, 2H, J = 7.5 Hz, 21.9 Hz), 3.73 (d, 6H, J 
= 12.6 Hz), 3.98 (s, 2H), 5.10 (t, 1H, J = 6.6 Hz), 5.18 (q, 1H, J = 5.0 Hz), and 5.39 (t, 
1H, J = 6.6 Hz); 31P NMR (300 MHz, CDCl3) δ 32.230 (s, 1P). HR-ESI-MS: calcd for 
C17H32O4PNa [M+Na]
+ : 353.1858, found 353.1849. 
 
5.4.20 Synthesis of compound 5.32: (2E,6E,10E)-12-(dimethoxyphosphoryl)-2,6,10-
trimethyldodeca-2,6,10-trien-1-yl3-(3-methyl-3H-diazirin-3-yl)propanoate. 
Compound 5.32 was synthesized using the same conditions and quantities as used for 
5.31. 1H NMR (300 MHz, CDCl3) δ: 1.02 (s, 3H) 1.61 (s 3H), 1.65 (s, 3H), 1.68 (m, 5H), 
2.18 (m, 8H), 2.26 (t, 2H, J = 4.5 Hz)  2.55 (dd, 2H, J = 7.6 Hz, 21.9 Hz), 3.65 (d, 6H, J = 
12.6 Hz), 4.51 (s, 2H) 5.15 (t, 2H, J = 6.6 Hz), and 5.46 (t, 1H, J = 6.6 Hz); 31P NMR 
(300 MHz, CDCl3) δ 31.648 (s, 1P). Compound was unable to be visualized by ESI-MS. 
 
5.4.21 Synthesis of compound 5.34:  (2E,6E,10E)-3,7,11-trimethyl-12-((3-(3-methyl-
3H-diazirin-3-yl)propanoyl)oxy)dodeca-2,6,10-trien-1-yl)phosphonic acid. 
Compound 5.34 was synthesized using the same conditions and quantities as used for 
5.33. HR-ESI-MS: calcd for C20H32N2O5P [M-H]
- : 411.2054, found 411.1982 
5.4.22 Synthesis of compound 5.8: ((2E,6E,10E)-3,7,11-trimethyl-12-((3-(3-methyl-
3H-diazirin-3-yl)propanoyl)oxy)dodeca-2,6,10-trien-1-yl)phosphonic (6-(prop-2-yn-
1-yloxy)hexyl phosphoric) anhydride. Compound 5.8 was synthesized using the same 
conditions and quantities as used for 5.7. 1H NMR (300 MHz, D2O) δ: 0.84 (s, 3H), 1.25 
(m, 6H), 1.40 (s, 3H), 1.51 (s, 6H) 1.54 (t, 2H, J = 7.2Hz) 1.98 (m, 8H), 2.13 (t, 2H, J = 
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7.2 Hz), 2.39 (dd, 2H, J = 7.8 Hz, 21.9 Hz), 2.68 (t, 1H, J = 2.2 Hz), 3.41 (t, 2H, J = 6.6 
Hz), 3.72 (q, 2H, J = 6.3 Hz ), 4.01 (d, 2H, J = 2.2 Hz), 4.34 (s, 2H), 5.06 (t, 1H, J = 6.6 
Hz), 5.09 (t, 1H, J = 6.3 Hz), and 5.55 (t, 1H, J = 6.6 Hz) ; 31P NMR (300 MHz, D2O) δ: 
16.05 (d, 1P), -10.97 (d, 1P). HR-ESI-MS: calcd for C29H47N2O9P2 [M-H]
-: 629.2762, 
found 626.2698. 
 
5.4.23 Synthesis of compound 5.10: 6-((1-(13,29-dioxo-33-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9,16,19,22,25-heptaoxa-12,28-
diazatritriacontyl)-1H-1,2,3-triazol-4-yl)methoxy)hexyl phosphoric) ((2E,6E,10E)-
3,7,11-trimethyl-12-((3-(3-methyl-3H-diazirin-3-yl)propanoyl)oxy)dodeca-2,6,10-
trien-1-yl)phosphonic anhydride. Compound 5.10 was synthesized using the same 
conditions and quantities as used for 5.9. 1H NMR (300 MHz, D2O) δ: 0.84 (s, 3H), 1.25 
(m, 6H), 1.45 – 1.55 (m, 16 H), 1.90 – 2.20 (m, 14H), 2.32-2.41 (m, 4H,), 2.60 (d, 1H, J 
= 13.2 Hz), 2.80 (dd, 1H, J = 4.8 Hz, 13.2 Hz), 3.14 (q, 1H, J = 6.0 Hz) 3.20 (t, 4H, J = 
5.4 Hz), 3.37-3.48 (m, 24H), 3.59 (t, 2H, J = 6.0 Hz), 3.70 (q, 2H, J = 6.6 Hz), 3.79 (t, 
2H, J = 4.5 Hz), 4.24 (dd, 1H, J = 4.5 Hz ,7.5 Hz) 4.32 (s, 2H), 4.42( dd, 1H, J = 4.5 Hz 
,7.5 Hz), 4.43 (s, 2H), ), 5.02 (t, 1H, J = 6.6 Hz), 5.08 (q, 1H, J = 5.0 Hz), and 5.29 (t, 1H, 
J = 6.6 Hz) and 7.89 (s, 1H). HR-ESI-MS: calcd for C58H100N9O19P2S [M-H]
-1
: 
1320.6337, found 1320.6297 
 
5.4.24 yPFTase Expression and Purification. was expressed and purified following a 
previously reported procedure.224 A frozen stock of BL21(DE3)pLysS E. coli cells 
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containing yeast PFTase on a CDF-Duet1 vector, created by the Lorena Beese lab using a 
design previously employed for the mammalian PFTase,225 was used to inoculate a small 
culture of LB containing 50 μg/mL of streptomycin and grown overnight at 37 °C with 
shaking at 240 rpm. The next morning, flasks containing 1 L LB media were inoculated 
with 10 mL of the overnight culture and grown to an OD600 of approximately 0.8. Cells 
were then induced with 1 mM IPTG and supplemented with 500 μM ZnSO4 followed by 
incubation overnight at 15 °C with shaking at 250 rpm. Cells were harvested by 
centrifugation at 5400g, and the pellets (one pellet equivalent to one liter of cell growth) 
were frozen and stored at −80 °C. 
Two cell pellets were thawed and resuspended in 50 mL of a buffer containing 
50 mM Tris–HCl (pH 7.0), 200 mM NaCl, 5 μM ZnCl2, 5 mM MgCl2, 20 mM imidazole, 
and 1 mM β-mercaptoethanol (lysis buffer). To this mixture was added 1 mL of protease 
inhibitor cocktail, a cocktail developed for His-tagged proteins from (Sigma Aldrich, No. 
P8849). Cells were pulse-sonicated for a total of 5 min (10 s on, 10 s off) at 50 W 
followed by centrifugation at 13,000g for 30 min to remove insoluble cell material. The 
soluble fraction was then loaded onto a 30 mL Ni-NTA column bed equilibrated with 
lysis buffer at a rate of approximately 2 mL/min and the column was washed with lysis 
buffer until the A280 dropped to 0.25 (approximately 200 mL). The desired protein was 
then eluted using buffer containing 50 mM Tris–HCl (pH 7.0), 20 mM NaCl, 5 μM 
ZnCl2, 5 mM MgCl2, 250 mM imidazole, and 1 mM β-mercaptoethanol. Fractions 
containing PFTase were pooled in an Amicon Ultra-15 centrifugal filter from Millipore, 
and concentrated to 4 mL. This was diluted three times at a 10-fold dilution with 50 mM 
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Tris–HCl, 200 mM NaCl, 5 μM ZnCl2, 5 mM MgCl2, and 1 mM β-mercaptoethanol 
buffer and stored in the latter buffer containing 50% glycerol at −80 °C. This purification 
typically yielded 100 mg/L of liquid culture of PFTase with a purity of 90%. 
 
5.4.25 rPFTase Expression and Purification. rPFTase was expressed and purified 
following a previously reported procedure,224 and is similar to that described for yPFTase 
Streptomycin (50 μg/mL) was used as the selection antibiotic for cell growth. IPTG and 
ZnSO4 were added, both with final concentration of 0.5 mM to induce protein expression. 
To purify the enzymes, lysis buffer (50 mM Tris·HCl, pH 7.5, 200 mM NaCl, 5 μM 
ZnCl2, 5 mM MgCl2, and 20 mM imidazole) and elution buffer (50 mM Tris·HCl, pH 
7.5, 200 mM NaCl, 5 μM ZnCl2, 5 mM MgCl2, and 250 mM imidazole) were used. 1 
mM β-mercaptoethanol was added to these two buffers before use. Fractions containing 
rPFTase were collected and concentrated. Buffer exchange was performed with lysis 
buffer and the rPFTase was stored in 50% glycerol at −80 °C. 
 
5.4.26 Continuous Fluorescence Assay for yPFTase Activity Measurement. N-dansyl-
GCVIA, prepared as previously described,170 was preincubated with DTT for 1h. After 
incubation, the peptide DTT solution was used to make a PFTase assay solution that had 
a final concentration of 2 μM dansyl-CVIA, 5 mM DTT, 50 mM Tris–HCl (pH 7.5), 
10 mM MgCl2, 10 μM ZnCl2, 0.04% n-dodecyl β-d-maltoside and 10 µM of 5.1 or 5.2.). 
For the enzyme concentration 70 nM of yPFTase was used. All these reagent 
concentrations were standard for all unless otherwise noted.  
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The reactions were performed in 96-well microtiter plates and the fluorescence 
emission for each sample was obtained using a DTX 880 Multimode Detector plate 
reader (Beckman Coulter). The reaction was performed in a black 96-well pinch bar plate 
(Nunc, No. 237105) with no top. The total volume of each reaction was 250 μL. 
Reactions were performed by adding 100 μL of a concentrated assay solution (5 μM 
dansyl-GCVIA, 12.5 mM DTT, 125 mM Tris–HCl (pH 7.5), 25 mM MgCl2, 25 μM 
ZnCl2, 0.1% n-dodecyl β-d-maltoside and 50 µM of 5.1 or 5.2) and 30 μL of H2O without 
enzyme to each well using a multichannel pipette. The initial fluorescence reading was 
recorded (λex = 340 nm, λem = 505 nm) followed by initiation of the reaction through the 
addition of 20 μL yPFTase in enzyme buffer (50 mM Tris–HCl (pH 7.5), 5 mM MgCl2, 
50 μM ZnCl2, 20 mM KCl, 1mM DTT, 1mg/mL BSA). The flourescense was monitored 
until it reached a plateau signifying that the reaction was complete. Initial velocities were 
obtained from linear regression analysis of the time-dependent fluorescence emission 
data using the fluorimeter software 
 
5.4.27 Continuous Fluorescence Assay for rPFTase Activity Measurement. The same 
the continuous fluorescence assay conditions except the enzyme concentration was 
altered to 50 nM, rPFTase was used, and the peptide N-dansyl GCVLS was used instead 
of N-dansyl GCVIA. The assay was performed in triplicate at differing concentrations of 
the diazirine substrate: 0.02, 0.3, 0.5, 1.0, 2.0, 3.0, and 5.0 µM The increase in 
fluorescence was monitored until completion. 
 
5.4.28 Product Studies. Large-scale reactions contained 50 mM Tris·HCl, pH 7.0, 10 
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mM MgCl2, 10 μM ZnCl2, 5.0 mM DTT, 2.4 μM N-dansyl-GCVIA, 70 nM PFTase, and 
5.2 (10 μM), where appropriate, in a final reaction volume of 10 mL. The reactions were 
equilibrated to 30 °C, initiated by the addition of PFTase, and allowed to react for 1 h. To 
desalt the samples, each reaction mixture was applied to a Sep-Pak C18 cartridge, and 
eluted with in 10% increments of acetonitrile in 25 mM NH4HCO3 The fluorescent 
fractions were assessed by ESI-MS. 
 
5.4.29 Enzyme Inhibition Experiments. To determine if 5.7 and 5.8 were competitive 
inhibitors of PFTase, a 4 × 6 grid of duplicate assays were run in which N-dansyl-GCVIA 
(2.4 μM) and FPP (5.0μM) maintained at a set of fixed concentrations and the inhibitor 
(5.8 or 5.8) concentrations were varied at each FPP concentration. Concentrations of 0, 
3.0, 5.0, 10.0,  25.0 and 30.0 μM for FPP and 0, 1.8, 3.6, 9.0, 18.0, and 40.0 μM for 5.7 
and 5.8 were chosen; the PFTase concentration in these experiments was 2.0 nM. The 
rates were determined from initial velocity measurements performed as described above.  
 
5.4.30 Photocrosslinking  of SmgGDS-607, SmgGDS-558, and rPFTase Recombinant 
SmgGDS-607, SmgGDS-558, and rPFTase (10 µg) was incubated with compound 5.9 or 
5.10 (10 µg) for 10 mins, and then irradiated with UV light (365 nm) for 30 min at a 
distance of 3 cm. Photo-cross-linking reaction was quenched in liquid nitrogen. A control 
sample was prepared as described above, and the tube was wrapped in tin foil before 
exposure to UV light. After the cross-linking procedure, the peptides were 
immunoprecipitated using streptavidin-Sepharose 4B beads (434341; Invitrogen) and 
subjected to ECL-Western blotting. 
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5.4 Supporting Information 
5.5.1 Characterization of compound 5.19  
 
Figure 5.7. 1H NMR spectrum of compound 5.19. 
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Figure 5.8. 31P NMR spectrum of compound 5.19. 
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5.5.2 Characterization of compound 5.23 
 
Figure 5.9. 1H NMR spectrum of compound 5.23. 
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5.5.3 Characterization of compound 5.24 
 
Figure 5.10. 1H NMR spectrum of compound 5.24. 
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Figure 5.11. 31P NMR spectrum of compound 5.24. 
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5.5.4 Characterization of compound 5.27 
 
Figure 5.12. 1H NMR spectrum of compound 5.27. 
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Figure 5.13. 31P NMR spectrum of compound 5.27. 
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5.5.5 Characterization of compound 5.29 
 
Figure 5.14. 1H NMR spectrum of compound 5.29. 
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Figure 5.15. 31P NMR spectrum of compound 5.29. 
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5.5.6 Characterization of compound 5.31 
 
Figure 5.16. 1H NMR spectrum of compound 5.31. 
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Figure 5.17. 31P NMR spectrum of compound 5.31.
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5.5.7 Characterization of compound 5.7 
 
Figure 5.18. 1H NMR spectrum of compound 5.7. 
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Figure 5.19. 31P NMR spectrum of compound 5.7. 
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5.5.8 Characterization of compound 5.35 
 
Figure 5.20. 1H NMR spectrum of compound 5.35. 
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5.5.9 Characterization of compound 5.9 
 
Figure 5.21. 1H NMR spectrum of compound 5.9. 
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5.5.10 Characterization of compound 5.28 
 
 
Figure 5.22. 1H NMR spectrum of compound 5.28. 
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Figure 5.23. 31P NMR spectrum of compound 5.28. 
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5.5.11 Characterization of compound 5.30 
 
 
Figure 5.24. 1H NMR spectrum of compound 5.30. 
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Figure 5.25. 31P NMR spectrum of compound 5.30. 
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5.5.12 Characterization of compound 5.32 
 
 
Figure 5.26. 1H NMR spectra of compound 5.32. 
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Figure 5.27. 31P NMR spectrum of compound 5.32. 
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5.5.13 Characterization of compound 5.8 
 
 
 
Figure 5.28. 1H NMR spectrum of compound 5.8. 
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Figure 5.29 31P NMR spectrum of compound 5.8. 
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5.5.14 Characterization of compound 5.10 
 
 
 
Figure 5.30. 1H NMR spectrum of compound 5.10. 
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Chapter 6: Synthesis and Evaluation of Bisubstrate Inhibitor for Icmt 
6.1 Introduction 
 
Among the many proteins in a mammalian host, roughly 2% of the proteome 
undergo the post-translational modification known as prenylation.5 A specific 
superfamily of prenylated proteins, known as Ras, has been a focus for anti-cancer 
research, due to studies relating Ras mutations with approximately 20-30% of known 
cancer.6 Ras proteins are translated with a CAAX motif that is first prenylated though a 
thioether bond to the C-terminal cysteine residue with either a farnesyl or geranylgeranyl 
group catalyzed by farnesyltransferase (FTase) or geranylgenaryltransferase (GGtase), 
respectively.22-24 After prenylation, the Ras protein is further processed at the 
endoplasmic reticulum by the endoprotease Ras converting enzyme 1 (Rce1) that cleaves 
the AAX tripeptide.26,27 The new prenylcysteine carboxylate C-terminus is then 
methylated by the S-adenosyl-methionine (SAM)-dependent enzyme isoprenylcysteine 
carboxylmethyltransferase (Icmt).82,83 These modifications increase protein 
hydrophobicity, assist in membrane localization, and facilitate signal transduction. 
Following the discovery that oncogenic Ras requires prenylation for its membrane 
association and transforming capabilities,201 the enzymes associated with the prenylation 
pathway have been targets for drug development. Of the three classes of enzymes, the 
protein prenyltransferases have been the primary focus for inhibitor development, with an 
emphasis on FTase.5,30 To date, several FTase inhibitors have reached clinical trials; 
however, due to the process of alternative prenylation by GGtase, the effect of inhibitors 
on oncogenic Ras suppression has been limited. Turning efforts toward Rce1 and Icmt, 
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mice knockout studies showed that in their absence, Ras proteins were mislocalized and 
tumorigenesis was impaired.36,37,103,104 Rce1 knockouts also have been shown to cause 
adverse effects compared to Icmt, with studies reporting induced cardiomyopathy and 
accelerated myeloproliferative diseases.39,79 Given these results, attention was directed at 
Icmt as a target in oncogenesis. 
Work to inhibit Icmt began with determining its substrate specificity. Initial 
studies worked with the small molecules N-acetyl-S-farnesyl-cysteine (AFC) and N-
acetyl-S-geranlygeranyl-cysteine (AGGC),19 and later S-farnesyl thiopropionic acid 
(FTP),98 to show that Icmt recognition was dependent upon the isoprenylcysteine motif. 
With this key requirement in mind, many different structural derivatives were designed 
and tested as Icmt inhibitors. These derivatives of AFC and FTP included heteroatom 
replacements,98,110,111 rigid carboxylic acid analogues,123,124 amino functionality 
variants,122,126-129 and modifications to the isoprenyl motif,111,130,131,171 all of which 
produced inhibitors of varying effect. Advancement in high-throughput screening 
techniques afforded effective non-prenylcysteine inhibitors, such as cysmethynil,138 and 
natural product derived inhibitors, like spermatinamine.148-150 In addition, inhibition 
attempts with the byproduct of the methylation reaction, S-adenosylhomocysteine (SAH), 
were also explored. With either direct treatment of SAH or compounds that increase its 
endogenous pool, studies confirmed that elevated concentration of the byproduct 
inhibited Icmt activity;132-135 however, other cellular SAM-dependent methyltransferases 
were also inhibited. 
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Bisubstrate analogues have been a popular approach in substrate and inhibitor 
design, due to their increased binding kinetics. As the name implies, bisubstrate 
analogues integrate the structural features of each of the two substrates, or products, into 
a single molecule. The substrates should bind to their target as one entity, affording 
stronger binding than each substrate individually. Stark et al. pioneered this approach 
with the development of N-(phosphonacetyl)-L-aspartate (PALA), which binds to 
aspartate transcarbamylase about 1000 times more tightly than carbamoyl phosphate 
alone, and similarly to L aspartate.226 More recently, the bisubstrate approach has been 
shown to elucidate substrate binding sites in crystal structures,227-229 study protein 
reaction mechanics,230-232 and develop inhibitors for a wide range of enzymes.233-237 
The importance of Icmt inhibition as a cancer therapeutic, and the lack of any 
Icmt specific bisubstrate inhibitor development inspired our efforts to produce compound 
6.1 (Figure 6.1.) By conjugating the adenosine motif though an amide bond to N-acetyl-
S-farnesyl-cysteine the first bisubstrate Icmt inhibitor was developed. Compound 6.1 was 
versioned to elevate the non-specific inhibition of cellular (SAM)-Dependent 
methyltransferases by increasing its specificity for Icmt through the affiliation with 
farnesylcysteine. Reaction kinetics were evaluated using mammalian Icmt and yeast 
Ste14p. Herein, we describe the synthesis and application the bisubstrate Icmt inhibitor 
6.1 
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Figure 6.1. Structure of bisubstrate Icmt inhibitor 6.1. 
 
6.2 Results and Discussion 
 
6.2.1 Design and synthesis of Icmt inhibitor. To prepare the desired bifunctional 
inhibitor for in vitro kinetic analyses of Ste14p and Icmt, the initial strategy was to first 
design a small molecule that embodied the isoprenylcysteine and S-adenosyl-methionine 
motifs. Compound 6.1 was selected as the target molecule to take advantage of the 
commercial availability of N-acetyl-S-farnesyl-cysteine, 6.2, and the established synthesis 
of the adenosine analogue, 6.3. Unfortunately, the coupling reaction (Scheme 6.1) 
produced a complex mixture of products, due to the number of exposed nucleophiles in 
compound 6.2, that were too difficult to resolve by chromatographic techniques.   
Scheme 6.1. Original strategy for the synthesis of bifunctional Icmt inhibitor 
 
Based on the above observations, it was decided to redesign the synthesis strategy 
to the target compound that installs the desired amide linkage selectively by blocking 
reactivity of the other nucleophiles with protecting groups (Scheme 6.2). Synthesis began 
following the previously reported route to the protected adenosine analogue 6.7.238 
Coupling of 6.7 and N-acetyl-S-trityl-cysteine in the presence of HCTU and DIEA 
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afforded the amide 6.8. Cleavage of the acid labile protecting groups by treatment with a 
mixture of TFA-CH2Cl2-H2O afforded compound 6.9. Alkylation of the free thiol was 
performed using farnesyl bromide in the presence of Zn(OAc)2 in acidic DMF to yield 
the prenylated molecule 6.1 whose identity was determined via 1H NMR and ESI-MS 
analysis. The complex splitting patterns observed in the NMR spectra for 6.1 was 
deconvoluted by COSY (Figure 6.10), which showed the correct orientation of the 5 
stereocenters. 
Scheme 6.2. Revised synthesis of bifunctional Icmt inhibitor 
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6.2.3 Bisubstrate inhibitor affects Icmt processing but not Ste14p. To test the 
bisubstrate compound, 6.1, as an inhibitor for Icmt, we used recombinant His10myc3N-
Icmt (His-Icmt) and His10myc3N-Ste14p (His-Ste14p). The ability of 6.1 to act as an 
inhibitor for His-Icmt and His-Ste14p was determined using an in vitro methyltransferase 
vapor diffusion assay.88 The IC50 value (Figure 6.2) for 6.1 was measured using crude 
membrane extracts overexpressing hIcmt or Ste14 (5µg) in the presence of N-acetyl-S-
farnesylcysteine (AFC) (10 µM), and [14C]-SAM (60 µM) were added to 1 µl of inhibitor 
at increasing concentrations. Interestingly, inhibitor 6.1 affected mammalian Icmt activity 
(IC50 = 30 µM), but had little effect of yeast Ste14p (Figure 6.2). Although the resulting 
inhibitor effect is milder than other reported Icmt inhibitors, 6.1 highlights previously 
unappreciated inhibitor specificity differences between the different Icmts. 
 
Figure 6.2. Inhibition of hIcmt and Ste14p activity by 6.1. 6.1 was evaluated as an 
inhibitor in an in vitro methyltransferase vapor diffusion assay with hIcmt (A) and the 
yeast homolog, Ste14p (B).  Methyltransferase activity values were plotted against 
inhibitor concentration and an IC50 value was calculated using GraphPad Prism 4.0. 
 
6.3 Future Direction 
 
Having determined the ability of compound 6.1 to act as a mild inhibitor for Icmt, 
a new bisubstrate target was envisioned that resembles the reaction transition state to a 
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greater extent. The design of the new bisubstrate inhibitor, 6.10 (Figure 6.3), incorporates 
an ethylene diamine linker between the isoprenoid and adenosine motifs. Similar to 6.1, 
compound 6.10 conjugates the AFC component though an amide bond; however, the 
distance between AFC and the adenosine component would increase by two methane 
units. Additionally, the linkage to the adenosine motif facilitated though a secondary 
amine, which under cellular conditions is protonated, allowing the positively charged 
sulfur in SAM to be more accurately represented. When comparing 6.1 and 6.10, it 
should also be noted that 6.1 is one methylene unit shorter than the actual transition state, 
and 6.10 being one methylene unit longer (Figure 6.3). Never the less, given the 
increased degree of rotational freedom, and the cationic element afforded through the 
new diamine linker, bisubstrate 6.10 should be a superior Icmt inhibitor. Efforts are 
underway to synthesize the new bisubstrate target. 
 
 
Figure 6.3. Design of new bisubstrate inhibitor 6.10. 
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6.4 Materials and Methods 
  
6.4.1 General. AFC was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY). 
[14C]-SAM was purchased from Perkin-Elmer (Waltham, MA). The anti-myc monoclonal 
antibody and goat antirabbit IgG were purchased from Invitrogen. Cell lines were 
purchased from ATCC. All other reagents and chemicals were purchased from either 
Sigma-Aldrich (St. Louis, MO) or Invitroge (Carlsbad, CA). Flash chromatography was 
performed with silica gel, 60-120 mesh. HPLC purification was performed on reverse 
phase c18 resin from. 1H NMR spectra were obtained at 300 or 500 MHz. HR-ESI-MS 
analysis was performed using a Bio-TOF-II (Bruker) mass spectrometer   
 
6.4.2 Synthesis of compound 6.5: 9-((3aR,4R,6R,6aR)-6-(azidomethyl)-2,2-
dimethyltetrahydrofuro [3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine. This compound 
was prepared via a modification of a previously described procedure.238 2′,3′-O-
Isopropylideneadenosine 6.4 (1.0 g, 3.26 mmol, 1eq) was suspended in dry 1,4-dioxane 
(1o mL) at room temperature under nitrogen. DPPA (1.89 g, 6.49 mmol, 2 eq) and DBU 
(1.49 g, 9.76 mmol, 3 eq) were added dropwise to the suspension, and the reaction 
mixture stirred at rt for 4 h. Sodium azide (1.06 g, 16.28 mmol, 5 eq) and 15-crown-5 
(71.8 mg, 0.326 mmol, 0.1 eq) were added, and the mixture heated at 110 °C for 4 h 
under nitrogen. The reaction was filtered, evaporated, and then re-dissolved in CHCl3 
(30mL). The CHCl3 solution was washed three times with water (15 mL), sat. NaCl 
(20 mL), and then dried over MgSO4. Purification by flash column chromatography on 
silica gel (CHCl3: MeOH, 10:1) afforded the azide 6.2 as an amorphous, yellow solid 
  189 
(0.98 g, 91%): 1H NMR (300 MHz, CDCl3) δ: 1.40 (s, 3H), 1.62 (s, 3H), 3.60 (d, 2H, J = 
5.1 Hz), 4.41 (dt, 1H, J = 3.9 Hz, 9 Hz), 5.06 (dd, J = 3.3 and 6.3 Hz, 1H, 3′-H), 5.43 (dd, 
J = 2.1 and 6.3 Hz, 1H, 2′-H), 5.83 (s, 2H), 6.18 (d, 1H, J= 1.8 Hz), 8.21 (s, 1H), 8.88 (s, 
1H). HR-ESI-MS; calcd for C13H17N8O3 [M+H]
+: 333.1423, found 333.1409 
 
 6.4.3 Synthesis of compound 6.6: (9-((3aR,4R,6R,6aR)-6-(azidomethyl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)-N,N-bis(tert-
butoxycarbonyl)-amide. This compound was prepared via a modification of a 
previously described procedure.238 DMAP (72 mg, 0.592 mmol, 0.2 eq) and Et3N (0.93 g, 
9.14 mmol, 3.0 eq) were added to a solution of azide 6.5 (0.98 g, 2.96 mmol, 1.0 eq) in 
anhydrous DMF (25 mL) at 0 °C under nitrogen. Boc2O (2.61 g, 12.0 mmol, 4.0 eq) was 
then added to this solution, and the mixture stirred at 0 °C for 1 h and then at rt for 4 h. 
The reaction mixture was filtered and evaporated. Purification by flash column 
chromatography on silica gel (Hexane: EtOAc, 1:1) afford compound 6.6 as an 
amorphous solid (1.29 g, 82%). 1H NMR (300 MHz, CDCl3) δ: 1.40 (s, 3H), 1.57 (2, 
18H) 1.62 (s, 3H), 3.60 (d, 2H, J = 5.1 Hz ), 4.41 (dt, 1H, J = 3.9 Hz, 9 Hz), 5.06 (dd, 
J = 3.3 and 6.3 Hz, 1H, 3′-H), 5.43 (dd, J = 2.1 and 6.3 Hz), 5.83 (s, 2H), 6.18 (d, 1H, 
J= 1.8 Hz), 8.21 (s, 1H), 8.88 (s, 1H). HR-ESI-MS; calcd for C23H33N8O7 [M+H]
+: 
533.2472, found 533.2453 
 
6.4.4 Synthesis of compound 6.7: (9-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)-N,N- bis(tert-
  190 
butoxycarbonyl)-amide. This compound was prepared via a modification of a 
previously described procedure.238 Compound 6.6 (1.29 g, 2.42 mmol, 1.0 eq) and 10% 
Pd on carbon (300 mg) were suspended in 9:1 MeOH–H2O (50 mL). A balloon of 
hydrogen gas was attached to the reaction flask and the mixture was stirred at rt for 5 h. 
After reaction was judged complete by TLC (CHCl3: MeOH, 10:1), the mixture was 
filtered through celite® 545, and evaporated affording amine 6.7 that was used in the next 
step without further purification (1.12g, 92%). 1H NMR (300 MHz, CDCl3) δ: 1.23 (s, 
3H), 1.45 (2, 18H) 1.57 (s, 3H), 3.33 – 3.52 (m, 2H), 4.52 (m, 1H) , 5.33 (m, 2H), 6.18 
(d, 1H, J= 1.8 Hz), 8.44 (s, 1H), 8.86 (s, 1H). HR-ESI-MS; calcd for C23H35N6O7 
[M+H]+: 507.2567, found 507.2589 
 
6.4.5 Synthesis of compound 6.8: (9-((3aR,4R,6R,6aR)-6-(((S)-2-acetamido-3-
(tritylthio)propanamido)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-
9H-purin-6-yl)-N,N-bis(tert-butoxycarbonyl)-amide. N-acetyl-S-trityl-cysteine (0.213 
g, 0.420 mmol, 1.0 eq), HCTU (0.174 g, 0.420 mmol, 1.0 eq), and DIEA (0.110 mg, 
0.840 mmol, 2.0 eq) were dissolved in anhydrous DMF (5 mL) and stirred for 30 mins 
under nitrogen at rt. Amine 6.7 (0.171, 0.420 mmol, 1.0 eq) dissolved in anhydrous DMF 
(5 mL) was added to the mixture and stirred overnight at rt. DMF was removed under 
high vacuum resulting in a yellow oil. Purification my flash chromatography on silica gel 
(Hexane: EtOAc, 1:1) affording the coupled product 6.5 (0.263 g, 70%). 1H NMR (300 
MHz, CDCl3) 1.31 (s, 3H), 1.55 (s, 18H), 1.583 (s, 3H), 1.88 (s, 3H), 2.53 – 2.69 (m, 
2H), 3.18 (m, 2H), 4.23 (m, 1H), 4.68 (dd, 1H, J = 1.2 Hz, 6 Hz), 4.76 (m, 1H) 5.02 (t, 
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1H, J = 6.0 Hz), 5.38 (t, 1H, J = 4.3 Hz), 5.72 (d, 1H, J = 5.4 Hz), 6.35 (s, 1H), 6.97 – 
7.40 (m, 15H), 7.84 (s, 1H), 8.34 (s, 1H). HR-ESI-MS; calcd for C47H55N7O9S [M+H]
+: 
894.3860, found 894.3823. 
 
6.4.6 Synthesis of compound 6.9: (S)-2-acetamido-N-(((2R,3S,4R,5R)-5-(6-amino-
9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)-3-
mercaptopropanamide. Compound 6.8 (0.100 g, 0.112 mmol, 1.0 eq) was dissolved in a 
solution of 5:1:4 TFA–H2O–CH2Cl2 (10 mL) and stirred for 6h at rt. The reaction was 
judged complete by TLC (CHCl3: MeOH, 10:1) and then diluted with H2O (10 mL). 
Purification by reverse-phase HPLC with a gradient of 0 to 25% CH3CN in H2O (0.1% 
TFA) over 50 min at a flow rate of 5 mL/min afforded the deprotected product 6.6 at 10 – 
12.4% CH3CN. Lyophilization yielded a white solid (40 mg, 80%) HR-ESI-MS;
 calcd for 
C15H22N7O5S [M+H]
+: 412.1403, found 412.1385 
 
6.4.7 Synthesis of compound 6.1: (S)-2-acetamido-N-(((2R,3S,4R,5R)-5-(6-amino-
9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)-3-(((2E,6E)-3,7,11-
trimethyldodeca-2,6,10-trien-1-yl)thio)propanamide (6.1) 1he free thiol compound 6.6 
(40 mg, 92.2 µmol, 1eq)  was dissolved in DMF/n-Butanol/H2O (0.10% TFA) (5:1:1 
v/v/v, 7 mL). Farnesyl bromide (66 mg, 0.312 mmol, 3.2 eq) and Zn(OAc)2·2H2O (67 
mg, 0.233 μmol, 2.5 eq) was then added to initiate the alkylation reaction that was stirred 
overnight at rt. Purification by reverse-phase HPLC with a gradient of 0 to 25% CH3CN 
in H2O (0.1% TFA) over 50 min at a flow rate 5 mL/min resulted in the elution of the 
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desired product 6.1 at 19 – 21% CH3CN. Lyophilization yielded a clear amorphous solid 
(29 mg 52%). 1H NMR (300 MHz, CDCl3) 1.56 (s, 6H), 1.58 (s, 3H), 1.65 (s 3H), 1.97 
(2, 3H), 2.00 (dt, 8H, J = 7.2 Hz, 23.1 Hz,) 2.65 (dd, 1H, J = 6.6 Hz, 13.6 Hz), 2.84 (dd, 
1H, J = 8.4 Hz, 13.5 Hz), 3.01 (dd, 1H, J = 6.9 Hz, 13.5 Hz), 3.13 (dd, 1H, J = 6.9 Hz, 
13.5 Hz), 3.35 (m, 2H), 3.98 (dd, 1H, J = 3.9 Hz, 14.4 Hz), 4.17 (d, 1H, J = 14.4 Hz), 
4.66 (t, 1H, J = 6.3 Hz), 4.84 (d, 1H, J = 7.2 Hz) 5.08 (m, 3H), 5.88 (d, 1H, 7.2 Hz), 8.22 
(s, 1H), 8.55 (s, 1H). HR-ESI-MS; calcd for C30H46N7O5S [M+H]
+:  616.3281, found 
616.3254. 
 
6.4.8 Crude Membrane Preparation.  Crude membrane extracts were prepared as 
previously described from His10myc3N-Icmt (His-Icmt) and His10myc3N-Ste14p (His-
Ste14p) yeast strains.239,240 Briefly, yeast cells were cultured in SC-URA medium to an 
OD600 of 4.0-5.0. The cells were then harvested by centrifugation and the resulting pellet 
was stored at -80 °C until use. Upon thawing, the pellet was resuspended in lysis buffer 
(0.3 M sorbitol, 10 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 5 mM MgCl2, 1% aprotinin, and 2 
mM AEBSF) and allowed to swell on ice for 15 min. The cells were rapidly frozen and 
thawed twice by submersion into liquid N2 and room temperature respectively. The cells 
were then lysed by two passes through a French press at 18,000 p.s.i. The lysate was then 
centrifuged at 500xg to removed cell debris. The supernatant was then ultracentrifuged at 
100,000xg for 1 h at 4 °C. The supernatant was then removed and the pellet was 
resuspended in 10 mM Tris-HCl, pH 7.5. The crude membrane extracts were separated 
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into aliquots, flash frozen in liquid N2 and stored at -80 °C. Total protein concentration 
was determined using Coomassie Plus protein reagent (Pierce).  
 
6.4.9 IC50 Methyltransferase Assays. Crude membrane extracts overexpressing hIcmt 
or Ste14(5µg) in the presence of a solution of Tris-HCl buffer (100 mM, pH 7.4), 10 µM 
N-acetyl-S-farnesylcysteine (AFC), and [14C]-SAM (60 µM) were added to 1 µl of 
inhibitor at increasing concentrations.  After incubating the samples at 37°C for 30 min, 
the reaction was stopped by the addition of 50 µl of 1 M NaOH/1% SDS.  The reaction 
mixture was spotted onto filter paper.  The filter paper was lodged into the neck of a 
scintillation tube filled with 10 mL of scintillation fluid and capped.  The filter papers 
were removed after 2.5h and the radioactivity was quantified using a Packard 1600CA 
Liquid Scintillation Analyzer.   IC50 values were calculated using GraphPad Prism 4. 
DMSO concentrations were kept constant at 5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  194 
6.5 Supporting information 
 
6.5.1 Characterization of compound 6.5  
 
Figure 6.4. 1H NMR spectrum of compound 6.5. 
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6.5.2 Characterization of compound 6.6  
 
 
 
Figure 6.5. 1H NMR of compound 6.6. 
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6.5.3 Characterization of compound 6.7 
 
 
Figure 6.6. 1H NMR spectrum of compound 6.7. 
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6.5.4 Characterization of compound 6.8 
 
Figure 6.7. 1H NMR spectrum of compound 6.8. 
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6.5.5 Characterization of compound 6.9 
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Figure 6.8. Mass spectrum and analytical RP-HPLC chromatogram for compound 6.9. 
Linear gradient 0-100% CH3CN (0.1%TFA) in 60 min, detected at 254 nm. 
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6.5.6 Characterization of compound 6.1 
 
 
 
Figure 6.9. 1H NMR spectrum of compound 6.1. 
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Figure 6.10. 1H-1H COSY NMR spectrum of compound 6.1. 
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